

#### **Table of Contents**

June 30, 2024



COMPANY HIGHLIGHTS	Page		Page
Mission and Cluster Model	iii	Corporate Responsibility	xxvi
EARNINGS PRESS RELEASE	Page		Page
Second Quarter Ended June 30, 2024 Financial and Operating Results	1	Earnings Call Information and About the Company	7
Guidance	4	Consolidated Statements of Operations	8
Acquisitions	5	Consolidated Balance Sheets	9
Dispositions and Sales of Partial Interests	6	Funds From Operations and Funds From Operations per Share	10
SUPPLEMENTAL INFORMATION	Page		Page
Company Profile	13	External Growth / Investments in Real Estate	
Investor Information	14	Investments in Real Estate	32
Financial and Asset Base Highlights	15	New Class A/A+ Development and Redevelopment Properties:	
High-Quality and Diverse Client Base	17	Recent deliveries	34
Occupancy	19	Current Projects	35
Internal Growth		Summary of Pipeline	39
Key Operating Metrics	20	Construction Spending and Capitalization of Interest	44
Same Property Performance	21	Joint Venture Financial Information	46
Leasing Activity	22	<b>Balance Sheet Management</b>	
Contractual Lease Expirations	23	Investments	48
Top 20 Tenants	24	Key Credit Metrics	49
Summary of Properties and Occupancy	25	Summary of Debt	50
Property Listing	26	<b>Definitions and Reconciliations</b>	
		Definitions and Reconciliations	54

#### **CONFERENCE CALL INFORMATION:**

Tuesday, July 23, 2024

3:00 p.m. Eastern Time 12:00 p.m. Pacific Time

(833) 366-1125 or (412) 902-6738

Ask to join the conference call for Alexandria Real Estate Equities, Inc.

#### **CONTACT INFORMATION:**

Alexandria Real Estate Equities, Inc. corporateinformation@are.com

#### **JOEL S. MARCUS**

Executive Chairman & Founder

#### PETER M. MOGLIA

Chief Executive Officer & Chief Investment Officer

#### **DANIEL J. RYAN**

Co-President & Regional Market Director - San Diego

HUNTER L. KASS
Co-President & Regional Market
Director - Greater Boston

#### MARC E. BINDA

Chief Financial Officer & Treasurer

#### **PAULA SCHWARTZ**

Managing Director, Rx Communications Group (917) 633-7790

#### SARA M. KABAKOFF

Senior Vice President -**Chief Content Officer** 



#### **OUR MISSION**

To create and grow life science ecosystems and clusters that ignite and accelerate the world's leading innovators in their noble pursuit to advance human health by curing disease and improving nutrition

#### **OUR CLUSTER MODEL**

Alexandria has identified four critical components for life science companies to thrive: *location*, *innovation*, *talent*, and *capital*.

Our proven cluster model unites cutting-edge innovation with leading scientific and managerial talent and strategic investment capital in best-in-class locations immediately adjacent to some of the world's top academic institutions.





# ALEXANDRIA'S ESSENTIAL LABSPACE® INFRASTRUCTURE

As the pioneering and trusted brand for life science real estate, Alexandria has been providing the complex infrastructure needed to enable the development of new medicines for over three decades. Our tenants require our essential, 24/7 integrated laboratory and nontechnical infrastructure to house, operate, and help safeguard billions of dollars of mission-critical equipment and scientific research.



### ALEXANDRIA'S COMPETITIVE ADVANTAGES

- First mover advantage in the top life science clusters
- High-quality assets aggregated in desirable and well-amenitized mega campuses
- High-quality cash flows and substantial embedded future net operating income
- Longstanding tenant relationships that demonstrate stellar brand loyalty
- Fortress balance sheet with significant liquidity
- Unique and deep life science industry expertise
- Long-tenured and highly experienced management team



As of June 30, 2024, Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

#### **ALEXANDRIA'S OUTSTANDING LONG-TERM VALUE**

Total Shareholder Return From ARE's IPO on May 27, 1997<sup>(1)</sup> to June 30, 2024

2.274% WELLTOWER ALEXANDRIA. 1,420% NATIONAL HEALTH 1,092% **INVESTORS FTSE NAREIT EQUITY** 1,091% **HEALTH CARE INDEX** LTC 1,048% **PROPERTIES** 862% **VENTAS MSCI US** 790% **REIT INDEX** OMEGA HEALTHCARE 605% **INVESTORS HEALTHPEAK** 589% **PROPERTIES HEALTHCARE** 305% **REALTY TRUST** 

Source: S&P Global Market Intelligence. Assumes reinvestment of dividends.


The REITs presented individually in the chart above are only those constituents of the FTSE NAREIT Equity Health Care Index as of June 30, 2024 for which TSR information since May 27, 1997 is available.

<sup>(1)</sup> Alexandria's initial public offering ("IPO") was priced at \$20.00 per share on May 27, 1997.


# ALEXANDRIA'S INTERNAL GROWTH



# ALEXANDRIA'S SOLID LEASING VOLUME IN 2024 REMAINS IN LINE WITH OUR HISTORICAL ANNUAL AVERAGE FROM 2013 THROUGH 2020



## ALEXANDRIA'S OPERATIONAL EXCELLENCE DRIVES STEADY AND CONSISTENTLY HIGH OCCUPANCY




<sup>(1)</sup> Represents the average of acquired vacancy percentages as of each years ended December 31, 2020 through 2023.

Represents the midpoint of our 2024 guidance range for occupancy percentage in North America as of December 31, 2024. Refer to "Guidance" in the Earnings Press Release for additional details.

<sup>(3)</sup> Represents occupancy percentage of operating properties in North America as of each period-end.


# ALEXANDRIA'S REIT INDUSTRY-LEADING CLIENT BASE OF APPROXIMATELY 800 TENANTS DRIVES STABLE, RESILIENT, AND LONG-DURATION CASH FLOWS



As of June 30, 2024. Annual rental revenue represents amounts in effect as of June 30, 2024. Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) Represents the percentage of our annual rental revenue generated by our top 20 tenants that are also investment-grade or publicly traded large cap tenants.
- (2) Represents the percentage of our annual rental revenue generated from space that is currently targeted for a future change in use to laboratory space, including 1.0% of annual rental revenue that is generated from covered land play projects for future development opportunities. The weighted-average remaining term of these leases is 2.9 years.
- (3) Represents the percentage of our annual rental revenue generated by "Other" tenants, which comprise technology, professional services, finance, telecommunications, and construction/real estate companies, and (by less than 1.0% of our annual rental revenue) retail-related tenants.

# ALEXANDRIA'S SUSTAINED OPERATIONAL EXCELLENCE AND STRENGTH IN TENANT COLLECTIONS



As of June 30, 2024.

<sup>(1)</sup> Represents tenant rents and receivables collected for each quarter-end as of each respective earnings release date.

## ALEXANDRIA'S EXTERNAL GROWTH



# ALEXANDRIA EXECUTES LONG-TERM 127,382 RSF LEASE IN 2Q24 WITH MULTINATIONAL PHARMA COMPANY FOR NEW LIFE SCIENCE R&D CENTER AT THE SD TECH BY ALEXANDRIA MEGA CAMPUS



Strategic anchor lease at 10075 Barnes Canyon Road increases the multinational pharma company's San Diego footprint by 53% and brings the 253,079 RSF Class A+ development project to 70% leased

# ALEXANDRIA'S VISIBILITY OF FUTURE GROWTH IN ANNUAL NET OPERATING INCOME FROM DEVELOPMENT AND REDEVELOPMENT DELIVERIES

# **\$480 MILLION**<sup>®</sup>

#### **Placed Into Service**

1H24

2024

\$42M

\$16M

628,427 RSF

284,982 RSF

100% Leased

#### Expected to Be Placed Into Service(2)

3Q24-4Q25

1Q26-1Q28

\$187M<sup>(3)</sup>

\$293M

Aggregating 5.4M RSF

61% Leased/Negotiating

Refer to "Net operating income" under "Definitions and reconciliations" in the Supplemental Information for additional details, including its reconciliation from the most directly comparable financial measure presented in accordance with GAAP.

<sup>1)</sup> Our share of incremental annual net operating income from development and redevelopment projects expected to be placed into service primarily commencing from 3Q24 through 1Q28 is projected to be \$380 million.

<sup>(2)</sup> Represents expected incremental annual net operating income to be placed into service from deliveries of projects undergoing construction and one committed near-term project expected to commence construction in the next two years.

Includes 1.5 million RSF that is expected to stabilize through 2025 and is 87% leased, and partial deliveries through 4Q25 from projects expected to stabilize in 2026 and beyond. In addition to the projects represented, we are evaluating one priority anticipated development project that could commence active construction in 2H24 and may have initial delivery in 2025. Refer to the initial and stabilized occupancy years under "New Class A/A+ development and redevelopment projects: current projects" in the Supplemental Information for additional details.

# ALEXANDRIA'S OPERATIONAL EXCELLENCE IN ASSET MANAGEMENT, DESIGN, DEVELOPMENT, AND SUSTAINABILITY

## **2024 BOMA Regional TOBY** (The Outstanding Building of the Year) **Award Winners LIFE SCIENCE**







60 BINNEY STREET, ALEXANDRIA CENTER\*
AT KENDALL SQUARE MEGA CAMPUS,
GREATER BOSTON

ALEXANDRIA CENTER\* FOR LIFE SCIENCE -SAN CARLOS MEGA CAMPUS, SAN FRANCISCO BAY AREA 1165 EASTLAKE AVENUE EAST, ALEXANDRIA CENTER\* FOR LIFE SCIENCE -EASTLAKE MEGA CAMPUS, SEATTLE







### ALEXANDRIA'S STRONG EXECUTION OF OUR ASSET RECYCLING PROGRAM

STRATEGIC DISPOSITIONS AND SALES OF PARTIAL INTERESTS SINCE 2019 (1)



\$8.4 BILLION
IN SALES

\$3.0 BILLION
IN GAINS (2)

<sup>(1)</sup> Includes amounts related to real estate dispositions and sales of partial interests completed from January 1, 2019 through June 30, 2024.

<sup>(2)</sup> Represents aggregate gains on real estate sales and associated real estate impairments and consideration in excess of book value of partial interests sold that were accounted as equity transactions.

# ALEXANDRIA'S FORTRESS BALANCE SHEET



## ALEXANDRIA'S STRONG AND FLEXIBLE BALANCE SHEET WITH SIGNIFICANT LIQUIDITY

### **TOP 10%**

CREDIT RATING RANKING AMONG ALL PUBLICLY TRADED U.S. REITS (1)

Baa1

MOODY'S INVESTORS SERVICE

BBB+

Stable

**S&P Global** Ratings

Stable

SIGNIFICANT LIQUIDITY (2)

\$5.6B

DEBT MATURING 2049 & BEYOND

32%

PERCENTAGE OF

PERCENTAGE OF DEBT AT FIXED RATES

97.3%

NET DEBT AND
PREFERRED STOCK TO
ADJUSTED EBITDA<sup>(3)</sup>

**≤5.1**x 40.24 TARGET

REMAINING DEBT TERM

13.0

**YEARS** 

INTEREST RATE

3.89%

**WEIGHTED AVERAGE** 



#### As of June 30, 2024.


<sup>(1)</sup> A credit rating is not a recommendation to buy, sell, or hold securities and may be subject to revision or withdrawal at any time. Top 10% ranking represents credit rating levels from S&P Global Ratings and Moody's Investors Service for publicly traded U.S. REITs, from Bloomberg Professional Services and Nareit.

<sup>2)</sup> Refer to "Key credit metrics" in the Supplemental Information for additional details.

<sup>(3)</sup> Quarter annualized. Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

# ALEXANDRIA'S HISTORICALLY CONSISTENT, STRONG, AND INCREASING DIVIDENDS WITH A FOCUS ON RETAINING SIGNIFICANT CASH FLOWS FROM OPERATING ACTIVITIES AFTER DIVIDENDS FOR REINVESTMENT

For 2Q24, we declared a cash dividend of \$1.30 per common share



<sup>(1)</sup> Dividend yield is calculated as the dividend declared for the three months ended June 30, 2024 of \$1.30 per common share annualized divided by the closing price of our common stock on June 30, 2024 of \$116.97.

<sup>(2)</sup> Represents the years ended December 31, 2020 through 2023 and the three months ended June 30, 2024 annualized.

<sup>3)</sup> Represents the years ended December 31, 2020 through 2023 and the midpoint of our 2024 guidance range. Refer to "Guidance" in the Earnings Press Release for additional details.

<sup>4)</sup> Represents common stock dividend declared for the three months ended June 30, 2024 annualized.

ALEXANDRIA: AT THE VANGUARD AND HEART OF THE \$5 TRILLION<sup>(1)</sup> SECULARLY GROWING LIFE SCIENCE INDUSTRY



### THE \$5 TRILLION® SECULARLY **GROWING LIFE SCIENCE INDUSTRY,** WITH OVER \$470 BILLION IN ANNUAL **R&D FUNDING FROM DIVERSE SOURCES, FUELS DEMAND FOR ALEXANDRIA'S LABSPACE® ASSETS**



**TOTAL LIFE SCIENCE** R&D FUNDING(6)

\$2.1T+

2019-2023

42%

**INCREASE IN TOTAL FUNDING COMPARED** TO 2014-2018



Source: YCharts. Represents the aggregate market capitalization for the life science industry, including companies in the biotechnology and pharmaceutical sectors, as of July 12, 2024.

Source: Evaluate Pharma, March 2024. Represents consensus forecast for global biopharma R&D spend in 2023.

Sources: PitchBook, BioCentury, and NASDAQ. Includes venture capital investments in U.S.-based life science companies and IPOs, follow-ons, and public equity financings raised by U.S. listed biopharma companies in 2023.

Sources: National Institutes of Health ("NIH") and National Science Foundation ("NSF"). Includes FY2023 NIH funding and FY2023 NSF research and related activities.

Source: The Giving Institute, "Giving USA 2024: The Annual Report on Philanthropy for the Year 2023."

Dollar amount represents aggregate funding from all sources presented, and percentage represents the aggregate increase in funding compared to the previous five-year period (2014–2018).

# ALEXANDRIA TENANTS ARE RESPONSIBLE FOR 50% OF NOVEL FDA-APPROVED THERAPIES SINCE 2013

21 FDA (CDER) Approvals in 1H24

**NOVEL THERAPIES FROM ALEXANDRIA TENANTS IN 2024** 

Lilly

Genentech

A Member of the Roche Group

#### **KISUNLA**

Therapy treating adults with early symptomatic Alzheimer's disease

#### PIASKY


Therapy treating paroxysmal nocturnal hemoglobinuria, a rare and life-threatening blood condition

#### **mRESVIA**

First mRNA vaccine approved for respiratory syncytial virus (RSV) infection



Near-Record Level of FDA Approvals in 2023 Reflects the Strength of the Life Science Industry




NOVEL THERAPIES APPROVED BY THE FDA (CDER) IN 2023 COMPARED TO PRIOR 10-YEAR AVERAGES

moderna

Source: U.S. Food and Drug Administration. Novel therapies approved by the FDA (Center for Drug Evaluation and Research ("CDER")) include new molecular entities and new biologics defined as products containing active moieties that have not previously been approved by the FDA. mRESVIA was approved under the FDA Center for Biologics Evaluation and Research ("CBER") pathway.

# LARGE BIOPHARMA DEMAND FOR ALEXANDRIA LABSPACE® STEMS FROM SIGNIFICANT INVESTMENT INTO R&D

R&D Is Critical for Biopharma Given Nearly \$200B in Revenue at Risk Due to Patent Expirations in the Next 5 Years<sup>(1)</sup>



#### ALEXANDRIA TENANTS REPRESENT 17 OF THE TOP 20 PHARMA R&D SPENDERS IN 2023



































Source: Evaluate Pharma, March 2024. Total corporate R&D spend by global biopharma companies. Includes analyst forecast values for companies that have not reported 2023 full-year results. Top 20 companies ranked by pharma R&D spend in 2023.


<sup>(1)</sup> Source: Evaluate Pharma, "World Preview 2022 Outlook to 2028: Patents and Pricing."

# 1H24 PUBLIC LIFE SCIENCE FOLLOW-ON AND PIPE FINANCINGS HAVE EXCEEDED ALL OF 2023, DRIVEN LARGELY BY POSITIVE CLINICAL DATA




Source: BioCentury, June 2024. Represents public follow-on and private investment in public equity ("PIPE") financings completed by U.S. listed biopharma companies.

# 2024 LIFE SCIENCE VENTURE CAPITAL DEPLOYMENT IS ON TRACK TO EXCEED 2023 FUNDING, FUELING DEMAND FOR ALEXANDRIA LABSPACE® FROM PRIVATE BIOTECHNOLOGY COMPANIES



## ALEXANDRIA'S CORPORATE RESPONSIBILITY






#### **ALEXANDRIA'S HIGHLY IMPACTFUL CORPORATE RESPONSIBILITY PILLARS**

Developing and implementing collaborative and innovative solutions to some of the nation's most pressing challenges



Supporting our military. our veterans, and their families







↑ Accelerating medical innovation to save lives



Prioritizing the mental health crisis



Harnessing agtech to combat hunger and improve nutrition



Revolutionizing addiction treatment



Inspiring future generations with the stories and values of our nation's heroes

Future National Medal of Honor Museum in Arlington, TX



Approaching homelessness as a healthcare problem, not a housing issue



#### ALEXANDRIA.

#### AT THE VANGUARD AND HEART OF THE LIFE SCIENCE ECOSYSTEM™

#### Alexandria Real Estate Equities, Inc. Reports:

2Q24 and 1H24 Net Income per Share – Diluted of \$0.25 and \$1.22, respectively; and 2Q24 and 1H24 FFO per Share – Diluted, as Adjusted, of \$2.36 and \$4.71, respectively

PASADENA, Calif. – July 22, 2024 – Alexandria Real Estate Equities, Inc. (NYSE: ARE) announced financial and operating results for the second quarter ended June 30, 2024.

#### Key highlights

Operating results	2	2Q24		2Q23		1H24		1H23
Total revenues:								
In millions	\$	766.7	\$	713.9	\$	1,535.8	\$	1,414.7
Growth		7.4%				8.6%		
Net income attributable to Alexandria's com-	mon s	stockholde	ers -	- diluted:				
In millions	\$	42.9	\$	87.3	\$	209.8	\$	162.5
Per share	\$	0.25	\$	0.51	\$	1.22	\$	0.95
Funds from operations attributable to Alexar	ndria's	s commor	า sto	ckholders	– dil	uted, as ac	ljuste	ed:
In millions	\$	405.5	\$	382.4	\$	809.4	\$	756.1
Per share	\$	2.36	\$	2.24	\$	4.71	\$	4.43

An operationally excellent, industry-leading REIT with a high-quality, diverse client base to support growing revenues, stable cash flows, and strong margins

(As of June 30, 2024, unless stated otherwise)		
Percentage of annual rental revenue in effect from mega campuses	74%	
Percentage of annual rental revenue in effect from investment-grade or publicly traded large cap tenants	53%	
Sustained strength in tenant collections:		
Tenant receivables as a percentage of 2Q24 rental revenues	0.9%	
July 2024 tenant rents and receivables collected as of July 22, 2024	99.7%	
2Q24 tenant rents and receivables collected as of July 22, 2024	99.9%	
Occupancy of operating properties in North America	94.6%	
Operating margin	72%	
Adjusted EBITDA margin	72%	
Percentage of leases containing annual rent escalations	96%	
Weighted-average remaining lease term:		
Top 20 tenants	9.4	years
All tenants	7.4	years

#### Strong leasing volume and solid rental rate increases

- Strong leasing volume aggregating 1.1 million RSF during 2Q24.
- Solid rental rate increases of 7.4% and 3.7% (cash basis) for 2Q24 and 26.2% and 15.0% (cash basis) for 1H24.
- 79% of our leasing activity during the last twelve months was generated from our existing tenant base.

2Q24	1H24
1,114,001	2,256,858
340,989	441,221
589,650	1,584,420
7.4%	26.2%
3.7%	15.0%
	1,114,001 340,989 589,650 7.4%

#### Continued solid net operating income and internal growth

- Net operating income (cash basis) of \$1.9 billion for 2Q24 annualized, up \$122.7 million, or 6.9%, compared to 2Q23 annualized.
- Same property net operating income growth of 1.5% and 3.9% (cash basis) for 2Q24 over 2Q23 and 1.1% and 3.7% (cash basis) for 1H24 over 1H23.
- 96% of our leases contain contractual annual rent escalations approximating 3%.

Strong and flexible balance sheet with significant liquidity; top 10% credit rating ranking among all publicly traded U.S. REITs

- Net debt and preferred stock to Adjusted EBITDA of 5.4x and fixed-charge coverage ratio of 4.5x for 2Q24 annualized.
- Significant liquidity of \$5.6 billion.
- 32% of our total debt matures in 2049 and beyond.
- 13.0 years weighted-average remaining term of debt.
- 97.3% of our debt has a fixed rate.
- Total debt and preferred stock to gross assets of 29%.
- \$1.1 billion of expected capital contribution commitments from existing consolidated real estate joint venture partners to fund construction from 3Q24 through 2027.

<u>Consistent dividend strategy with a focus on retaining significant net cash flows from operating activities after dividends for reinvestment</u>

- Common stock dividend declared for 2Q24 of \$1.30 per common share aggregating \$5.08 per common share for the twelve months ended June 30, 2024, up 24 cents, or 5%, over the twelve months ended June 30, 2023.
- Dividend yield of 4.4% as of June 30, 2024.
- Dividend payout ratio of 55% for the three months ended June 30, 2024.
- · Average annual dividend per-share growth of 5% from 2020 through 2Q24 annualized.
- Significant net cash flows from operating activities after dividends retained for reinvestment aggregating \$2.1 billion for the years ended December 31, 2020 through 2023 and including the midpoint of our 2024 guidance range for net cash provided by operating activities after dividends.

#### Ongoing execution of Alexandria's 2024 capital strategy

We expect to continue pursuing our strategy to fund a significant portion of our capital requirements for the year ending December 31, 2024 with dispositions and sales of partial interests and are actively pursuing several dispositions and partial interest sale opportunities.

#### (in millions)

Completed dispositions of 100% interest in properties not integral to our mega campus strategy	\$ 77 (1)
Pending transactions subject to letters of intent or purchase and sale agreement negotiations	807
Forward equity sales agreements expected to be settled in 2024	 27
	911
Additional targeted dispositions, sales of partial interests, and common equity	 639
2024 guidance midpoint for dispositions, sales of partial interests, and common equity	\$ 1,550

(1) Refer to "Dispositions and sales of partial interests" in the Earnings Press Release for additional details.

#### Second Quarter Ended June 30, 2024 Financial and Operating Results (continued)

June 30, 2024



Alexandria's highly leased value-creation pipeline delivered incremental annual net operating income of \$16 million commencing during 2Q24 and is expected to deliver incremental annual net operating income aggregating \$480 million by 1Q28

- During 2Q24, we placed into service development and redevelopment projects aggregating 284,982 RSF that are 100% leased across multiple submarkets and delivered incremental annual net operating income of \$16 million. 2Q24 deliveries included:
  - 195,435 and 25,655 RSF at 9810 Darnestown Road and 9808 Medical Center Drive, respectively, located on the Alexandria Center<sup>®</sup> for Life Science – Shady Grove mega campus in our Rockville submarket.
- Annual net operating income (cash basis) is expected to increase by \$80 million upon the burn-off of initial free rent, with a weighted-average burn-off period of approximately seven months, from recently delivered projects.
- 69% of the RSF in our total value-creation pipeline is within our mega campuses.

Development and Redevelopment Projects	Anı	remental nual Net ting Income	RSF	Leased/ Negotiating Percentage
(dollars in millions)				
Placed into service:				
1Q24	\$	26	343,445	100%
2Q24		16	284,982	100
Placed into service in 1H24	\$	42	628,427	100%
Expected to be placed into service <sup>(1)</sup> : 3Q24 through 4Q25	\$	187 <sup>(2)</sup>		
1Q26 through 1Q28		293	5,432,915	61% <sup>(3)</sup>
	\$	480		

- (1) Represents expected incremental annual net operating income to be placed into service from deliveries of projects undergoing construction and one committed near-term project expected to commence construction in the next two years.
- (2) Includes 1.5 million RSF that is expected to stabilize through 2025 and is 87% leased, and partial deliveries through 4Q25 from projects expected to stabilize in 2026 and beyond. In addition to the projects represented, we are evaluating one priority anticipated development project that could commence active construction in 2H24 and may have initial delivery in 2025. Refer to the initial and stabilized occupancy years under "New Class A/A+ development and redevelopment properties: current projects" in the Supplemental Information for additional details.
- (3) 71% of the leased RSF of our value-creation projects was generated from our existing tenant base.

#### Strong balance sheet management

Key metrics as of or for the three months ended June 30, 2024

- \$32.5 billion in total market capitalization.
- \$20.1 billion in total equity capitalization, which ranks in the top 10% among all publicly traded U.S. REITs.

	2Q:	24	Target
	Quarter	Trailing	4Q24
	Annualized	12 Months	Annualized
Net debt and preferred stock to Adjusted EBITDA	5.4x	5.6x	Less than or equal to 5.1x
Fixed-charge coverage ratio	4.5x	4.6x	Greater than or equal to 4.5x

#### Key capital events

- In July 2024, we executed an agreement with the lender group to amend and restate our
  unsecured senior line of credit to, among other changes, extend the maturity date from
  January 22, 2028 to January 22, 2030, including extension options that we control. We
  expect that the amendment and restatement will become effective in September 2024 upon
  the satisfaction of certain conditions.
- During 2Q24, we entered into new forward equity sales agreements aggregating \$27.8 million
  to sell 230 thousand shares of common stock under our ATM program at an average price of
  \$122.32 (before underwriting discounts). We expect to settle these forward equity sales
  agreements in 2024. As of July 22, 2024, the remaining aggregate amount available under
  our ATM program for future sales of common stock was \$1.47 billion.

#### Investments

- · As of June 30, 2024:
- Our non-real estate investments aggregated \$1.5 billion.
- Unrealized gains presented in our consolidated balance sheet were \$159.8 million, comprising gross unrealized gains and losses aggregating \$284.2 million and \$124.4 million, respectively.
- Investment loss of \$43.7 million for 2Q24 presented in our consolidated statement of operations consisted of \$33.4 million of realized gains, partially offset by \$12.8 million of impairment charges and \$64.2 million of unrealized losses.

#### Second Quarter Ended June 30, 2024 Financial and Operating Results (continued)

June 30, 2024



#### Other key highlights

 In June 2024, Alexandria was added to the Health Care REITs industry under the Global Industry Classification Standard (GICS®) by S&P Dow Jones Indices and MSCI, and to the FTSE NAREIT Equity Health Care Index.

#### Key items included in net income attributable to Alexandria's common stockholders:

	2Q24	2Q23	2Q24	2Q23	1H24	1H23	1H24	1H23
(in millions, except per share amounts)	Amo	ount	Per Sh Dilu		Amo	ount	Per Sh Dilu	
Unrealized losses on non-real estate investments	\$ (64.2)	\$ (77.9)	\$ (0.37)	\$ (0.46)	\$ (35.1)	\$(143.8)	\$ (0.20)	\$ (0.84)
Gain on sales of real estate	_	214.8	_	1.26	0.4	214.8	_	1.26
Impairment of non-real estate investments	(12.8)	(23.0)	(80.0)	(0.13)	(27.5)	(23.0)	(0.16)	(0.13)
Impairment of real estate	(30.8)	(168.6)	(0.18)	(0.99)	(30.8)	(168.6)	(0.18)	(0.99)
Total	\$(107.8)	\$ (54.7)	\$ (0.63)	\$ (0.32)	\$ (93.0)	\$(120.6)	\$ (0.54)	\$ (0.70)

Refer to "Funds from operations and funds from operations per share" in the Earnings Press Release for additional details.

#### Subsequent event

• In July 2024, we executed an amendment to our existing ground lease agreement at the Alexandria Technology Square® mega campus aggregating 1.2 million RSF in our Cambridge submarket to extend the term by 24 years from January 1, 2065 to December 31, 2088. The amendment requires that we prepay our entire rent obligation for the extended lease term aggregating \$270.0 million in two equal installments during the fourth quarter of 2024 and the first quarter of 2025. This amount will be amortized on a straight-line basis over the remaining lease term from July 2024 through December 2088, and the amended operating lease will result in an incremental annual rent expense of approximately \$3.6 million. Alexandria Technology Square® is a foundational mega campus in the heart of the global life science ecosystem in Cambridge and is the Greater Boston base of operations of key strategic long-tenured tenants such as Novartis AG, GlaxoSmithKline plc, Massachusetts Institute of Technology, and Mass General Brigham. Securing this ground lease through December 2088 significantly enhances the long-term value of our investment in this critical mega campus.

#### Industry and corporate responsibility leadership: catalyzing and leading the way for positive change to benefit human health and society

- In June 2024, we released our 2023 Corporate Responsibility Report, which reinforces our longstanding operational excellence across our differentiated Labspace<sup>®</sup> platform and highlights:
- Our new target to reduce operational greenhouse gas (GHG) emissions intensity by
  advancing our energy efficiency, electrification, alternative energy, and renewable electricity
  initiatives. As an example of our renewable electricity initiatives, a recent long-term power
  purchase agreement in our Greater Boston market is expected to enable us to meet 100%
  of the electricity needs for Alexandria-paid accounts in this market with renewable energy.
- Our pioneering corporate responsibility pillars, which aim to address the most pressing issues facing our nation, including the mental health and addiction crises.

#### Industry and corporate responsibility leadership (continued)

- In April 2024, Alexandria earned several 2024 regional TOBY (The Outstanding Building of the Year) Awards from BOMA (Building Owners and Managers Association). The TOBY Awards are the commercial real estate industry's highest recognition honoring excellence in commercial building management and operations.
- In the BOMA Mid-Atlantic region, 60 Binney Street on the Alexandria Center<sup>®</sup> at Kendall Square mega campus won in the Life Science category and Building 1400 on the Alexandria Center<sup>®</sup> at One Kendall Square mega campus won in the Renovated Building category.
- In the BOMA Pacific Southwest region, the Alexandria Center<sup>®</sup> for Life Science San Carlos mega campus won in the Life Science category.
- In the BOMA Pacific Northwest region, 1165 Eastlake Avenue East on the Alexandria Center<sup>®</sup> for Life Science – Eastlake mega campus won in the Life Science category.
- Additionally, our innovative energy district at the Alexandria Center® for Life Science South Lake Union mega campus received the Seattle 2030 District's 2024 Vision Award for Energy, and 6040 George Watts Hill Drive, Phase II, in Research Triangle was recognized as the Best Development Project in the 2024 Triangle Commercial Real Estate Women's (TCREW) Champion Awards.

#### About Alexandria Real Estate Equities, Inc.

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500<sup>®</sup> company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of June 30, 2024, Alexandria has a total market capitalization of \$32.5 billion and an asset base in North America that includes 42.1 million RSF of operating properties and 5.3 million RSF of Class A/A+ properties undergoing construction and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For additional information on Alexandria, please visit www.are.com.

#### Guidance

June 30, 2024

(Dollars in millions, except per share amounts)



The following guidance for 2024 has been updated to reflect our current view of existing market conditions and assumptions for the year ending December 31, 2024. There can be no assurance that actual results will not be materially higher or lower than these expectations. Also, refer to our discussion of "forward-looking statements" on page 7 of the Earnings Press Release for additional details.

Changes to our guidance for 2024 key sources and uses of capital include a \$150 million increase to the midpoint of our guidance range for dispositions, sales of partial interests, and common equity primarily to fund the first \$135 million installment of the ground lease prepayment at our Alexandria Technology Square® mega campus aggregating 1.2 million RSF in our Cambridge submarket due in the fourth quarter of 2024 in connection with an amendment of our existing ground lease agreement to extend the term of the lease by 24 years from January 1, 2065 to December 31, 2088. Refer to "Subsequent event" in the Earnings Press Release for additional information.

Summary of Key Changes in Guidance	As of 7/22/24	As of 4/22/24	Summary of Key Changes in Sources and Uses of Capital
EPS, FFO per share, and FFO per share, as adjusted	See upda	ites below	Dispositions, sales of partial interests, and common equity

#### Projected 2024 Earnings per Share and Funds From Operations per Share Attributable to Alexandria's Common Stockholders – Diluted

	As of 7/22/24	As of 4/22/24
Earnings per share <sup>(3)</sup>	\$2.98 to \$3.10	\$3.60 to \$3.72
Depreciation and amortization of real estate assets	5.95	5.95
Impairment of real estate - rental properties and land	0.01	_
Allocation to unvested restricted stock awards	(0.05)	(0.06)
Funds from operations per share <sup>(2)</sup>	\$8.89 to \$9.01	\$9.49 to \$9.61
Unrealized losses (gains) on non-real estate investments	0.20	(0.17)
Impairment of non-real estate investments	0.16	0.09
Impairment of real estate	0.17	_
Allocation to unvested restricted stock awards	(0.01)	
Funds from operations per share, as adjusted <sup>(2)</sup>	\$9.41 to \$9.53	\$9.41 to \$9.53
Midpoint	\$9.47	\$9.47

Key Assumptions	Low	High
Occupancy percentage in North America as of December 31, 2024	94.6%	95.6%
Lease renewals and re-leasing of space:		
Rental rate increases	11.0%	19.0%
Rental rate increases (cash basis)	5.0%	13.0%
Same property performance:		
Net operating income increases	0.5%	2.5%
Net operating income increases (cash basis)	3.0%	5.0%
Straight-line rent revenue	\$ 169	\$ 184
General and administrative expenses	\$ 181	\$ 191
Capitalization of interest	\$ 325	\$ 355
Interest expense	\$ 154	\$ 184
Realized gains on non-real estate investments <sup>(6)</sup>	\$ 95	\$ 125

	2024 Guidance Midpoint			
Summary of Key Changes in Sources and Uses of Capital	As of 7/22/24	As of 4/22/24		
Dispositions, sales of partial interests, and common equity	\$1,550	\$1,400		
Ground lease prepayment <sup>(1)</sup>	\$135	<b>\$</b> —		

#### Key Credit Metric Targets<sup>(2)</sup>

Net debt and preferred stock to Adjusted EBITDA – 4Q24 annualized	Less than or equal to 5.1x
Fixed-charge coverage ratio – 4Q24 annualized	Greater than or equal to 4.5x

Key Sources and Uses of Capital	Range		М	idpoint	Certain Completed Items					
Sources of capital:										
Incremental debt	\$	885	\$	885	\$	885	ξ	See below		
Net cash provided by operating activities after dividends		400		500		450				
Dispositions, sales of partial interests, and common equity <sup>(4)</sup> (refer to page 6)		1,050		2,050		1,550		(4)		
Total sources of capital	\$	2,335	\$	3,435	\$	2,885				
Uses of capital:										
Construction	\$	1,950	\$	2,550	\$	2,250				
Acquisitions (refer to page 5)		250		750		500	\$	202		
Ground lease prepayment <sup>(1)</sup>		135		135		135				
Total uses of capital	\$	2,335	\$	3,435	\$	2,885				
Incremental debt (included above):			_							
Issuance of unsecured senior notes payable <sup>(5)</sup>	\$	1,000	\$	1,000	\$	1,000	\$	1,000 (5)		
Unsecured senior line of credit, commercial paper, and other		(115)		(115)		(115)				
Net incremental debt	\$	885	\$	885	\$	885				

Cortain

Refer to "Subsequent event" in the Earnings Press Release for additional details.

<sup>(2)</sup> Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

<sup>(3)</sup> Excludes unrealized gains or losses on non-real estate investments after June 30, 2024 that are required to be recognized in earnings and are excluded from funds from operations per share, as adjusted.

<sup>(4)</sup> We expect to continue pursuing our strategy to fund a significant portion of our capital requirements for the year ending December 31, 2024 with dispositions and sales of partial interests in properties not integral to our mega campus strategy and are actively pursuing several dispositions and partial interest sale opportunities. As of July 22, 2024, we completed dispositions aggregating \$77.2 million, have additional pending transactions subject to letters of intent or purchase and sale agreement negotiations aggregating \$806.7 million, and entered into new forward equity sales agreements aggregating \$27.8 million, which, in aggregate, represents 59% of the \$1.55 billion midpoint of our guidance

<sup>(5)</sup> Represents \$1.0 billion of unsecured senior notes payable issued in February 2024. Subject to market conditions, we may seek additional opportunities in 2024 to fund the repayment of our \$600.0 million of 3.45% unsecured senior notes payable due on April 30, 2025 through issuance of additional unsecured senior notes payable, which is not assumed in our current 2024 guidance.

<sup>(6)</sup> Represents realized gains and losses included in funds from operations per share – diluted, as adjusted, and excludes significant impairments realized on non-real estate investments, if any. Refer to "Investments" in the Supplemental Information for additional details.

#### **Acquisitions**

June 30, 2024

(Dollars in thousands)



Property	Submarket/Market	Date of Purchase	Operating Occupancy			Purchase Price	
Completed in 1Q24:							
285, 299, 307, and 345 Dorchester Avenue (60% interest in consolidated JV)	Seaport Innovation District/Greater Boston	1/30/24	N/A	1,040,000	\$	155,321	
Other						39,490	
						194,811	
Completed in 2Q24:							
Other						7,000	
						201,811	
Pending acquisitions subject to signed letters of intent or purchase and sale agreements						47,600	
					\$	249,411	
2024 guidance range					\$250,00	00 – \$750,000	

<sup>(1)</sup> We expect to provide total estimated costs and related yields for development and redevelopment projects in the future, subsequent to the commencement of construction.

#### **Dispositions and Sales of Partial Interests**

June 30, 2024

(Dollars in thousands)



Property	Submarket/Market	Date of Sale	Interest Sold	RSF	Sales Price		
Dispositions of 100% interest in properties not integral to our mega campus strategy							
Completed in 1H24:							
99 A Street <sup>(1)</sup>	Seaport Innovation District/Greater Boston	3/8/24	100%	235,000	\$ 13,350		
Other					3,863		
					17,213		
Completed in July 2024:							
Other <sup>(2)</sup>					60,000		
					77,213		
Pending transactions subject to letters of intent or purchase and sale agreement negotiations					806,728		
Additional targeted dispositions and sales of partial interests					TBD		
					\$ 883,941		
2024 guidance range for dispositions, sales of partial interests, and common equity				\$1,050	0,000 - \$2,050,000		

<sup>(1)</sup> We completed the sale during the three months ended March 31, 2024 and recognized no gain or loss.

<sup>(2)</sup> The disposition completed in July 2024 was leased to a single tenant with a July 2024 lease expiration and had annual net operating income of \$18.6 million based upon 2Q24 annualized. This asset was previously considered to be a potential development project upon expiration of an in-place non-laboratory space lease in July 2024.

#### **Earnings Call Information and About the Company**

June 30, 2024



We will host a conference call on Tuesday, July 23, 2024, at 3:00 p.m. Eastern Time ("ET")/noon Pacific Time ("PT"), which is open to the general public, to discuss our financial and operating results for the second quarter ended June 30, 2024. To participate in this conference call, dial (833) 366-1125 or (412) 902-6738 shortly before 3:00 p.m. ET/noon PT and ask the operator to join the call for Alexandria Real Estate Equities, Inc. The audio webcast can be accessed at www.are.com in the "For Investors" section. A replay of the call will be available for a limited time from 5:00 p.m. ET/2:00 p.m. PT on Tuesday, July 23, 2024. The replay number is (877) 344-7529 or (412) 317-0088, and the access code is 8478776.

Additionally, a copy of this Earnings Press Release and Supplemental Information for the second quarter ended June 30, 2024 is available in the "For Investors" section of our website at www.are.com or by following this link: https://www.are.com/fs/2024q2.pdf.

For any questions, please contact corporateinformation@are.com; Joel S. Marcus, executive chairman and founder; Peter M. Moglia, chief executive officer and chief investment officer; Marc E. Binda, chief financial officer and treasurer; Paula Schwartz, managing director of Rx Communications Group, at (917) 633-7790; or Sara M. Kabakoff, senior vice president – chief content officer.

#### **About the Company**

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500<sup>®</sup> company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of June 30, 2024, Alexandria has a total market capitalization of \$32.5 billion and an asset base in North America that includes 42.1 million RSF of operating properties and 5.3 million RSF of Class A/A+ properties undergoing construction and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For additional information on Alexandria, please visit www.are.com.

#### **Forward-Looking Statements**

This document includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding our 2024 earnings per share, 2024 funds from operations per share, 2024 funds from operations per share, as adjusted, net operating income, and our projected sources and uses of capital. You can identify the forward-looking statements by their use of forward-looking words, such as "forecast," "guidance," "goals," "projects," "estimates," "anticipates," "believes," "expects," "intends," "may," "plans," "seeks," "should," "targets," or "will," or the negative of those words or similar words. These forward-looking statements are based on our current expectations, beliefs, projections, future plans and strategies, anticipated events or trends, and similar expressions concerning matters that are not historical facts, as well as a number of assumptions concerning future events. There can be no assurance that actual results will not be materially higher or lower than these expectations. These statements are subject to risks, uncertainties, assumptions, and other important factors that could cause actual results to differ materially from the results discussed in the forward-looking statements. Factors that might cause such a difference include, without limitation, our failure to obtain capital (debt, construction financing, and/or equity) or refinance debt maturities, lower than expected yields, increased interest rates and operating costs, adverse economic or real estate developments in our markets, our failure to successfully place into service and lease any properties undergoing development or redevelopment and our existing space held for future development or redevelopment (including new properties acquired for that purpose), our failure to successfully operate or lease acquired properties, decreased rental rates, increased vacancy rates or failure to renew or replace expiring leases, defaults on or non-renewal of leases by tenants, adverse general and local economic conditions, an unfavorable capital market environment, decreased leasing activity or lease renewals, failure to obtain LEED and other healthy building certifications and efficiencies, and other risks and uncertainties detailed in our filings with the Securities and Exchange Commission ("SEC"). Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are made as of the date of this Earnings Press Release and Supplemental Information, and unless otherwise stated, we assume no obligation to update this information and expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. For more discussion relating to risks and uncertainties that could cause actual results to differ materially from those anticipated in our forward-looking statements, and risks to our business in general, please refer to our SEC filings, including our most recent annual report on Form 10-K and any subsequent quarterly reports on Form 10-Q.

This document is not an offer to sell or a solicitation to buy securities of Alexandria Real Estate Equities, Inc. Any offers to sell or solicitations to buy our securities shall be made only by means of a prospectus approved for that purpose. Unless otherwise indicated, the "Company," "Alexandria," "ARE," "we," "us," and "our" refer to Alexandria Real Estate Equities, Inc. and our consolidated subsidiaries. Alexandria®, Lighthouse Design® logo, Building the Future of Life-Changing Innovation®, That's What's in Our DNA®, Labspace®, At the Vanguard and Heart of the Life Science Ecosystem™, Alexandria Center®, Alexandria Technology Square®, Alexandria Technology Center®, and Alexandria Innovation Center® are copyrights and trademarks of Alexandria Real Estate Equities, Inc. All other company names, trademarks, and logos referenced herein are the property of their respective owners.

#### **Consolidated Statements of Operations**

June 30, 2024

(Dollars in thousands, except per share amounts)



	Three Months Ended									nded			
		6/30/24		3/31/24	1	2/31/23	9/30/23		6/30/23		6/30/24		6/30/23
Revenues:													
Income from rentals	\$	755,162	\$	755,551	\$	742,637	\$	707,531	\$ 704,339	\$	1,510,713	\$	1,392,288
Other income		11,572		13,557		14,579		6,257	9,561		25,129		22,407
Total revenues		766,734		769,108		757,216		713,788	713,900		1,535,842		1,414,695
Expenses:													
Rental operations		217,254		218,314		222,726		217,687	211,834		435,568		418,767
General and administrative		44,629		47,055		59,289		45,987	45,882		91,684		94,078
Interest		45,789		40,840		31,967		11,411	17,072		86,629		30,826
Depreciation and amortization		290,720		287,554		285,246		269,370	273,555		578,274		538,857
Impairment of real estate		30,763				271,890		20,649	168,575		30,763		168,575
Total expenses		629,155		593,763		871,118		565,104	716,918		1,222,918		1,251,103
Equity in earnings of unconsolidated real estate joint ventures		130		155		363		242	181		285		375
Investment (loss) income		(43,660)		43,284		8,654		(80,672)	(78,268)		(376)		(123,379)
Gain on sales of real estate				392		62,227			214,810		392		214,810
Net income (loss)		94,049		219,176		(42,658)		68,254	133,705		313,225		255,398
Net income attributable to noncontrolling interests		(47,347)		(48,631)		(45,771)		(43,985)	(43,768)		(95,978)		(87,599)
Net income (loss) attributable to Alexandria Real Estate Equities, Inc.'s stockholders		46,702		170,545		(88,429)		24,269	89,937		217,247		167,799
Net income attributable to unvested restricted stock awards		(3,785)		(3,659)		(3,498)		(2,414)	(2,677)		(7,444)		(5,283)
Net income (loss) attributable to Alexandria Real Estate Equities, Inc.'s common stockholders	\$	42,917	\$	166,886	\$	(91,927)	\$	21,855	\$ 87,260	\$	209,803	\$	162,516
Net income (loss) per share attributable to Alexandria Real Estate Equities, Inc.'s common stockholders:													
Basic	\$	0.25	\$	0.97	\$	(0.54)	\$	0.13	\$ 0.51	\$	1.22	\$	0.95
Diluted	\$	0.25	\$	0.97	\$	(0.54)	\$	0.13	\$ 0.51	\$	1.22	\$	0.95
Weighted-average shares of common stock outstanding:													
Basic		172,013		171,949		171,096		170,890	170,864		171,981		170,824
Diluted		172,013		171,949		171,096		170,890	170,864		171,981		170,824
Dividends declared per share of common stock	\$	1.30	\$	1.27	\$	1.27	\$	1.24	\$ 1.24	\$	2.57	\$	2.45

# **Consolidated Balance Sheets**

June 30, 2024 (In thousands)



	6/30/24	3/31/24	12/31/23	9/30/23	6/30/23
Assets					
Investments in real estate	\$ 32,673,839	\$ 32,323,138	\$ 31,633,511	\$ 31,712,731	\$ 31,178,054
Investments in unconsolidated real estate joint ventures	40,535	40,636	37,780	37,695	37,801
Cash and cash equivalents	561,021	722,176	618,190	532,390	924,370
Restricted cash	4,832	9,519	42,581	35,321	35,920
Tenant receivables	6,822	7,469	8,211	6,897	6,951
Deferred rent	1,190,336	1,138,936	1,050,319	1,012,666	984,366
Deferred leasing costs	519,629	520,616	509,398	512,216	520,610
Investments	1,494,348	1,511,588	1,449,518	1,431,766	1,495,994
Other assets	1,356,503	1,424,968	1,421,894	1,501,611	1,475,191
Total assets	\$ 37,847,865	\$ 37,699,046	\$ 36,771,402	\$ 36,783,293	\$ 36,659,257
Liabilities, Noncontrolling Interests, and Equity					
Secured notes payable	\$ 134,942	\$ 130,050	\$ 119,662	\$ 109,110	\$ 91,939
Unsecured senior notes payable	12,089,561	12,087,113	11,096,028	11,093,725	11,091,424
Unsecured senior line of credit and commercial paper	199,552	_	99,952	_	_
Accounts payable, accrued expenses, and other liabilities	2,529,535	2,503,831	2,610,943	2,653,126	2,494,087
Dividends payable	227,408	222,134	221,824	214,450	214,555
Total liabilities	15,180,998	14,943,128	14,148,409	14,070,411	13,892,005
Commitments and contingencies					
Redeemable noncontrolling interests	16,440	16,620	16,480	51,658	52,628
Alexandria Real Estate Equities, Inc.'s stockholders' equity:					
Common stock	1,720	1,720	1,719	1,710	1,709
Additional paid-in capital	18,284,611	18,434,690	18,485,352	18,651,185	18,812,318
Accumulated other comprehensive loss	(27,710)	(23,815)	(15,896)	(24,984)	(16,589)
Alexandria Real Estate Equities, Inc.'s stockholders' equity	18,258,621	18,412,595	18,471,175	18,627,911	18,797,438
Noncontrolling interests	4,391,806	4,326,703	4,135,338	4,033,313	3,917,186
Total equity	22,650,427	22,739,298	22,606,513	22,661,224	22,714,624
Total liabilities, noncontrolling interests, and equity	\$ 37,847,865	\$ 37,699,046	\$ 36,771,402	\$ 36,783,293	\$ 36,659,257

# **Funds From Operations and Funds From Operations per Share**

June 30, 2024

(In thousands)



The following table presents a reconciliation of net income (loss) attributable to Alexandria's common stockholders, the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP"), including our share of amounts from consolidated and unconsolidated real estate joint ventures, to funds from operations attributable to Alexandria's common stockholders – diluted, and funds from operations attributable to Alexandria's common stockholders – diluted, and funds from operations attributable to Alexandria's common stockholders – diluted, and funds from operations attributable to Alexandria's common stockholders – diluted, as adjusted, for the periods below:

		Th		Six Months Ended			
	6/30/24	3/31/24	12/31/23	9/30/23	6/30/23	6/30/24	6/30/23
Net income (loss) attributable to Alexandria's common stockholders – basic and diluted	\$ 42,917	\$ 166,886	\$ (91,927)	\$ 21,855	\$ 87,260	\$ 209,803	\$ 162,516
Depreciation and amortization of real estate assets	288,118	284,950	281,939	266,440	270,026	573,068	532,150
Noncontrolling share of depreciation and amortization from consolidated real estate JVs	(31,364)	(30,904)	(30,137)	(28,814)	(28,220)	(62,268)	(56,398)
Our share of depreciation and amortization from unconsolidated real estate JVs	1,068	1,034	965	910	855	2,102	1,714
Gain on sales of real estate	_	(392)	(62,227)	_	(214,810)	(392)	(214,810)
Impairment of real estate – rental properties and land	2,182	_	263,982	19,844	166,602	2,182	166,602
Allocation to unvested restricted stock awards	(1,305)	(3,469)	(2,268)	(838)	(872)	(4,736)	(2,220)
Funds from operations attributable to Alexandria's common stockholders – diluted <sup>(1)</sup>	301,616	418,105	360,327	279,397	280,841	719,759	589,554
Unrealized losses (gains) on non-real estate investments	64,238	(29,158)	(19,479)	77,202	77,897	35,080	143,752
Impairment of non-real estate investments	12,788 (2)	14,698	23,094	28,503	22,953	27,486	22,953
Impairment of real estate	28,581 <sup>(3)</sup>	_	7,908	805	1,973	28,581	1,973
Acceleration of stock compensation expense due to executive officer resignations	_	_	18,436	1,859	_	_	_
Allocation to unvested restricted stock awards	(1,738)	247	(472)	(1,330)	(1,285)	(1,528)	(2,164)
Funds from operations attributable to Alexandria's common stockholders – diluted, as adjusted	\$ 405,485	\$ 403,892	\$ 389,814	\$ 386,436	\$ 382,379	\$ 809,378	\$ 756,068

- (1) Calculated in accordance with standards established by the Nareit Board of Governors.
- (2) Primarily related to two non-real estate investments in privately held entities that do not report NAV.
- (3) Primarily related to two potential acquisitions in our Greater Boston market, which aggregated 1.4 million of future development RSF. We initially expected to close these acquisitions after 2024 for an aggregate purchase price of \$366.8 million. Our intent for each site included the demolition of existing buildings upon expiration of the existing in-place leases and the development of life science properties. During the three months ended June 30, 2024, we decided to no longer proceed with these acquisitions as a result of the current macroeconomic environment that negatively impacted the financial outlooks for these projects, and recognized this impairment charge.

# **Funds From Operations and Funds From Operations per Share (continued)**

June 30, 2024

(In thousands, except per share amounts)



The following table presents a reconciliation of net income (loss) per share attributable to Alexandria's common stockholders, the most directly comparable financial measure presented in accordance with GAAP, including our share of amounts from consolidated and unconsolidated real estate joint ventures, to funds from operations per share attributable to Alexandria's common stockholders – diluted, and funds from operations per share attributable to Alexandria's common stockholders – diluted, as adjusted, for the periods below. Per share amounts may not add due to rounding.

	Three Months Ended								Six Months Ended					
	6/3	30/24	3/	31/24	12	2/31/23	9/30/23		6/30/23		6/	30/24	6/	30/23
Net income (loss) per share attributable to Alexandria's common stockholders – diluted	\$	0.25	\$	0.97	\$	(0.54)	\$	0.13	\$	0.51	\$	1.22	\$	0.95
Depreciation and amortization of real estate assets		1.50		1.48		1.48		1.40		1.42		2.98		2.80
Gain on sales of real estate		_		_		(0.36)		_		(1.26)		_		(1.26)
Impairment of real estate – rental properties and land		0.01		_		1.54		0.12		0.98		0.01		0.98
Allocation to unvested restricted stock awards		(0.01)		(0.02)		(0.01)		(0.01)		(0.01)		(0.02)		(0.02)
Funds from operations per share attributable to Alexandria's common stockholders – diluted		1.75		2.43		2.11		1.64		1.64		4.19		3.45
Unrealized losses (gains) on non-real estate investments		0.37		(0.17)		(0.11)		0.45		0.46		0.20		0.84
Impairment of non-real estate investments		80.0		0.09		0.13		0.17		0.13		0.16		0.13
Impairment of real estate		0.17		_		0.05		_		0.02		0.17		0.02
Acceleration of stock compensation expense due to executive officer resignations		_		_		0.11		0.01		_		_		_
Allocation to unvested restricted stock awards		(0.01)		_		(0.01)		(0.01)		(0.01)		(0.01)		(0.01)
Funds from operations per share attributable to Alexandria's common stockholders – diluted, as adjusted	\$	2.36	\$	2.35	\$	2.28	\$	2.26	\$	2.24	\$	4.71	\$	4.43
Weighted-average shares of common stock outstanding – diluted	1	72,013	1	71,949	1	171,096	1	70,890	1	170,864	1	71,981	1	70,824

# **SUPPLEMENTAL INFORMATION**



Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of June 30, 2024, Alexandria has a total market capitalization of \$32.5 billion and an asset base in North America that includes 42.1 million RSF of operating properties and 5.3 million RSF of Class A/A+ properties undergoing construction and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For additional information on Alexandria, please visit www.are.com.

#### **Tenant base**

Alexandria is known for our high-quality and diverse tenant base, with 53% of our annual rental revenue being generated from tenants that are investment-grade rated or publicly traded large cap companies. The quality, diversity, breadth, and depth of our significant relationships with our tenants provide Alexandria with high-quality and stable cash flows. Alexandria's underwriting team and long-term industry relationships positively distinguish us from all other publicly traded REITs and real estate companies.

#### **Executive and senior management team**

Alexandria's executive and senior management team has unique experience and expertise in creating, owning, and operating highly dynamic and collaborative life science mega campuses in key cluster locations to catalyze innovation. From design to development to the management of our high-quality, sustainable real estate, as well as our ongoing cultivation of collaborative environments with unique amenities and events, the Alexandria team has a best-in-class reputation of excellence in life science real estate. Alexandria's highly experienced management team includes regional market directors with leading reputations and longstanding relationships within the life science communities in their respective innovation clusters. We believe that our experience, expertise, reputation, and key relationships in the real estate and life science industries provide Alexandria significant competitive advantages in attracting new business opportunities.

Alexandria's executive and senior management team consists of 64 individuals, averaging 23 years of real estate experience, including 13 years with Alexandria. Our executive management team alone averages 19 years with Alexandria.

## **EXECUTIVE MANAGEMENT TEAM**

Joel S. Marcus

Executive Chairman & Founder

Daniel J. Ryan

Co-President & Regional Market Director – San Diego

Marc E. Binda

Chief Financial Officer & Treasurer

Lawrence J. Diamond

Co-Chief Operating Officer & Regional Market Director – Maryland

Hart Cole

Executive Vice President – Capital Markets/Strategic Operations & Co-Regional Market Director – Seattle

Gary D. Dean

Executive Vice President – Real Estate Legal Affairs

Onn C. Lee

Executive Vice President – Accounting

Madeleine T. Alsbrook

Executive Vice President – Talent Management

Peter M. Moglia

Chief Executive Officer & Chief Investment Officer

Hunter L. Kass

Co-President & Regional Market Director – Greater Boston

Vincent R. Ciruzzi

Chief Development Officer

Joseph Hakman

Co-Chief Operating Officer & Chief Strategic Transactions Officer

Jackie B. Clem

General Counsel & Secretary

Andres R. Gavinet

**Chief Accounting Officer** 

Kristina A. Fukuzaki-Carlson

Executive Vice President – Business Operations

## **Investor Information**

June 30, 2024



**Corporate Headquarters** 

**New York Stock Exchange Trading Symbol** 

**Information Requests** 

26 North Euclid Avenue

Pasadena, California 91101

Common stock: ARE

(626) 578-0777 Email: corporateinformation@are.com

Phone:

www.are.com

Website: investor.are.com

**Equity Research Coverage** 

Alexandria is currently covered by the following research analysts. This list may be incomplete and is subject to change as firms initiate or discontinue coverage of our company. Please note that any opinions, estimates, or forecasts regarding our historical or predicted performance made by these analysts are theirs alone and do not represent opinions, estimates, or forecasts of Alexandria or our management. Alexandria does not by our reference or distribution of the information below imply our endorsement of or concurrence with any opinions, estimates, or forecasts of these analysts. Interested persons may obtain copies of analysts' reports on their own as we do not distribute these reports. Several of these firms may, from time to time, own our stock and/or hold other long or short positions in our stock and may provide compensated services to us.

	•	_	•••		_	
×	N		srin	20	-v:	ane

Nate Crossett / Monir Koummal (646) 342-1588 / (646) 342-1554

#### **BofA Securities**

Jeff Spector / Joshua Dennerlein (646) 855-1363 / (646) 855-1681

#### BTIG, LLC

Tom Catherwood / John Nickodemus (212) 738-6140 / (212) 738-6050

#### **CFRA**

Michael Elliott (646) 517-5742

#### Citigroup Global Markets Inc.

Nicholas Joseph / Michael Griffin (212) 816-1909 / (212) 816-5871

#### Citizens JMP Securities, LLC

Aaron Hecht (415) 835-3963

#### **Evercore ISI**

Steve Sakwa / James Kammert (212) 446-9462 / (312) 705-4233

#### **Green Street**

Dylan Burzinski (949) 640-8780

#### Jefferies Research Services, LLC

Peter Abramowitz / Ahmed Mehri (212) 336-7241 / (212) 778-8456

#### J.P. Morgan Securities LLC

Anthony Paolone / Ray Zhong (212) 622-6682 / (212) 622-5411

#### Mizuho Securities USA LLC

Vikram Malhotra / Georgi Dinkov (212) 282-3827 / (617) 352-1721

#### **RBC Capital Markets**

Michael Carroll / Aditi Balachandran (440) 715-2649 / (212) 428-6200

#### Robert W. Baird & Co. Incorporated

Wesley Golladay / Nicholas Thillman (216) 737-7510 / (414) 298-5053

#### Wedbush Securities

Richard Anderson / Jay Kornreich (212) 931-7001 / (212) 938-9942

#### **Fixed Income Research Coverage**

# **Barclays Capital Inc.** Srinjoy Banerjee / Japheth Otieno

(212) 526-3521 / (212) 526-6961

#### J.P. Morgan Securities LLC

Mark Streeter (212) 834-5086

Moody's Investors Service

(212) 553-0376

# **Rating Agencies S&P Global Ratings**

Alan Zigman (416) 507-2556

# **Financial and Asset Base Highlights**

June 30, 2024

(Dollars in thousands, except per share amounts)



	Three Months Ended (unless stated otherwise)								
	6/30/24	3/31/24	12/31/23	9/30/23	6/30/23				
Selected financial data from consolidated financial statements and related information									
Rental revenues	\$ 576,835 <sup>(1</sup>	<sup>1)</sup> \$ 581,400	\$ 561,428	\$ 526,352	\$ 537,889				
Tenant recoveries	\$ 178,327	\$ 174,151	\$ 181,209	\$ 181,179	\$ 166,450				
General and administrative expenses	\$ 44,629	\$ 47,055	\$ 59,289	\$ 45,987	\$ 45,882				
General and administrative expenses as a percentage of net operating income – trailing 12 months	9.2%	9.5%	9.8%	9.3%	9.7%				
Operating margin	72%	72%	71%	70%	70%				
Adjusted EBITDA margin	72%	72%	69%	69%	70%				
Adjusted EBITDA – quarter annualized	\$ 2,216,144	\$ 2,206,428	\$ 2,094,988	\$ 1,971,440	\$ 1,986,760				
Adjusted EBITDA – trailing 12 months	\$ 2,122,250	\$ 2,064,904	\$ 1,997,518	\$ 1,935,505	\$ 1,895,336				
Net debt at end of period	\$ 11,940,144	\$ 11,569,666	\$ 10,731,200	\$ 10,713,620	\$ 10,303,736				
Net debt and preferred stock to Adjusted EBITDA – quarter annualized	5.4x	5.2x	5.1x	5.4x	5.2x				
Net debt and preferred stock to Adjusted EBITDA – trailing 12 months	5.6x	5.6x	5.4x	5.5x	5.4x				
Total debt and preferred stock at end of period	\$ 12,424,055	\$ 12,217,163	\$ 11,315,642	\$ 11,202,835	\$ 11,183,363				
Gross assets at end of period	\$ 43,305,279	\$ 42,915,903	\$ 41,756,421	\$ 41,639,729	\$ 41,306,090				
Total debt and preferred stock to gross assets at end of period	29%	28%	27%	27%	27%				
Fixed-charge coverage ratio – quarter annualized	4.5x	4.7x	4.5x	4.8x	4.7x				
Fixed-charge coverage ratio – trailing 12 months	4.6x	4.7x	4.7x	4.9x	4.9x				
Unencumbered net operating income as a percentage of total net operating income	99.1%	99.3%	99.8%	99.8%	99.8%				
Closing stock price at end of period	\$ 116.97	\$ 128.91	\$ 126.77	\$ 100.10	\$ 113.49				
Common shares outstanding (in thousands) at end of period	172,018	172,008	171,911	170,997	170,870				
Total equity capitalization at end of period	\$ 20,120,907	\$ 22,173,547	\$ 21,793,107	\$ 17,116,784	\$ 19,392,011				
Total market capitalization at end of period	\$ 32,544,962	\$ 34,390,710	\$ 33,108,749	\$ 28,319,619	\$ 30,575,374				
Dividend per share – quarter/annualized	\$1.30/\$5.20	\$1.27/\$5.08	\$1.27/\$5.08	\$1.24/\$4.96	\$1.24/\$4.96				
Dividend payout ratio for the quarter	55%	54%	56%	55%	55%				
Dividend yield – annualized	4.4%	3.9%	4.0%	5.0%	4.4%				
Amounts related to operating leases:									
Operating lease liabilities at end of period	\$ 379,223	\$ 381,578	\$ 382,883	\$ 384,958	\$ 386,545				
Rent expense	\$ 9,412	\$ 8,683	\$ 8,964	\$ 8,317	\$ 8,518				
Capitalized interest	\$ 81,039	\$ 81,840	\$ 89,115	\$ 96,119	\$ 91,674				
Average real estate basis capitalized during the period	\$ 7,936,612	\$ 8,163,289	\$ 9,116,700	\$ 9,872,650	\$ 9,580,655				
Weighted-average interest rate for capitalization of interest during the period	3.96%	3.92%	3.92%	3.77%	3.77%				

<sup>(1)</sup> Decline in rental revenues from 1Q24 includes the temporary loss of revenues from 308,446 RSF at 311 Arsenal Street, which was placed into redevelopment during 1H24.

# **Financial and Asset Base Highlights (continued)**

June 30, 2024


(Dollars in thousands, except annual rental revenue per occupied RSF amounts)



	Three Months Ended (unless stated otherwise)									
		6/30/24	;	3/31/24	1	12/31/23	9/30/23			6/30/23
Amounts included in funds from operations and non-revenue-enhancing capital expenditures										
Straight-line rent revenue	\$	48,338	\$	48,251	\$	41,586	\$	29,805	\$	29,335
Amortization of acquired below-market leases	\$	22,515	\$	30,340	\$	23,684	\$	23,222	\$	24,789
Straight-line rent expense on ground leases	\$	341	\$	358	\$	366	\$	372	\$	373
Stock compensation expense	\$	14,507	\$	17,125	\$	34,592	\$	16,288	\$	15,492
Amortization of loan fees	\$	4,146	\$	4,142	\$	4,059	\$	4,059	\$	3,729
Amortization of debt discounts	\$	(328)	\$	(318)	\$	(309)	\$	(306)	\$	(304)
Non-revenue-enhancing capital expenditures:										
Building improvements	\$	4,210	\$	4,293	\$	4,167	\$	4,510	\$	4,376
Tenant improvements and leasing commissions	\$	15,724	\$	21,144	\$	12,155	\$	7,560	\$	38,587
Funds from operations attributable to noncontrolling interests	\$	78,711	\$	79,535	\$	75,908	\$	72,799	\$	71,988
Operating statistics and related information (at end of period)										
Number of properties – North America		408		410		411		419		414
RSF – North America (including development and redevelopment projects under construction)	4	7,085,993	4	7,206,639	47,228,485		47,089,826		46,408,793	
Total square feet – North America	7	4,103,404	7	4,069,321	7	73,532,305	7	75,057,289		74,854,150
Annual rental revenue per occupied RSF – North America	\$	56.87	\$	56.86	\$	56.08	\$	53.34	\$	53.09
Occupancy of operating properties – North America		94.6%		94.6%		94.6%		93.7%		93.6%
Occupancy of operating and redevelopment properties – North America		89.9%		90.2%		90.2%		89.4%		89.2%
Weighted-average remaining lease term (in years)		7.4		7.5		7.4		7.0		7.2
Total leasing activity – RSF		1,114,001		1,142,857		889,737		867,582		1,325,326
Lease renewals and re-leasing of space – change in average new rental rates over expiring rates:										
Rental rate increases		7.4%		33.0%		9.2%		28.8%		16.6%
Rental rate increases (cash basis)		3.7%		19.0%		5.5%		19.7%		8.3%
RSF (included in total leasing activity above)		589,650		994,770		477,142		396,334		1,052,872
Top 20 tenants:	•	005 754	•	000 005	•	700 000	•	055.000	•	200 000
Annual rental revenue	\$	805,751	\$	802,605	\$	769,066	\$	655,990	\$	629,362
Annual rental revenue from investment-grade or publicly traded large cap tenants		92%		92%		92%		91%		90%
Weighted-average remaining lease term (in years)		9.4		9.7		9.6		8.9		9.4
Same property – percentage change over comparable quarter from prior year:										
Net operating income increases		1.5%		1.0%		0.7%		3.1%		3.0%
Net operating income increases (cash basis)		3.9%		4.2%		0.8%		4.6%		4.9%



# Stable Cash Flows From Our High-Quality and Diverse Mix of Approximately 800 Tenants



Percentage of ARE's Annual Rental Revenue

Investment-Grade or Publicly Traded Large Cap Tenants

92%

of ARE's Top 20 Tenant Annual Rental Revenue

53%

of ARE's Annual Rental Revenue

As of June 30, 2024. Annual rental revenue represents amounts in effect as of June 30, 2024. Refer to "Definitions and reconciliations" in the Supplemental Information for additional details, including our methodology of calculating annual rental revenue from unconsolidated real estate joint ventures.

<sup>(1)</sup> Represents annual rental revenue generated from space that is currently targeted for a future change in use to laboratory space, including 1.0% of annual rental revenue that is generated from covered land play projects for future development opportunities. The weighted-average remaining term of these leases is 2.9 years.

<sup>(2)</sup> Represents the percentage of our annual rental revenue generated by "Other" tenants, which comprise technology, professional services, finance, telecommunications, and construction/real estate companies, and (by less than 1.0% of our annual rental revenue) retail-related tenants.



# Long-Duration and Stable Cash Flows From High-Quality and Diverse Tenants

Sustained Strength in Tenant Collections<sup>(1)</sup>

99.9%

99.7%

2Q24

July 2024

**Long-Duration Lease Terms** 

9.4 Years

7.4 Years

Top 20 Tenants

**All Tenants** 

Weighted-Average Remaining Term<sup>(2)</sup>

Represents the portion of total receivables billed for each period collected as of July 22, 2024.


<sup>(2)</sup> Based on annual rental revenue in effect as of June 30, 2024.



# Solid Historical Occupancy of 96% Over Past 10 Years<sup>(1)</sup> From Historically Strong Demand for Our Class A/A+ Properties in AAA Locations

# **Mega Campuses**

# **Occupancy Across Key Locations**




As of June 30, 2024. Annual rental revenue represents amounts in effect as of June 30, 2024. Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) Represents average occupancy of operating properties as of each December 31 from 2015 through 2023 and as of June 30, 2024.
- (2) Refer to footnote 1 under "Summary of occupancy" in "Summary of properties and occupancy" in the Supplemental Information for additional details.





# Rental Rate Growth: Renewed/Re-Leased Space





# Margins<sup>(1)</sup>

**Operating** 

**Adjusted EBITDA** 

72%

72%

Weighted-Average Lease Term of Executed Leases<sup>(3)</sup>

8.8 Years

# Favorable Lease Structure<sup>(2)</sup>

Strategic Lease Structure by Owner and Operator of Collaborative Life Science Mega Campuses

Increasing cash flows

Percentage of leases containing	96%
annual rent escalations	<b>30</b> /0

Stable cash flows

Percentage of triple	94%
net leases	<b>34</b> /0

Lower capex burden

Percentage of leases providing for the	93%
recapture of capital expenditures	<b>33</b> /0

Refer to "Same property performance" and "Definitions and reconciliations" in the Supplemental Information for additional details. "Definitions and reconciliations" contains the definition of "Net operating income" and its reconciliation from the most directly comparable financial measure presented in accordance with GAAP.

- (1) For the three months ended June 30, 2024.
- (2) Percentages calculated based on our annual rental revenue in effect as of June 30, 2024.
- (3) Represents the weighted-average lease term of executed leases for the 10-year period from December 31, 2015 through June 30, 2024.

# **Same Property Performance**

June 30, 2024

(Dollars in thousands)



	June 30	), 2024		June 30	), 2024
Same Property Financial Data	Three Months Ended	Six Months Ended	Same Property Statistical Data	Three Months Ended	Six Months Ended
Percentage change over comparable period from prior year:			Number of same properties	350	346
Net operating income increase	1.5%	1.1%	Rentable square feet	35,626,897	34,775,838
Net operating income increase (cash basis)	3.9%	3.7%	Occupancy – current-period average	94.6%	94.2%
Operating margin	70%	70%	Occupancy – same-period prior-year average	94.4%	94.6%

	Three Months Ended June 30,							Six Months Ended June 30,						
		2024		2023	\$	Change	% Change		2024		2023	\$	Change	% Change
Income from rentals:														
Same properties	\$	464,917	\$	454,603	\$	10,314	2.3%	\$	910,423	\$	893,008	\$	17,415	2.0%
Non-same properties		111,918		83,286		28,632	34.4		247,812		163,183		84,629	51.9
Rental revenues		576,835		537,889		38,946	7.2		1,158,235		1,056,191		102,044	9.7
Same properties		156,945		153,802		3,143	2.0		311,894		303,702		8,192	2.7
Non-same properties		21,382		12,648		8,734	69.1		40,584		32,395		8,189	25.3
Tenant recoveries		178,327		166,450		11,877	7.1		352,478		336,097		16,381	4.9
Income from rentals		755,162		704,339		50,823	7.2		1,510,713		1,392,288		118,425	8.5
Same properties		377		300		77	25.7		715		737		(22)	(3.0)
Non-same properties		11,195		9,261		1,934	20.9		24,414		21,670		2,744	12.7
Other income		11,572		9,561		2,011	21.0		25,129		22,407		2,722	12.1
Same properties		622,239		608,705		13,534	2.2		1,223,032		1,197,447		25,585	2.1
Non-same properties		144,495		105,195		39,300	37.4		312,810		217,248		95,562	44.0
Total revenues		766,734		713,900		52,834	7.4		1,535,842	_	1,414,695		121,147	8.6
Same properties		185,721		178,544		7,177	4.0		366,985		350,672		16,313	4.7
Non-same properties		31,533		33,290		(1,757)	(5.3)		68,583		68,095		488	0.7
Rental operations		217,254		211,834		5,420	2.6		435,568		418,767		16,801	4.0
Same properties		436,518		430,161		6,357	1.5		856,047		846,775		9,272	1.1
Non-same properties		112,962		71,905		41,057	57.1		244,227		149,153		95,074	63.7
Net operating income	\$	549,480	\$	502,066	\$	47,414	9.4%	\$	1,100,274	\$	995,928	\$	104,346	10.5%
Net operating income – same properties	\$	436,518	\$	430,161	\$	6,357	1.5%	\$	856,047	\$	846,775	\$	9,272	1.1%
Straight-line rent revenue		(17,856)		(26,981)		9,125	(33.8)		(32,773)		(51,793)		19,020	(36.7)
Amortization of acquired below-market leases		(15,910)		(15,619)		(291)	1.9		(30,910)		(30,758)		(152)	0.5
Net operating income – same properties (cash basis)	\$	402,752	\$	387,561	\$	15,191	3.9%	\$	792,364	\$	764,224	\$	28,140	3.7%

Refer to "Same property comparisons" under "Definitions and reconciliations" in the Supplemental Information for additional details, including a reconciliation of same properties to total properties. "Definitions and reconciliations" also contains definitions of "Tenant recoveries" and "Net operating income" and their respective reconciliations from the most directly comparable financial measures presented in accordance with GAAP.

# **Leasing Activity**

June 30, 2024 (Dollars per RSF)



	Three Months June 30, 2		Six Months June 30,		Year Ended December 31, 2023			
	Including Straight-Line Rent	Cash Basis	Including Straight-Line Rent	Cash Basis	Including Straight-Line Rent	Cash Basis		
Leasing activity:								
Renewed/re-leased space <sup>(1)</sup>								
Rental rate changes	<b>7.4%</b> (2)	<b>3.7%</b> <sup>(2)</sup>	26.2%	15.0%	29.4%	15.8%		
New rates	\$46.56	\$47.92	\$69.43	\$68.20	\$52.35	\$50.82		
Expiring rates	\$43.34	\$46.23	\$55.02	\$59.32	\$40.46	\$43.87		
RSF	589,650		1,584,420		3,046,386			
Tenant improvements/leasing commissions	\$31.83		\$25.32		\$26.09			
Weighted-average lease term	4.4 years		8.0 years		8.7 years			
Developed/redeveloped/previously vacant space leased <sup>(3)</sup>								
New rates	\$67.96	\$65.59	\$68.85	\$66.73	\$65.66	\$59.74		
RSF	524,351		672,438		1,259,686			
Weighted-average lease term	7.4 years		7.2 years		13.8 years			
Leasing activity summary (totals):								
New rates	\$57.55	\$56.99	\$69.26	\$67.78	\$56.09	\$53.33		
RSF	1,114,001		2,256,858		4,306,072			
Weighted-average lease term	6.6 years		7.7 years		11.3 years			
Lease expirations <sup>(1)</sup>								
Expiring rates	\$46.19	\$48.02	\$52.27	\$55.24	\$43.84	\$45.20		
RSF	888,415		2,301,346		5,027,773			

Leasing activity includes 100% of results for properties in North America in which we have an investment.

<sup>(1)</sup> Excludes month-to-month leases aggregating 129,549 RSF and 86,092 RSF as of June 30, 2024 and December 31, 2023, respectively. During the trailing twelve months ended June 30, 2024, we granted free rent concessions averaging 0.8 months per annum.

<sup>(2)</sup> Includes one renewal aggregating 34,611 RSF in our Greater Stanford submarket. Excluding this renewal, rental rate changes for 2Q24 were 13.6% and 9.1% (cash basis). Rental rate changes can experience volatility from quarter to quarter based on the volume and mix of leases executed. Refer to "Guidance" in the Earnings Press Release for rental rate changes expected from leases executed for the year ending December 31, 2024.

<sup>(3)</sup> Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" in the Supplemental Information for additional details, including total project costs.



Year	(0)		ental Revenue er RSF) <sup>(1)</sup>	Percentage of Annual Rental Revenue
2024 <sup>(2)</sup>	1,629,725	4.1%	\$ 52.61	3.9%
2025	3,969,159	10.1%	\$ 52.32	9.4%
2026	2,741,258	6.9%	\$ 52.81	6.6%
2027	3,155,424	8.0%	\$ 52.84	7.6%
2028	4,697,787	11.9%	\$ 51.91	11.1%
2029	2,519,629	6.4%	\$ 51.26	5.9%
2030	2,732,244	6.9%	\$ 46.39	5.8%
2031	3,655,986	9.3%	\$ 54.89	9.1%
2032	1,078,558	2.7%	\$ 59.67	2.9%
2033	2,872,541	7.3%	\$ 51.57	6.7%
Thereafter	10,398,273	26.4%	\$ 65.96	31.0%

2024 Contractual Lease Expirations (in RSF)

Targeted for Future

2025 Contractual Lease Expirations (in RSF)

			Development/Re	edevelopment <sup>(3)</sup>										
Market	Leased	Negotiating/ Anticipating	Committed Near-Term/ Priority Anticipated	Future	Remaining Expiring Leases <sup>(4)</sup>	Total <sup>(2)</sup>	Annual Rental Revenue (per RSF) <sup>(1)</sup>	Leased	Negotiating/ Anticipating	Targeted for Future Development/ Redevelopment <sup>(3)</sup>	Remaining Expiring Leases <sup>(5)</sup>	Total	R Re	nnual lental evenue · RSF) <sup>(1)</sup>
Greater Boston	14,075	57,179	_	104,500	210,588	386,342	\$ 78.66	44,332	38,705	25,312	890,639 <sup>(6)</sup>	998,988	\$	78.18
San Francisco Bay Area	_	58,517	107,250	_	252,300	418,067	55.48	35,797	83,980	_	491,082	610,859		71.91
San Diego	27,119	_	_	226,144	17,408	270,671	29.33	22,324	28,854	269,048	257,832	578,058		27.46
Seattle	18,107	_	_	_	111,263	129,370	20.78	_	14,058	50,552	215,294	279,904		31.76
Maryland	_	_	_	_	10,919	10,919	5.62	35,055	_	_	185,357	220,412		28.41
Research Triangle	_	10,478	_	_	18,439	28,917	37.70	_	_	_	320,957	320,957		51.34
New York City	_	5,896	_	_	355,792 <sup>(7)</sup>	361,688	53.71	_	_	_	67,215	67,215		106.25
Texas	_	_	_	_	_	_	_	_	357,136	198,972	247,246	803,354		36.27
Canada	13,321	_	_	_	_	13,321	26.58	_	_	_	88,412	88,412		20.31
Non-cluster/other markets					10,430	10,430	57.02				1,000	1,000		49.20
Total	72,622	132,070	107,250	330,644	987,139	1,629,725	\$ 52.61	137,508	522,733	543,884	2,765,034	3,969,159	\$	52.32
Percentage of expiring leases	4%	8%	7%	20%	61%	100%		3%	13%	14%	70%	100%		

- 1) Represents amounts in effect as of June 30, 2024.
- (2) Excludes month-to-month leases aggregating 129,549 RSF as of June 30, 2024.
- Primarily represents assets that were recently acquired for future value-creation opportunities, for which we expect, subject to market conditions and leasing, to commence first-time conversion from non-laboratory space to laboratory space, or to commence future ground-up development. As of June 30, 2024, annual rental revenue from these leases expiring in 2024 and 2025 is \$42.98 per RSF and \$32.71 per RSF, respectively. The weighted-average expiration date of these leases expiring in 2024 and 2025 is September 29, 2024 and January 12, 2025, respectively. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including value-creation square feet currently included in rental properties.
- (4) Excluding the expiration described in footnote 7, the largest remaining contractual lease expiration in 2024 is 97,702 RSF in our Mission Bay submarket, where we are working to retain the current tenant.
- (5) Key remaining expiring leases in 2025 include 600,477 RSF in three submarkets with a weighted-average expiration date of February 1, 2025 and annual rental revenue as of June 30, 2024 aggregating approximately \$37 million comprised of the following: (i) 248,700 RSF at our Alexandria Technology Square® mega campus in our Cambridge submarket, of which 171,945 RSF is expected to be repositioned from single-tenancy to multi-tenancy, and we are evaluating options to reposition the remaining 76,755 RSF; (ii) 247,246 RSF of industrial and R&D space in our Austin submarket for which we are evaluating options to market for re-lease or reposition the space; and (iii) 104,531 RSF in our Research Triangle market that is currently being marketed for re-lease. We expect downtime on these spaces to range from 12 to 24 months on a weighted average basis.
- (6) Includes 816,048 RSF of contractual lease expirations in our Cambridge/Inner Suburbs submarket. Refer to footnote 5 for additional details.
- (7) Includes 349,947 RSF at 219 East 42nd Street that was classified as held for sale as of June 30, 2024 and was sold in July 2024.



Investment Cuada

# 92% of Top 20 Tenant Annual Rental Revenue Is From Investment-Grade or Publicly Traded Large Cap Tenants<sup>(1)</sup>

		Remaining Lease	A	Annual Rental	Percentage of Annual Rental	Investme Credit F	nt-Grade Ratings	Average rket Cap <sup>(1)</sup>
	Tenant	Term <sup>(1)</sup> (in years)	Aggregate RSF	Revenue <sup>(1)</sup>	Revenue <sup>(1)</sup>	Moody's	S&P	billions)
1	Moderna, Inc.	12.9	1,385,536	\$ 127,122	5.7%		_	\$ 40.5
2	Eli Lilly and Company	8.6	1,134,349	92,931	4.2	A2	A+	\$ 620.0
3	Bristol-Myers Squibb Company	6.6	999,379	76,363	3.4	A2	A+	\$ 107.4
4	Takeda Pharmaceutical Company Limited	10.9	549,759	47,899	2.2	Baa2	BBB+	\$ 45.4
5	Roche	5.8	770,279	45,888	2.1	Aa2	AA	\$ 224.0
6	Illumina, Inc.	6.6	955,669	41,588	1.9	Baa3	BBB	\$ 21.4
7	Alphabet Inc.	3.0	724,223	39,155	1.8	Aa2	AA+	\$ 1,805.5
8	2seventy bio, Inc. (2)	9.2	312,805	33,543	1.5	_	_	\$ 0.2
9	Novartis AG	4.1	450,563	30,969	1.4	A1	AA-	\$ 227.3
10	Harvard University	6.3	343,858	28,872	1.3	Aaa	AAA	\$ 
11	Cloud Software Group, Inc.	2.7 (3)	292,013	28,537	1.3	_	_	\$ 
12	United States Government	6.1	429,359	28,491	1.3	Aaa	AA+	\$ 
13	Uber Technologies, Inc.	58.3 <sup>(4)</sup>	1,009,188	27,765	1.3	_	_	\$ 123.5
14	AstraZeneca PLC	5.3	450,848	27,156	1.2	A3	Α	\$ 213.0
15	Pfizer Inc.	0.7 (5)	504,716	23,730	1.1	A1	A+	\$ 171.0
16	Sanofi	6.5	267,278	21,444	1.0	A1	AA	\$ 126.0
17	Merck & Co., Inc.	9.0	337,703	21,401	1.0	A1	A+	\$ 293.8
18	Amgen Inc.	8.5	428,227	21,314	1.0	Baa1	_	\$ 148.0
19	New York University	7.6	218,983	21,056	0.9	Aa2	AA-	\$ 
20	Massachusetts Institute of Technology	5.0	246,725	20,527	0.9	Aaa	AAA	\$ _
	Total/weighted-average	9.4 (4)	11,811,460	\$ 805,751	36.5%			

Annual rental revenue and RSF include 100% of each property managed by us in North America. Refer to "Annual rental revenue" and "Investment-grade or publicly traded large cap tenants" under "Definitions and reconciliations" in the Supplemental Information for additional details, including our methodology of calculating annual rental revenue from unconsolidated real estate joint ventures and average market capitalization, respectively.

<sup>(1)</sup> Based on annual rental revenue in effect as of June 30, 2024.

<sup>(2)</sup> As of March 31, 2024, 2seventy bio, Inc. held \$181.4 million of cash, cash equivalents, and marketable securities. In March 2024, Regeneron Pharmaceuticals, Inc., a publicly traded biotechnology company with investment-grade credit ratings of Baa1 and BBB+ assigned by Moody's and S&P, respectively, entered into a sublease for approximately 195,000 RSF, or 69.6% of our annual rental revenue generated from 2seventy bio as of June 30, 2024. Additionally, 90.2% of the annual rental revenue generated by 2seventy bio is guaranteed by another related public biotechnology company.

<sup>(3)</sup> Consists of one lease at a property acquired in 2022 with future development and redevelopment opportunities. This lease with Cloud Software Group, Inc. (formerly known as TIBCO Software, Inc.) was in place when we acquired the property.

<sup>(4)</sup> Includes (i) ground leases for land at 1455 and 1515 Third Street (two buildings aggregating 422,980 RSF) and (ii) leases at 1655 and 1725 Third Street (two buildings aggregating 586,208 RSF) in our Mission Bay submarket owned by our unconsolidated real estate joint venture in which we have an ownership interest of 10%. Annual rental revenue is presented using 100% of the annual rental revenue from our unconsolidated real estate joint ventures. Refer to footnote 1 for additional details. Excluding these ground leases, the weighted-average remaining lease term for our top 20 tenants was 8.0 years as of June 30, 2024.

<sup>5)</sup> Primarily relates to one office building in our New York City submarket aggregating 349,947 RSF with a contractual lease expiration in July 2024, which was classified as held for sale as of June 30, 2024 and sold in July 2024.

# **Summary of Properties and Occupancy**

June 30, 2024

(Dollars in thousands, except per RSF amounts)



### **Summary of properties**

			RSF			Number of		Annı	ıal Rental Rev	enue	
Market	Operating	Development	Redevelopment	Total	% of Total	Properties		Total	% of Total	Pe	er RSF
Greater Boston	10,751,016	764,036	1,638,878 (1	13,153,930	28%	73	\$	848,799	38%	\$	83.84
San Francisco Bay Area	7,863,964	498,142	282,054	8,644,160	18	66		449,633	20		65.52
San Diego	7,757,132	1,186,104	_	8,943,236	19	88		328,872	15		44.60
Seattle	3,188,135	31,270	34,306	3,253,711	7	44		138,136	6		45.73
Maryland	3,804,438	292,946	_	4,097,384	9	51		135,978	6		37.45
Research Triangle	3,923,169	_	_	3,923,169	8	40		123,315	6		32.27
New York City	922,477	_	_	922,477	2	4		72,885	3		92.89
Texas	1,845,159	_	73,298	1,918,457	4	15		57,830	3		32.83
Canada	933,660	_	139,311	1,072,971	2	12		20,353	1		22.98
Non-cluster/other markets	347,806	_	_	347,806	1	10		15,180	1		57.70
Properties held for sale	808,692	_	_	808,692	2	5		25,994	1		N/A
North America	42,145,648	2,772,498	2,167,847	47,085,993	100%	408	\$	2,216,975	100%	\$	56.87
		4,94	0,345				_				

<sup>(1)</sup> Primarily includes our active redevelopment projects aggregating 716,604 RSF at 40, 50, and 60 Sylvan Road and 840 Winter Street located on the Alexandria Center® for Life Science – Waltham mega campus, which are 43% leased/negotiating on a combined basis. This mega campus project is expected to capture demand in our Route 128 submarket.

## **Summary of occupancy**

	Op	perating Properties		Operating and Redevelopment Properties				
Market	6/30/24	3/31/24	6/30/23	6/30/24	3/31/24	6/30/23		
Greater Boston	94.2%	94.5%	92.5%	81.7%	83.3%	83.2%		
San Francisco Bay Area	94.0	94.4	95.5	90.7	91.2	91.9		
San Diego	95.1	95.2	92.8	95.1	95.2	92.8		
Seattle	94.7	94.9	95.1	93.7	93.9	89.5		
Maryland	96.5	95.4	96.2	96.5	95.4	94.9		
Research Triangle	97.4	97.8	94.3	97.4	97.8	94.3		
New York City	85.1 <sup>(1)</sup>	84.4	88.9	85.1	84.4	88.9		
Texas	95.5	95.1	95.1	91.8	91.5	91.0		
Subtotal	94.7	94.9	93.8	90.2	90.6	89.8		
Canada	94.9	91.8	87.3	82.5	77.8	69.2		
Non-cluster/other markets	75.6	75.4	81.3	75.6	75.4	81.3		
North America	94.6%	94.6%	93.6%	89.9%	90.2%	89.2%		

<sup>(1)</sup> The Alexandria Center<sup>®</sup> for Life Science – New York City mega campus is 95.5% occupied as of June 30, 2024. Occupancy percentage in our New York City market reflects vacancy at the Alexandria Center<sup>®</sup> for Life Science – Long Island City property, which was 41.7% occupied as of June 30, 2024.



# Mega Campuses Encompass 74% of Our Annual Rental Revenue

	Por					Annual	Occupancy Percentage		
Market / Submarket / Address	Onevetina		RSF Redevelopment	Total	Number of	Rental	Onevetina	Operating and	
Warket / Submarket / Address	Operating	Development	Redevelopment	Total	Properties	Revenue	Operating	Redevelopment	
Greater Boston									
Cambridge/Inner Suburbs									
Mega Campus: Alexandria Center® at Kendall Square	2,856,042	_	_	2,856,042	11	\$ 279,665	99.7%	99.7%	
50 <sup>(1)</sup> , 60 <sup>(1)</sup> , 75/125 <sup>(1)</sup> , 100 <sup>(1)</sup> , and 225 <sup>(1)</sup> Binney Street, 140 and 215 First Street, 150 Second Street, 300 Third Street <sup>(1)</sup> , 11 Hurley Street, and 100 Edwin H. Land Boulevard									
Mega Campus: Alexandria Center® at One Kendall Square	1,370,401	_	_	1,370,401	12	143,806	85.2	85.2	
One Kendall Square (Buildings 100, 200, 300, 400, 500, 600/700, 1400, 1800, and 2000), 325 and 399 Binney Street, and One Hampshire Street <sup>(2)</sup>									
Mega Campus: Alexandria Technology Square® 100, 200, 300, 400, 500, 600, and 700 Technology Square	1,185,284	_	_	1,185,284	7	116,345	100.0	100.0	
Mega Campus: The Arsenal on the Charles	702,623	109,481	308,446	1,120,550	13	56,034	100.0	69.5	
311, 321, and 343 Arsenal Street, 300, 400, and 500 North Beacon Street, 1, 2, 3, and 4 Kingsbury Avenue, and 100, 200, and 400 Talcott Avenue									
Mega Campus: 480 Arsenal Way and 446, 458, 500, and 550 Arsenal Street	517,442	_	_	517,442	5	24,993	96.7	96.7	
99 Coolidge Avenue <sup>(1)</sup>	116,414	204,395	_	320,809	1	15,265	100.0	100.0	
Cambridge/Inner Suburbs	6,748,206	313,876	308,446	7,370,528	49	636,108	96.6	92.4	
Fenway									
Mega Campus: Alexandria Center® for Life Science – Fenway 401 and 421 <sup>(1)</sup> Park Drive and 201 Brookline Avenue <sup>(1)</sup>	1,218,257	450,160	159,959	1,828,376	3	93,450	89.3	78.9	
Seaport Innovation District 5 and 15 <sup>(1)</sup> Necco Street	444 206			441.396	2	39,570	75.7	75.7	
	441,396			,	2				
Seaport Innovation District Route 128	441,396	_	_	441,396	2	39,570	75.7	75.7	
Mega Campus: Alexandria Center® for Life Science – Waltham	326.110		716.604	1,042,714	5	23,198	100.0	31.3	
40, 50, and 60 Sylvan Road, 35 Gatehouse Drive, and 840 Winter Street	320,110	_	710,004	1,042,714	3	23,190	100.0	31.3	
Mega Campus: One Moderna Way	721,988	_	_	721,988	4	31,135	100.0	100.0	
19, 225, and 235 Presidential Way	585,226	_	_	585,226	3	14,474	100.0	100.0	
Route 128	1,633,324		716,604	2,349,928	12	68,807	100.0	69.3	
Other	709,833	_	453,869	1,163,702	7	10,864	77.2	47.1	
Greater Boston	10,751,016	764,036	1,638,878	13,153,930	73	\$ 848,799	94.2%	81.7%	

We own a partial interest in this property through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details. Subject to market conditions and leasing, we may consider options to redevelop our One Hampshire Street property into new Class A+ laboratory space.

June 30, 2024

(Dollars in thousands)



				Annual	Occupancy Percentage			
Market / Submarket / Address	Operating	Development	RSF Redevelopment	Total	Number of Properties	Rental Revenue	Operating	Operating and Redevelopment
	Operating	Development	Redevelopment	Total	Properties	Revenue	Operating	Redevelopment
San Francisco Bay Area								
Mission Bay								
Mega Campus: Alexandria Center <sup>®</sup> for Science and Technology – Mission Bay <sup>(1)</sup>	2,009,054	212,796	_	2,221,850	10	\$ 91,820	95.2%	95.2%
1455 <sup>(2)</sup> , 1515 <sup>(2)</sup> , 1655, and 1725 Third Street, 409 and 499 Illinois Street, 1450, 1500, and 1700 Owens Street, and 455 Mission Bay Boulevard South								
Mission Bay	2,009,054	212,796		2,221,850	10	91,820	95.2	95.2
South San Francisco								
Mega Campus: Alexandria Technology Center® – Gateway <sup>(1)</sup> 600 <sup>(2)</sup> , 601, 611, 630 <sup>(2)</sup> , 650 <sup>(2)</sup> , 651, 681, 685, 701, 751, 901 <sup>(2)</sup> , and 951 <sup>(2)</sup> Gateway Boulevard	1,386,971	_	282,054	1,669,025	12	72,964	82.5	68.5
Mega Campus: Alexandria Center <sup>®</sup> for Advanced Technologies – South San Francisco	919,703	_	_	919,703	5	57,788	100.0	100.0
213 <sup>(1)</sup> , 249, 259, 269, and 279 East Grand Avenue								
Alexandria Center <sup>®</sup> for Life Science – South San Francisco 201 Haskins Way and 400 and 450 East Jamie Court	503,388	_	_	503,388	3	32,134	92.2	92.2
Mega Campus: Alexandria Center <sup>®</sup> for Advanced Technologies – Tanforan 1122 and 1150 El Camino Real	445,232	_	_	445,232	2	4,020	100.0	100.0
Alexandria Center <sup>®</sup> for Life Science – Millbrae <sup>(1)</sup> 230 Harriet Tubman Way	_	285,346	_	285,346	1	_	N/A	N/A
500 Forbes Boulevard <sup>(1)</sup>	155,685	_	_	155,685	1	10,680	100.0	100.0
South San Francisco	3.410.979	285,346	282,054	3,978,379	24	177,586	91.7	84.7
Greater Stanford	0, 0, 0 . 0	200,0.0	_0_,00.	0,0.0,0.0		,000	· · · ·	· · · ·
Mega Campus: Alexandria Center <sup>®</sup> for Life Science – San Carlos 825, 835, 960, and 1501-1599 Industrial Road	739,157	_	_	739,157	9	49,891	97.4	97.4
Alexandria Stanford Life Science District	703,843	_	_	703,843	9	65.462	97.4	97.4
3160, 3165, 3170, and 3181 Porter Drive and 3301, 3303, 3305, 3307, and 3330 Hillview Avenue						,		
3412, 3420, 3440, 3450, and 3460 Hillview Avenue	340,103	_	_	340,103	5	23,610	82.9	82.9
3875 Fabian Way	228,000	_	_	228,000	1	9,402	100.0	100.0
2475 and 2625/2627/2631 Hanover Street and 1450 Page Mill Road	193,688	_	_	193,688	3	18,032	100.0	100.0
2100, 2200, and 2400 Geng Road	78,501	_	_	78,501	3	4,803	100.0	100.0
2425 Garcia Avenue/2400/2450 Bayshore Parkway	99,208	_	_	99,208	1	4,257	100.0	100.0
3350 West Bayshore Road	61,431	_	_	61,431	1	4,770	100.0	100.0
Greater Stanford	2,443,931			2,443,931	32	180,227	96.1	96.1
San Francisco Bay Area	7,863,964	498.142	282,054	8,644,160	66	\$ 449.633	94.0%	90.7%

We own a partial interest in this property through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details. We own 100% of this property.

June 30, 2024

(Dollars in thousands)



						Annual	Occupancy Percentage		
			RSF	=	Number of	Rental		Operating and	
Market / Submarket / Address	Operating	Development	Redevelopment	Total	Properties	Revenue	Operating	Redevelopment	
San Diego									
Torrey Pines									
Mega Campus: One Alexandria Square	748,573	334,996	_	1,083,569	10	\$ 47,330	99.9%	99.9%	
3115 and 3215 <sup>(1)</sup> Merryfield Row, 3010, 3013, and 3033 Science Park Road, 10935, 10945, and 10955 Alexandria Way, 10975 North Torrey Pines Road, and 10996 Torreyana Road, and 3545 Cray Court									
ARE Torrey Ridge 10578, 10618, and 10628 Science Center Drive	296,290	_	_	296,290	3	14,045	85.8	85.8	
ARE Nautilus	218,459	_	_	218,459	4	12,743	86.3	86.3	
3530 and 3550 John Hopkins Court and 3535 and 3565 General Atomics Court									
Torrey Pines	1,263,322	334,996		1,598,318	17	74,118	94.3	94.3	
University Town Center									
Mega Campus: Campus Point by Alexandria <sup>(1)</sup>	1,666,590	598,029	_	2,264,619	13	78,609	99.0	99.0	
9880 <sup>(2)</sup> , 10010 <sup>(2)</sup> , 10140 <sup>(2)</sup> , 10210, 10260, 10290, and 10300 Campus Point Drive and 4135, 4155, 4161, 4224, 4242, and 4275 <sup>(2)</sup> Campus Point Court									
Mega Campus: 5200 Illumina Way <sup>(1)</sup>	792,687	_	_	792,687	6	29,978	100.0	100.0	
ARE Esplanade	243,084	_	_	243,084	4	10,407	74.6	74.6	
4755, 4757, and 4767 Nexus Center Drive and 4796 Executive Drive									
9625 Towne Centre Drive <sup>(1)</sup>	163,648	_	_	163,648	1	6,520	100.0	100.0	
Costa Verde by Alexandria	8,730	_	_	8,730	2	879	100.0	100.0	
8505 Costa Verde Boulevard and 4260 Nobel Drive									
University Town Center	2,874,739	598,029		3,472,768	26	126,393	97.3	97.3	
Sorrento Mesa									
Mega Campus: SD Tech by Alexandria <sup>(1)</sup>	1,066,607	253,079	_	1,319,686	15	41,227	87.1	87.1	
9605, 9645, 9675, 9685, 9725, 9735, 9808, 9855, and 9868 Scranton Road, 5505 Morehouse Drive <sup>(2)</sup> , and 10055, 10065, 10075, 10121 <sup>(2)</sup> , and 10151 <sup>(2)</sup> Barnes Canyon Road									
Mega Campus: Sequence District by Alexandria 6260, 6290, 6310, 6340, 6350, 6420, and 6450 Sequence Drive	801,575	_	_	801,575	7	28,766	100.0	100.0	
Pacific Technology Park <sup>(1)</sup>	544,352	_	_	544,352	5	8,936	89.1	89.1	
9389, 9393, 9401, 9455, and 9477 Waples Street	0,002			0,002	· ·	0,000			
Summers Ridge Science Park <sup>(1)</sup>	316,531	_	_	316,531	4	11,521	100.0	100.0	
9965, 9975, 9985, and 9995 Summers Ridge Road	,			,		,-			
Scripps Science Park by Alexandria 10102 Hoyt Park Drive	144,113	_	_	144,113	1	11,379	100.0	100.0	
ARE Portola	101,857			101,857	3	4,022	100.0	100.0	
6175, 6225, and 6275 Nancy Ridge Drive	101,037	_	_	101,007	3	4,022	100.0	100.0	
5810/5820 Nancy Ridge Drive	83,354		_	83,354	1	4,581	100.0	100.0	
9877 Waples Street	63,774	_	_	63,774	1	<del>-</del> ,501	100.0	100.0	
5871 Oberlin Drive	33.842	_	_	33,842	1	1,909	100.0	100.0	
Sorrento Mesa	3,156,005	253,079		3,409,084	38	\$ 112,341	93.5%	93.5%	
CONTONIO IVICCA	5, 150,005	200,019	_	5,705,004	30	Ψ 112,041	JJ.J /0	33.370	

Refer to "New Class A/A+ development and redevelopment properties: summary of pipeline" and "Definitions and reconciliations" in the Supplemental Information for additional details.

2) We own 100% of this property.

<sup>(1)</sup> We own a partial interest in this property through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

June 30, 2024

(Dollars in thousands)



			205			Annual	Occupancy Percentage		
Market / Submarket / Address	Operating	Development	RSF Redevelopment	Total	Number of Properties	Rental Revenue	Operating	Operating and Redevelopment	
San Diego (continued)									
Sorrento Valley									
3911, 3931, and 3985 Sorrento Valley Boulevard	108,812	_	_	108,812	3	\$ 3,782	68.5 %	68.5 %	
11045 and 11055 Roselle Street	43,233	_	_	43,233	2	2,273	100.0	100.0	
Sorrento Valley	152,045			152,045	5	6,055	89.3	89.3	
Other	311,021	_	_	311,021	2	9,965	100.0	100.0	
San Diego	7,757,132	1,186,104		8,943,236	88	328,872	95.1	95.1	
Seattle									
Lake Union									
Mega Campus: Alexandria Center® for Life Science – Eastlake	1,218,025	31,270	_	1,249,295	9	81,129	95.7	95.7	
1150, 1165, 1201 <sup>(1)</sup> , 1208 <sup>(1)</sup> , 1551, and 1616 Eastlake Avenue East, 188 and 199 <sup>(1)</sup> East Blaine Street, and 1600 Fairview Avenue East									
Mega Campus: Alexandria Center <sup>®</sup> for Life Science – South Lake Union 400 Dexter Avenue North <sup>(1)</sup>	290,754	_	_	290,754	1	17,856	100.0	100.0	
219 Terry Avenue North	33,242	_	_	33,242	1	614	92.7	92.7	
Lake Union	1,542,021	31,270		1,573,291	11	99,599	96.5	96.5	
SoDo									
830 4th Avenue South	42,380	_	_	42,380	1	698	32.1	32.1	
Elliott Bay									
410 West Harrison Street and 410 Elliott Avenue West	36,848	_	_	36,848	2	675	54.6	54.6	
Bothell									
Mega Campus: Alexandria Center <sup>®</sup> for Advanced Technologies – Canyon Park	1,061,184	_	_	1,061,184	22	23,933	94.7	94.7	
22121 and 22125 17th Avenue Southeast, 22021, 22025, 22026, 22030, 22118, and 22122 20th Avenue Southeast, 22333, 22422, 22515, 22522, 22722, and 22745 29th Drive Southeast, 21540, 22213 and 22309 30th Drive Southeast, and 1629, 1631, 1725, 1916, and 1930 220th Street Southeast									
Alexandria Center <sup>®</sup> for Advanced Technologies – Monte Villa Parkway 3301, 3303, 3305, 3307, 3555, and 3755 Monte Villa Parkway	429,143	_	34,306	463,449	6	12,415	97.5	90.3	
Bothell	1,490,327	_	34,306	1,524,633	28	36,348	95.5	93.3	
Other	76,559	_	· —	76,559	2	816	100.0	100.0	
Seattle	3,188,135	31,270	34,306	3,253,711	44	\$ 138,136	94.7%	93.7%	

<sup>(1)</sup> We own a partial interest in this property through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

June 30, 2024

(Dollars in thousands)



	RSF					Annual Rental	Occupancy Percentage Operating and		
Market / Submarket / Address	Operating	Development	Redevelopment	Total	Number of Properties	Revenue	Operating	Redevelopment	
Maryland									
Rockville									
Mega Campus: Alexandria Center® for Life Science – Shady Grove	1,399,020	292,946	_	1,691,966	20	\$ 63,991	99.1%	99.1%	
9601, 9603, 9605, 9704, 9708, 9712, 9714, 9800, 9804, 9808, 9900, and 9950 Medical Center Drive, 14920 and 15010 Broschart Road, 9920 Belward Campus Drive, and 9810 and 9820 Darnestown Road									
1330 Piccard Drive	131,508	_	_	131,508	1	4,210	100.0	100.0	
1405 and 1450 <sup>(1)</sup> Research Boulevard	114,849	_	_	114,849	2	3,029	73.3	73.3	
1500 and 1550 East Gude Drive	91,359	_	_	91,359	2	1,844	100.0	100.0	
5 Research Place	63,852	_	_	63,852	1	3,073	100.0	100.0	
5 Research Court	51,520	_	_	51,520	1	1,779	100.0	100.0	
12301 Parklawn Drive	49,185	_	_	49,185	1	1,598	100.0	100.0	
Rockville	1,901,293	292,946		2,194,239	28	79,524	97.8	97.8	
Gaithersburg		•		, ,		,			
Alexandria Technology Center® – Gaithersburg I	619,241	_	_	619,241	9	19,483	93.1	93.1	
9, 25, 35, 45, 50, and 55 West Watkins Mill Road and 910, 930, and 940 Clopper Road				,		,			
Alexandria Technology Center® – Gaithersburg II	486,301	_	_	486,301	7	18,788	100.0	100.0	
700, 704, and 708 Quince Orchard Road and 19, 20, 21, and 22 Firstfield Road									
20400 Century Boulevard	81,006	_	_	81,006	1	3,340	100.0	100.0	
401 Professional Drive	63,154	_	_	63,154	1	1,931	100.0	100.0	
950 Wind River Lane	50,000	_	_	50,000	1	1,234	100.0	100.0	
620 Professional Drive	27,950	_	_	27,950	1	1,207	100.0	100.0	
Gaithersburg	1,327,652			1,327,652	20	45,983	96.8	96.8	
Beltsville									
8000/9000/10000 Virginia Manor Road	191,884	_	_	191,884	1	3,021	100.0	100.0	
101 West Dickman Street <sup>(1)</sup>	135,423	_	_	135,423	1	1,323	64.4	64.4	
Beltsville	327,307			327,307	2	4,344	85.3	85.3	
Northern Virginia	,			,	_	.,			
14225 Newbrook Drive	248,186	_	_	248,186	1	6.127	100.0	100.0	
Maryland	3,804,438	292,946		4,097,384	51	135,978	96.5	96.5	
·		·							
Research Triangle									
Research Triangle									
Mega Campus: Alexandria Center® for Life Science – Durham	2,155,252	_	_	2,155,252	15	52,407	97.4	97.4	
6, 8, 10, 12, 14, 40, 42, and 65 Moore Drive, 21, 25, 27, 29, and 31 Alexandria Way, 2400 Ellis Road, and 14 TW Alexander Drive									
Mega Campus: Alexandria Center® for Sustainable Technologies 104, 108, 110, 112, and 114 TW Alexander Drive and 5 and 7 Triangle Drive	364,493	_	_	364,493	7	12,201	93.7	93.7	
Alexandria Center® for AgTech 5 and 9 Laboratory Drive	342,928	_	_	342,928	2	\$ 16,862	98.2 %	98.2 %	

<sup>(1)</sup> We own a partial interest in this property through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

June 30, 2024

(Dollars in thousands)



	RSF				Number of	Annual Rental	Occupar	ncy Percentage Operating and
Market / Submarket / Address	Operating	Development	Redevelopment	Total	Properties	Revenue	Operating	Redevelopment
Research Triangle (continued)								
Research Triangle (continued)								
Mega Campus: Alexandria Center® for Advanced Technologies – Research	044.500			044.500			00.0.0/	22.2.2/
Triangle	344,539		_	344,539	4	\$ 16,343	99.8 %	99.8 %
6, 8, 10, and 12 Davis Drive Alexandria Technology Center <sup>®</sup> – Alston	4EE E00			1EE E22	2	2 005	00.0	00.0
100, 800, and 801 Capitola Drive	155,533	_	_	155,533	3	3,895	90.9	90.9
6040 George Watts Hill Drive	149,585		_	149,585	2	7,375	100.0	100.0
Alexandria Innovation Center® – Research Triangle	136,692	_	_	136,692	3	4,260	100.0	100.0
7010, 7020, and 7030 Kit Creek Road	130,032	_	_	130,032	3	4,200	100.0	100.0
2525 East NC Highway 54	82,996		_	82,996	1	3,651	100.0	100.0
407 Davis Drive	81,956	_	_	81,956	1	3,323	100.0	100.0
601 Keystone Park Drive	77,595	_	_	77,595	1	2,137	100.0	100.0
6101 Quadrangle Drive	31,600	_	_	31,600	1	861	100.0	100.0
Research Triangle	3,923,169			3,923,169	40	123,315	97.4	97.4
11000aron mangio	0,020,100			0,020,100		.20,0.0	•	· · · · ·
New York City								
New York City								
Mega Campus: Alexandria Center® for Life Science – New York City	743,377	_	_	743,377	3	67,607	95.5	95.5
430 and 450 East 29th Street	7 10,077			7 10,017	Ü	01,001	00.0	00.0
Alexandria Center® for Life Science – Long Island City	179,100	_	_	179,100	1	5,278	41.7	41.7
30-02 48th Avenue	,			,	•	-,		
New York City	922,477			922,477	4	72,885	85.1	85.1
Texas								
Austin								
Mega Campus: Intersection Campus	1,525,359	_	_	1,525,359	12	43,028	99.2	99.2
507 East Howard Lane, 13011 McCallen Pass, 13813 and 13929 Center Lake								
Drive, and 12535, 12545, 12555, and 12565 Riata Vista Circle	400.070			400.070	0	44.000	400.0	400.0
1001 Trinity Street and 1020 Red River Street	198,972			198,972	2	11,630	100.0	100.0
Austin	1,724,331	_	_	1,724,331	14	54,658	99.3	99.3
Greater Houston								
Alexandria Center® for Advanced Technologies at The Woodlands	120,828	_	73,298	194,126	1	3,172	41.5	25.8
8800 Technology Forest Place								
Texas	1,845,159	_	73,298	1,918,457	15	57,830	95.5	91.8
Canada	933,660	_	139,311	1,072,971	12	20,353	94.9	82.5
Non-cluster/other markets	347,806	_	_	347,806	10	15,180	75.6	75.6
North America, excluding properties held for sale	41,336,956	2,772,498	2,167,847	46,277,301	403	2,190,981	94.6%	89.9%
Properties held for sale	808,692	_	_	808,692	5	25,994	59.9%	59.9%
Total – North America	42,145,648	2,772,498	2,167,847	47,085,993	408	\$ 2,216,975	•	
		, 11 =, 130	,,,,,,,,	,,			:	



# ALEXANDRIA'S VISIBILITY OF FUTURE GROWTH IN ANNUAL NET OPERATING INCOME FROM DEVELOPMENT AND REDEVELOPMENT DELIVERIES

**\$480 MILLION**<sup>®</sup>

**Placed Into Service** 

1H24

**2Q24** 

\$42M

\$16M

628,427 RSF

284,982 RSF

100% Leased

Expected to Be Placed Into Service<sup>(2)</sup>

3Q24-4Q25

1Q26-1Q28

\$187M<sup>(3)</sup>

\$293M

Aggregating 5.4M RSF

61% Leased/Negotiating

Refer to "Net operating income" under "Definitions and reconciliations" in the Supplemental Information for additional details, including its reconciliation from the most directly comparable financial measure presented in accordance with GAAP.

<sup>1)</sup> Our share of incremental annual net operating income from development and redevelopment projects expected to be placed into service primarily commencing from 3Q24 through 1Q28 is projected to be \$380 million.

<sup>2)</sup> Represents expected incremental annual net operating income to be placed into service from deliveries of projects undergoing construction and one committed near-term project expected to commence construction in the next two years.

Includes 1.5 million RSF that is expected to stabilize through 2025 and is 87% leased, and partial deliveries through 4Q25 from projects expected to stabilize in 2026 and beyond. In addition to the projects represented, we are evaluating one priority anticipated development project that could commence active construction in 2H24 and may have initial delivery in 2025. Refer to the initial and stabilized occupancy years under "New Class A/A+ development and redevelopment properties: current projects" in the Supplemental Information for details.

# **Investments in Real Estate**

June 30, 2024

(Dollars in thousands)



#### Investments in real estate

			Development and Redevelopment									
		Active and Near-	Γerm Construction	Future Opportun Market Condition								
	Operating	Under Construction 61% Leased/ Negotiating	Committed Near Term 51% Leased/ Negotiating <sup>(1)</sup>	Priority Anticipated	Future	Subtotal	Total					
Square footage												
Operating	41,336,956	_	_	_	_	_	41,336,956					
New Class A/A+ development and redevelopment properties	_	4,940,345	492,570	2,670,922	27,261,766	35,365,603	35,365,603					
Value-creation square feet currently included in rental properties <sup>(2)</sup>			(159,884)	(309,148)	(2,938,815)	(3,407,847)	(3,407,847)					
Total square footage, excluding properties held for sale	41,336,956	4,940,345	332,686	2,361,774	24,322,951	31,957,756	73,294,712					
Properties held for sale	808,692				<u> </u>		808,692					
Total square footage	42,145,648	4,940,345	332,686	2,361,774	24,322,951	31,957,756	74,103,404					
Investments in real estate												
Gross book value as of June 30, 2024 <sup>(3)</sup>	\$ 29,178,679	\$ 3,888,714	\$ 58,751	\$ 762,507	\$ 4,242,602	\$ 8,952,574	\$ 38,131,253					

<sup>(1)</sup> Represents one committed near-term project expected to commence construction during the next two years after June 30, 2024.

<sup>(2)</sup> Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including value-creation square feet currently included in rental properties.

<sup>(3)</sup> Balances exclude accumulated depreciation and our share of the cost basis associated with our properties held by our unconsolidated real estate joint ventures, which is classified as investments in unconsolidated real estate joint ventures in our consolidated balance sheets. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details.



# Incremental Annual Net Operating Income Generated From 1H24 Deliveries Aggregated \$42 Million, Including \$16 Million in 2Q24

500 North Beacon Street and 4 Kingsbury Avenue<sup>(1)</sup>

Greater Boston/ Cambridge/Inner Suburbs 138,537 RSF



1150 Eastlake Avenue East
Seattle/Lake Union

280,361 RSF 100% Occupancy



9810 Darnestown Road

Maryland/Rockville 195,435 RSF 100% Occupancy



9808 Medical Center Drive

Maryland/Rockville 52,115 RSF 100% Occupancy



				RSF Place	d in Servic	е				Unleve	red Yields
	2Q24 Delivery	Our Ownership	Prior to				Occupancy	Total Project		Initial	Initial Stabilized
Property/Market/Submarket	Date <sup>(2)</sup>	Interest	1/1/24	1Q24	2Q24	Total	Percentage <sup>(3)</sup>	RSF	Investment	Stabilized	(Cash Basis)
Development projects											
99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs	N/A	75.0%	43,568	72,846	_	116,414	100%	320,809	\$ 468,000	7.1%	7.0%
500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/Cambridge/Inner Suburbs	5/10/24	100%	_	100,624	37,913	138,537	100%	248,018	427,000	6.2	5.5
1150 Eastlake Avenue East/Seattle/Lake Union	4/13/24	100%	278,282	_	2,079	280,361	100%	311,631	443,000	6.6	6.7
9810 Darnestown Road/Maryland/Rockville	4/1/24	100%	_	_	195,435	195,435	100%	195,435	135,000	7.1	6.2
9808 Medical Center Drive/Maryland/Rockville	6/18/24	100%	26,460	_	25,655	52,115	100%	95,061	113,000	5.5	5.5
Redevelopment projects											
651 Gateway Boulevard/San Francisco Bay Area/South San Francisco	N/A	50.0%	_	44,652	_	44,652	100%	326,706	487,000	5.0	5.1
Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Seattle/Bothell	N/A	100%	65,086	115,598	_	180,684	100%	460,934	229,000	6.3	6.2
Canada	4/17/24	100%	44,862	9,725	23,900	78,487	100%	250,790	113,000	6.4	6.3
Weighted average/total	4/21/24		458,258	343,445	284,982	1,086,685		2,209,384	\$ 2,415,000	6.2%	6.1%

Refer to "New Class A/A+ development and redevelopment properties: current projects" in the Supplemental Information for details on the square footage in service and under construction, if applicable.

<sup>(1)</sup> Image represents 500 North Beacon Street on the Arsenal on the Charles mega campus.

<sup>(2)</sup> Represents the average delivery date for deliveries that occurred during the current quarter, weighted by annual rental revenue.

<sup>(3)</sup> Occupancy relates to total operating RSF placed in service as of the most recent delivery.

# New Class A/A+ Development and Redevelopment Properties: Current Projects

June 30, 2024



#### 99 Coolidge Avenue

Greater Boston/ Cambridge/Inner Suburbs 204,395 RSF 36% Leased



# 500 North Beacon Street and 4 Kingsbury Avenue<sup>(1)</sup>

Greater Boston/ Cambridge/Inner Suburbs 109,481 RSF 92% Leased/Negotiating



#### 311 Arsenal Street

Greater Boston/ Cambridge/Inner Suburbs 308,446 RSF 21% Leased



#### 201 Brookline Avenue

Greater Boston/Fenway 58,149 RSF 99% Leased/Negotiating



#### 401 Park Drive

Greater Boston/Fenway 159,959 RSF 14% Leased



#### **421 Park Drive**

Greater Boston/Fenway 392,011 RSF 13% Leased



# 40, 50, and 60 Sylvan Road(2)

Greater Boston/Route 128 576,924 RSF 29% Leased



## 840 Winter Street

Greater Boston/Route 128 139,680 RSF 100% Leased



# 1450 Owens Street<sup>(3)</sup>

San Francisco Bay Area/ Mission Bay 212,796 RSF —% Leased/Negotiating



# 651 Gateway Boulevard

San Francisco Bay Area/ South San Francisco 282,054 RSF 21% Leased



- (1) Image represents 500 North Beacon Street on the Arsenal on the Charles mega campus.
- (2) Image represents 60 Sylvan Road on the Alexandria Center® for Life Science Waltham mega campus. The project is expected to capture demand in our Route 128 submarket.
- (3) Image represents a single- or multi-tenant project expanding our existing Alexandria Center® for Science and Technology Mission Bay mega campus, where our joint venture partner will fund 100% of the construction cost until it attains an ownership interest of 75%, after which it will contribute its respective share of additional capital. We are currently marketing the space for lease and have initial interest from publicly traded biotechnology and institutional tenants.

# New Class A/A+ Development and Redevelopment Properties: Current Projects (continued)

June 30, 2024



#### 230 Harriet Tubman Way

San Francisco Bay Area/ South San Francisco 285,346 RSF 100% Leased



### 10935, 10945, and 10955 Alexandria Way<sup>(1)</sup>

San Diego/Torrey Pines 334,996 RSF 100% Leased



#### **4135 Campus Point Court**

San Diego/ University Town Center 426,927 RSF 100% Leased



#### **4155 Campus Point Court**

San Diego/ University Town Center 171,102 RSF 100% Leased



#### 10075 Barnes Canyon Road

San Diego/Sorrento Mesa 253,079 RSF 70% Leased



#### 1150 Eastlake Avenue East

Seattle/Lake Union 31,270 RSF 100% Leased



#### Alexandria Center® for Advanced Technologies – Monte Villa Parkway<sup>(2)</sup>

Seattle/Bothell 34,306 RSF 98% Leased



# 9820 Darnestown Road

Maryland/Rockville 250,000 RSF 100% Leased



#### 9808 Medical Center Drive

Maryland/Rockville 42,946 RSF 69% Leased



#### 8800 Technology Forest Place

Texas/Greater Houston 73,298 RSF 41% Leased



- (1) Image represents 10955 Alexandria Way on the One Alexandria Square mega campus.
- (2) Image represents 3755 Monte Villa Parkway.

# New Class A/A+ Development and Redevelopment Properties: Current Projects (continued)





		Square Footage			Per	centage	Occupancy <sup>(1)</sup>	
Property/Market/Submarket	Dev/Redev	In Service	CIP	Total	Leased	Leased/ Negotiating	Initial	Stabilized
Under construction								
2024 and 2025 stabilization								
99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs	Dev	116,414	204,395	320,809	36%	36%	4Q23	2025
500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/ Cambridge/Inner Suburbs	Dev	138,537	109,481	248,018	85	92	1Q24	2025
201 Brookline Avenue/Greater Boston/Fenway	Dev	451,967	58,149	510,116	98	99	3Q22	4Q24
840 Winter Street/Greater Boston/Route 128	Redev	28,534	139,680	168,214	100	100	4Q24	2025
230 Harriet Tubman Way/San Francisco Bay Area/South San Francisco	Dev	20,554	285,346	285,346	100	100	1Q25	1Q25
4155 Campus Point Court/San Diego/University Town Center	Dev	_	205,540 171,102	171,102	100	100	4Q24	4Q24
1150 Eastlake Avenue East/Seattle/Lake Union		 280,361	31,270	311,631	100	100	4Q24 4Q23	3Q24
Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Seattle/Bothell	Dev Redev	426,628	34,306	460,934	98	98	1Q23	4Q24
9820 Darnestown Road/Maryland/Rockville		•	250,000	*	100		4Q24	4Q24 4Q24
•	Dev Dev			250,000		100		
9808 Medical Center Drive/Maryland/Rockville		52,115	42,946	95,061	69 44	69	3Q23	4Q24
8800 Technology Forest Place/Texas/Greater Houston	Redev	50,094	73,298	123,392 250,790	41 73	41	2Q23 3Q23	2025 2025
Canada	Redev	111,479	139,311	3,195,413	87	73 87	3Q23	2025
2026 and havend stabilization		1,656,129	1,539,284	3, 195,413	01	01		
2026 and beyond stabilization	Redev	82,216 <sup>(2)</sup>	308,446	390,662	21	21	2027	2027
311 Arsenal Street/Greater Boston/Cambridge/Inner Suburbs 401 Park Drive/Greater Boston/Fenway	Redev	02,210	159,959	159,959		14	2027	2027
401 Park Drive/Greater Boston/Fenway 421 Park Drive/Greater Boston/Fenway	Dev	_	,	,	14	13	2024	2026
42 Faik Drive/Greater Boston/Penway 40, 50, and 60 Sylvan Road/Greater Boston/Route 128	Redev	_	392,011 576,924	392,011 576,924	13 29	13 29	2026	2027
Other/Greater Boston	Redev	_	453,869	453,869		<sup>(3)</sup>	2025	2027
1450 Owens Street/San Francisco Bay Area/Mission Bay	Dev	_	212,796	212,796	_	(4)	2027	2027
651 Gateway Boulevard/San Francisco Bay Area/South San Francisco	Redev	— 44,652	282,054	326,706	<u> </u>	21	2025 1Q24	2026
10935, 10945, and 10955 Alexandria Way/San Diego/Torrey Pines	Dev	44,032	334,996	334,996	100	100	4Q24	2026
4135 Campus Point Court/San Diego/University Town Center	Dev	_	426,927	426,927	100	100	2026	2026
10075 Barnes Canyon Road/San Diego/Sorrento Mesa	Dev	_ _	253,079	253,079	70	70	2025	2026
10073 Barries Carryon Road/Sari Diego/Soriento Mesa	Dev	126,868	3,401,061	3,527,929	38	38	2023	2020
		1,782,997	4,940,345	6,723,342	61	61		
Committed near-term project expected to commence construction in the next two	/ears	1,102,331	7,340,343	0,720,042	O I	01		
4165 Campus Point Court/San Diego/University Town Center	Dev	_	492,570	492,570	_	51		
Total	201	1,782,997	5,432,915	7,215,912	57%	61%		
			3,.02,0.0	.,,	0.70			

<sup>(1)</sup> Initial occupancy dates are subject to leasing and/or market conditions. Stabilized occupancy may vary depending on single tenancy versus multi-tenant projects may increase in occupancy over a period of time.

<sup>(2)</sup> We expect to redevelop an additional 25,312 RSF of space occupied as of June 30, 2024 into laboratory space upon expiration of the existing leases through 1H25. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details.

<sup>(3)</sup> Represents a project focused on demand from our existing tenants in our adjacent properties/campuses and that will also address demand from other non-Alexandria properties/campuses.

<sup>(4)</sup> Represents a single- or multi-tenant project expanding our existing mega campus, where our joint venture partner will fund 100% of the construction cost until it attains an ownership interest of 75%, after which it will contribute its respective share of additional capital. We are currently marketing the space for lease and have initial interest from publicly traded biotechnology and institutional tenants.

# New Class A/A+ Development and Redevelopment Properties: Current Projects (continued)

June 30, 2024

(Dollars in thousands)



	Our	At 100%							<b>Unlevered Yields</b>		
Property/Market/Submarket	Ownership Interest		n Service		CIP	Cost to Complete		Total at Completion		Initial Stabilized	Initial Stabilized (Cash Basis)
Under construction											
2024 and 2025 stabilization											
99 Coolidge Avenue/Greater Boston/Cambridge/Inner Suburbs	75.0%	\$	135,922	\$	184,887	\$	147,191	\$	468,000	7.1%	7.0%
500 North Beacon Street and 4 Kingsbury Avenue/Greater Boston/ Cambridge/Inner Suburbs	100%		279,029		110,110		37,861		427,000	6.2%	5.5%
201 Brookline Avenue/Greater Boston/Fenway	99.0%		664,823		88,711		21,466		775,000	7.2%	6.5%
840 Winter Street/Greater Boston/Route 128	100%		13,651		184,050		39,299		237,000	7.6%	6.5%
230 Harriet Tubman Way/San Francisco Bay Area/South San Francisco	47.7%		_		312,344		197,656		510,000	7.4%	6.4%
4155 Campus Point Court/San Diego/University Town Center	55.0%		_		124,823		48,177		173,000	7.4%	6.5%
1150 Eastlake Avenue East/Seattle/Lake Union	100%		373,827		45,984		23,189		443,000	6.6%	6.7%
Alexandria Center® for Advanced Technologies – Monte Villa Parkway/Seattle/Bothell	100%		193,641		11,144		24,215		229,000	6.3%	6.2%
9820 Darnestown Road/Maryland/Rockville	100%		_		161,736		15,264		177,000	6.3%	5.6%
9808 Medical Center Drive/Maryland/Rockville	100%		63,410		47,451		2,139		113,000	5.5%	5.5%
8800 Technology Forest Place/Texas/Greater Houston	100%		57,055		45,377		9,568		112,000	6.3%	6.0%
Canada	100%		49,303		44,036		19,661		113,000	6.4%	6.3%
			1,830,661		1,360,653						
2026 and beyond stabilization <sup>(1)</sup>											
311 Arsenal Street/Greater Boston/Cambridge/Inner Suburbs	100%		60,555		228,799						
401 Park Drive/Greater Boston/Fenway	100%		_		178,178						
421 Park Drive/Greater Boston/Fenway	99.7%		_		376,163				ТВ	n	
40, 50, and 60 Sylvan Road/Greater Boston/Route 128	100%		_		419,034				10	Ь	
Other/Greater Boston	100%		_		141,776						
1450 Owens Street/San Francisco Bay Area/Mission Bay	26.3%		_		230,909						
651 Gateway Boulevard/San Francisco Bay Area/South San Francisco	50.0%		59,265		275,841		151,894		487,000	5.0%	5.1%
10935, 10945, and 10955 Alexandria Way/San Diego/Torrey Pines	100%		_		283,079	_	219,921		503,000	6.2%	5.8%
4135 Campus Point Court/San Diego/University Town Center	55.0%		_		236,595				TB		
10075 Barnes Canyon Road/San Diego/Sorrento Mesa	50.0%				157,687		163,313		321,000	5.5%	5.7%
			119,820		2,528,061						
			1,950,481		3,888,714						
Committed near-term project expected to commence construction in the next two y											
4165 Campus Point Court/San Diego/University Town Center	55.0%				58,751				TB	D	
Total		\$	1,950,481	\$	3,947,465	\$	3,840,000 (2	\$	9,740,000 (2)		
Our share of investment <sup>(2)(3)</sup>		\$	1,880,000	\$	3,170,000	\$	3.040.000	\$	8,090,000		

Refer to "Initial stabilized yield (unlevered)" under "Definitions and reconciliations" in the Supplemental Information for additional details.

We expect to provide total estimated costs and related yields for each project with estimated stabilization in 2026 and beyond over the next several quarters. Represents dollar amount rounded to the nearest \$10 million and includes preliminary estimated amounts for projects listed as TBD.

Represents our share of investment based on our ownership percentage upon completion of development or redevelopment projects.



# 69% of Our Total Value-Creation Pipeline RSF Is Within Our Mega Campuses

	Our		Active and Near-To	erm Construction	Future Opportunit Market Conditions	ties Subject to s and Leasing	
Market Property/Submarket	Ownership Interest	Book Value	Under Construction	Committed Near Term	Priority Anticipated	Future	Total <sup>(1)</sup>
Greater Boston							
Mega Campus: The Arsenal on the Charles/Cambridge/Inner Suburbs	100%	\$ 350,306	417,927	_	25,312	34,157	477,396
311 Arsenal Street, 500 North Beacon Street, and 4 Kingsbury Avenue							
99 Coolidge Avenue/Cambridge/Inner Suburbs	75.0%	184,887	204,395	_	_	_	204,395
Mega Campus: Alexandria Center <sup>®</sup> for Life Science – Fenway/ Fenway	(2)	643,052	610,119	_	_	_	610,119
201 Brookline Avenue and 401 and 421 Park Drive							
Mega Campus: Alexandria Center <sup>®</sup> for Life Science – Waltham/ Route 128	100%	665,082	716,604	_	_	515,000	1,231,604
40, 50, and 60 Sylvan Road, 35 Gatehouse Drive, and 840 Winter Street							
Mega Campus: Alexandria Center <sup>®</sup> at Kendall Square/ Cambridge	100%	124,868	_	_	_	216,455	216,455
100 Edwin H. Land Boulevard							
Mega Campus: Alexandria Technology Square®/Cambridge	100%	7,881	_	_	_	100,000	100,000
Mega Campus: 480 Arsenal Way and 446, 458, 500, and 550 Arsenal Street/Cambridge/Inner Suburbs	100%	85,126	_	_	_	902,000	902,000
446, 458, 500, and 550 Arsenal Street							
Mega Campus: 285, 299, 307, and 345 Dorchester Avenue/ Seaport Innovation District	60.0%	283,744	_	_	_	1,040,000	1,040,000
10 Necco Street/Seaport Innovation District	100%	104,966	_	_	_	175,000	175,000
Mega Campus: One Moderna Way/Route 128	100%	26,500	_	_	_	1,085,000	1,085,000
215 Presidential Way/Route 128	100%	6,816	_	_	_	112,000	112,000
Other value-creation projects	(3)	295,006	453,869			1,323,541	1,777,410
		\$ 2,778,234	2,402,914		25,312	5,503,153	7,931,379

<sup>(1)</sup> Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment or properties. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including value-creation square feet currently included in rental properties.

<sup>(2)</sup> We have a 99.0% interest in 201 Brookline Avenue aggregating 58,149 RSF, a 100% interest in 401 Park Drive aggregating 159,959 RSF, and a 99.7% interest in 421 Park Drive aggregating 392,011 RSF.

<sup>(3)</sup> Includes a property in which we own a partial interest through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

June 30, 2024

(Dollars in thousands)



			Square Footage								
				Development and Redevelopment							
	Our		Active and Near-To	erm Construction	Future Opportunite Market Condition						
Market Property/Submarket	Ownership Interest	Book Value	Under Construction	Committed Near Term	Priority Anticipated	Future	Total <sup>(1)</sup>				
San Francisco Bay Area											
Mega Campus: Alexandria Center <sup>®</sup> for Science and Technology – Mission Bay/Mission Bay	26.3%	\$ 230,909	212,796	_	_	_	212,796				
1450 Owens Street											
Alexandria Center® for Life Science – Millbrae/South San Francisco	47.7%	469,434	285,346	_	198,188	150,213	633,747				
230 Harriet Tubman Way, 201 and 231 Adrian Road, and 6 and 30 Rollins Road											
Mega Campus: Alexandria Technology Center <sup>®</sup> – Gateway/ South San Francisco	50.0%	302,398	282,054	_	_	291,000	573,054				
651 Gateway Boulevard											
Mega Campus: Alexandria Center <sup>®</sup> for Advanced Technologies – Tanforan/South San Francisco	100%	388,661	_	_	150,000	1,780,000	1,930,000				
1122, 1150, and 1178 El Camino Real											
Mega Campus: Alexandria Center <sup>®</sup> for Advanced Technologies – South San Francisco/South San Francisco	100%	6,655	_	_	107,250	90,000	197,250				
211 <sup>(2)</sup> and 269 East Grand Avenue											
Mega Campus: Alexandria Center <sup>®</sup> for Life Science – San Carlos/Greater Stanford	100%	435,269	_	_	105,000	1,392,830	1,497,830				
960 Industrial Road, 987 and 1075 Commercial Street, and 888 Bransten Road											
3825 and 3875 Fabian Way/Greater Stanford	100%	151,762	_	_	_	478,000	478,000				
2100, 2200, 2300, and 2400 Geng Road/Greater Stanford	100%	35,759	_	_	_	240,000	240,000				
901 California Avenue/Greater Stanford	100%	18,640	_	_	_	56,924	56,924				
Mega Campus: 88 Bluxome Street/SoMa	100%	388,020	_	_	_	1,070,925	1,070,925				
Other value-creation projects	100%		<u> </u>			25,000	25,000				
		\$ 2,427,507	780,196		560,438	5,574,892	6,915,526				
		÷ =, :=: , = 3 ·	. 55, .00		222, .30	-,,	2,2 . 2,020				

<sup>(1)</sup> Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment or properties. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including value-creation square feet currently included in rental properties.

<sup>(2)</sup> Includes a property in which we own a partial interest through a real estate joint venture. Refer to "Joint venture financial information" in the Supplemental Information for additional details.

June 30, 2024

(Dollars in thousands)



			Square Footage				
				Development and	d Redevelopment		
	Our		Active and Near-Te	erm Construction	Future Opportunit Market Conditions	ties Subject to s and Leasing	
Market Property/Submarket	Ownership Interest	Book Value	Under Construction	Committed Near Term	Priority Anticipated	Future	Total <sup>(1)</sup>
San Diego							
Mega Campus: One Alexandria Square/Torrey Pines	100%	\$ 339,673	334,996	_	_	125,280	460,276
10935, 10945, and 10955 Alexandria Way and 10975 and 10995 Torreyana Road							
Mega Campus: Campus Point by Alexandria/University Town Center	55.0%	584,337	598,029	492,570	_	650,000	1,740,599
10010 <sup>(2)</sup> , 10140 <sup>(2)</sup> , and 10260 Campus Point Drive and 4135, 4155, 4161, 4165, and 4275 <sup>(2)</sup> Campus Point Court							
Mega Campus: SD Tech by Alexandria/Sorrento Mesa	50.0%	283,420	253,079	_	250,000	243,845	746,924
9805 Scranton Road and 10065 and 10075 Barnes Canyon Road							
11255 and 11355 North Torrey Pines Road/Torrey Pines	100%	146,905	_	_	153,000	62,000	215,000
ARE Towne Centre/University Town Center	100%	19,163	_	_	230,000	_	230,000
9363, 9373, and 9393 Towne Centre Drive							
Costa Verde by Alexandria/University Town Center	100%	135,662	_	_	_	537,000	537,000
8410-8750 Genesee Avenue and 4282 Esplanade Court							
Mega Campus: 5200 Illumina Way/University Town Center	51.0%	17,443	_	_	_	451,832	451,832
9625 Towne Centre Drive/University Town Center	30.0%	837	_	_	_	100,000	100,000
Mega Campus: Sequence District by Alexandria/Sorrento Mesa	100%	46,323	_	_	_	1,798,915	1,798,915
6260, 6290, 6310, 6340, 6350, and 6450 Sequence Drive							
Scripps Science Park by Alexandria/Sorrento Mesa	100%	118,800	_	_	_	598,349	598,349
10048, 10219, 10256, and 10260 Meanley Drive and 10277 Scripps Ranch Boulevard							
Pacific Technology Park/Sorrento Mesa	50.0%	23,845	_	_	_	149,000	149,000
9444 Waples Street							
4025, 4031, 4045, and 4075 Sorrento Valley Boulevard/Sorrento Valley	100%	43,064	_	_	_	247,000	247,000
Other value-creation projects	100%	74,588				475,000	475,000
		\$ 1,834,060	1,186,104	492,570	633,000	5,438,221	7,749,895

<sup>(1)</sup> Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment opportunities. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including value-creation square feet currently included in rental properties.

<sup>(2)</sup> We have a 100% interest in this property.

June 30, 2024

(Dollars in thousands)



				Square Footage							
					Development and	d Redevelopment					
	Our			Active and Near-To	erm Construction	Future Opportuni Market Condition					
Market Property/Submarket	Ownership Interest	Вос	ok Value	Under Construction	Committed Near Term	Priority Anticipated	Future	Total <sup>(1)</sup>			
Seattle			·								
Mega Campus: Alexandria Center <sup>®</sup> for Life Science – Eastlake/ Lake Union	100%	\$	45,984	31,270	_	_	_	31,270			
1150 Eastlake Avenue East											
Alexandria Center <sup>®</sup> for Advanced Technologies – Monte Villa Parkway/Bothell	100%		11,144	34,306	_	50,552	_	84,858			
3301 Monte Villa Parkway											
Mega Campus: Alexandria Center <sup>®</sup> for Life Science – South Lake Union/Lake Union	(2)		452,222	_	_	1,095,586	188,400	1,283,986			
601 and 701 Dexter Avenue North and 800 Mercer Street											
830 and 1010 4th Avenue South/SoDo	100%		58,530	_	_	_	597,313	597,313			
Mega Campus: Alexandria Center <sup>®</sup> for Advanced Technologies – Canyon Park/Bothell	100%		16,891	_	_	_	230,000	230,000			
21660 20th Avenue Southeast											
Other value-creation projects	100%		140,480				706,087	706,087			
			725,251	65,576	_	1,146,138	1,721,800	2,933,514			
Maryland											
Mega Campus: Alexandria Center® for Life Science – Shady Grove/Rockville	100%		230,578	292,946	_	_	296,000	588,946			
9808 Medical Center Drive and 9820 and 9830 Darnestown Road											
			230,578	292,946	_	_	296,000	588,946			
Research Triangle											
Mega Campus: Alexandria Center <sup>®</sup> for Advanced Technologies – Research Triangle/Research Triangle	100%		101,026	_	_	180,000	990,000	1,170,000			
4 and 12 Davis Drive											
Mega Campus: Alexandria Center <sup>®</sup> for Life Science – Durham/ Research Triangle	100%		174,404	_	_	_	2,210,000	2,210,000			
41 Moore Drive											
Mega Campus: Alexandria Center <sup>®</sup> for NextGen Medicines/ Research Triangle	100%	\$	106,777	_	_	_	1,055,000	1,055,000			
3029 East Cornwallis Road											

<sup>(1)</sup> Represents total square footage upon completion of development or redevelopment of one or more new Class A/A+ properties. Square footage presented includes the RSF of buildings currently in operation at properties that also have future development or redevelopment or properties. Upon expiration of existing in-place leases, we have the intent to demolish or redevelop the existing property. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including value-creation square feet currently included in rental properties.

<sup>(2)</sup> We have a 100% interest in 601 and 701 Dexter Avenue North aggregating 414,986 RSF and a 60% interest in the priority anticipated development project at 800 Mercer Street aggregating 869,000 RSF.

June 30, 2024

(Dollars in thousands)



				Development an	d Redevelopment		
	Our		Active and Near-T	erm Construction	Future Opportuni Market Condition		
Market Property/Submarket	Ownership Interest	Book Value	Under Construction	Committed Near Term	Priority Anticipated Future		Total <sup>(1)</sup>
Research Triangle (continued)							
Mega Campus: Alexandria Center <sup>®</sup> for Sustainable Technologies/Research Triangle	100%	\$ 52,777	_	_	_	750,000	750,000
120 TW Alexander Drive, 2752 East NC Highway 54, and 10 South Triangle Drive							
100 Capitola Drive/Research Triangle	100%		_	_	_	65,965	65,965
Other value-creation projects	100%	4,185	<u></u>			76,262	76,262
		439,169	_	_	180,000	5,147,227	5,327,227
New York City							
Mega Campus: Alexandria Center <sup>®</sup> for Life Science – New York City/New York City	100%	161,482				550,000	550,000
		161,482	_	_	_	550,000	550,000
Texas							
Alexandria Center <sup>®</sup> for Advanced Technologies at The Woodlands/ Greater Houston	100%	48,250	73,298	_	_	116,405	189,703
8800 Technology Forest Place							
1001 Trinity Street and 1020 Red River Street/Austin	100%	9,929	_	_	126,034	123,976	250,010
Other value-creation projects	100%	135,323				1,694,000	1,694,000
		193,502	73,298	_	126,034	1,934,381	2,133,713
Canada	100%	44,036	139,311	_	_	371,743	511,054
Other value-creation projects	100%	118,755				724,349	724,349
Total pipeline as of June 30, 2024		<b>\$ 8,952,574</b>	4,940,345	492,570	2,670,922	27,261,766	35,365,603

<sup>(1)</sup> Total square footage includes 3,407,847 RSF of buildings currently in operation that we expect to demolish or redevelop and commence future construction. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including value-creation square feet currently included in rental properties.

<sup>(2)</sup> Pursuant to an option agreement, we are currently negotiating a long-term ground lease with the City of New York for the future site of a new life science building aggregating approximately 550,000 SF.

<sup>(3)</sup> Includes \$3.9 billion of projects that are currently under construction and are 61% leased/negotiating. We also expect to commence construction on one committed near-term project aggregating \$58.8 million, which is 51% leased/negotiating, in the next two years after June 30, 2024.

# **Construction Spending and Capitalization of Interest**

June 30, 2024

(Dollars in thousands)



Construction spending		Six Months Ended June 30, 2024		Projected Midpoint for the Year Ending December 31, 2024	
Construction of Class A/A+ properties:					
Active construction projects					
Under construction and committed near-term projects <sup>(1)</sup> and projects expected to commence active construction in 2024 <sup>(2)</sup>	\$	888,641	\$	1,778,000	
Future pipeline pre-construction					
Primarily mega campus expansion pre-construction work (entitlement, design, and site work)		257,218		652,000	
Revenue- and non-revenue-enhancing capital expenditures		115,659		250,000	
Construction spend (before contributions from noncontrolling interests)		1,261,518		2,680,000	
Contributions from noncontrolling interests (consolidated real estate joint ventures)		(176,497)		$(430,000)^{(3)}$	
Total construction spending	\$	1,085,021	\$	2,250,000	
2024 guidance range	-		\$1,9	50,000 – \$2,550,000	
Projected capital contributions from partners in consolidated real estate joint ventures to fund construction					
Projected Timing				Amount <sup>(4)</sup>	
3Q24 through 4Q24			\$	253,503	
2025 through 2027				804,528	
Total			\$	1,058,031	

#### Capitalization of interest

Key Categories of Interest Capitalized During 1H24	Bas	ge Real Estate is Capitalized uring 1H24	Percentage of Total Capitalized Interest	RSF Upon Completion of Construction	
Construction of Class A/A+ properties:					
Active construction projects					
Under construction and committed near-term projects <sup>(1)</sup>	\$	2,723,268	34%	5,432,915	77%
Future pipeline pre-construction					
Priority anticipated projects		624,317 <sup>(5)</sup>	8	2,670,922	Potential Growth
Primarily mega campus expansion pre-construction work (entitlement, design, and site work)		3,579,182 (5)	44	27,261,766	in Operating RSF
Smaller redevelopments and repositioning capital projects		1,123,183	14	N/A	in operating ito
	\$	8,049,950	100%	35,365,603	

- (1) Includes projects under construction aggregating 4.9 million RSF and one committed near-term project aggregating 492,570 RSF expected to commence construction during the next two years after June 30, 2024, which are 61% leased/negotiating and expected to generate \$480 million in annual incremental net operating income primarily commencing from 3Q24 through 1Q28.
- (2) Includes certain priority anticipated development and redevelopment projects expected to commence active construction in 2024, subject to market conditions and leasing. Refer to "Investments in real estate" under "Definitions and reconciliations" in the Supplemental Information for additional details, including value-creation square feet currently included in rental properties.
- (3) Represents contractual capital commitments expected from existing consolidated real estate joint venture partners to fund construction.
- 4) Represents reductions to our consolidated construction spending.
- (5) Average real estate basis capitalized related to our future pipeline pre-construction includes 32% from four key active and future value-creation projects on mega campuses. See next page for additional details.



# **Key Active and Future Value-Creation Projects on Mega Campuses**

## Alexandria Center® for Advanced Technologies – Tanforan

San Francisco Bay Area/South San Francisco
1.9 million future SF



## **Campus Point by Alexandria**

San Diego/University Town Center
1.7 million active and future SF



Refer to "Mega campus" under "Definitions and reconciliations" in the Supplemental Information for additional details.

## Alexandria Center® for Life Science – San Carlos

San Francisco Bay Area/Greater Stanford

1.5 million future SF



## Alexandria Center® for Life Science – South Lake Union

Seattle/Lake Union
1.3 million future SF





### **Consolidated Real Estate Joint Ventures**

Property	Market	Submarket	Noncontrolling Interest Share <sup>(1)</sup>	Operating RSF at 100%
50 and 60 Binney Street	Greater Boston	Cambridge/Inner Suburbs	66.0%	532,395
75/125 Binney Street	Greater Boston	Cambridge/Inner Suburbs	60.0%	388,269
100 and 225 Binney Street and 300 Third Street	Greater Boston	Cambridge/Inner Suburbs	70.0%	870,106
99 Coolidge Avenue	Greater Boston	Cambridge/Inner Suburbs	25.0%	116,414 <sup>(2)</sup>
15 Necco Street	Greater Boston	Seaport Innovation District	43.3%	345,996
285, 299, 307, and 345 Dorchester Avenue	Greater Boston	Seaport Innovation District	40.0%	(2)
Alexandria Center® for Science and Technology – Mission Bay(3)	San Francisco Bay Area	Mission Bay	75.0%	999,866
1450 Owens Street	San Francisco Bay Area	Mission Bay	73.7% (4)	(2)
601, 611, 651 <sup>(2)</sup> , 681, 685, and 701 Gateway Boulevard	San Francisco Bay Area	South San Francisco	50.0%	831,326
751 Gateway Boulevard	San Francisco Bay Area	South San Francisco	49.0%	230,592
211 <sup>(2)</sup> and 213 East Grand Avenue	San Francisco Bay Area	South San Francisco	70.0%	300,930
500 Forbes Boulevard	San Francisco Bay Area	South San Francisco	90.0%	155,685
Alexandria Center® for Life Science – Millbrae	San Francisco Bay Area	South San Francisco	52.3%	(2)
3215 Merryfield Row	San Diego	Torrey Pines	70.0%	170,523
Campus Point by Alexandria <sup>(5)</sup>	San Diego	University Town Center	45.0%	1,342,164
5200 Illumina Way	San Diego	University Town Center	49.0%	792,687
9625 Towne Centre Drive	San Diego	University Town Center	70.0%	163,648
SD Tech by Alexandria <sup>(6)</sup>	San Diego	Sorrento Mesa	50.0%	884,270
Pacific Technology Park	San Diego	Sorrento Mesa	50.0%	544,352
Summers Ridge Science Park <sup>(7)</sup>	San Diego	Sorrento Mesa	70.0%	316,531
1201 and 1208 Eastlake Avenue East and 199 East Blaine Street	Seattle	Lake Union	70.0%	321,115
400 Dexter Avenue North	Seattle	Lake Union	70.0%	290,754
800 Mercer Street	Seattle	Lake Union	40.0%	(2)

### **Unconsolidated Real Estate Joint Ventures**

Property	Market	Submarket	Our Ownership Share <sup>(8)</sup>	Operating RSF at 100%
1655 and 1725 Third Street	San Francisco Bay Area	Mission Bay	10.0%	586,208
1401/1413 Research Boulevard	Maryland	Rockville	65.0% <sup>(9)</sup>	(10)
1450 Research Boulevard	Maryland	Rockville	73.2% <sup>(9)</sup>	42,679
101 West Dickman Street	Maryland	Beltsville	58.2% <sup>(9)</sup>	135,423

Refer to "Joint venture financial information" under "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) In addition to the consolidated real estate joint ventures listed, various joint venture partners hold insignificant noncontrolling interests in three other real estate joint ventures in North America.
- (2) Represents a property currently under construction or in our value-creation pipeline. Refer to the sections under "New Class A/A+ development and redevelopment properties" in the Supplemental Information for additional details.
- 3) Includes 409 and 499 Illinois Street, 1500 and 1700 Owens Street, and 455 Mission Bay Boulevard South.
- 4) The noncontrolling interest share of our joint venture partner is anticipated to increase to 75% as our partner contributes equity to fund the construction of the project over time.
- (5) Includes 10210, 10260, 10290, and 10300 Campus Point Drive and 4110, 4135, 4155, 4161, 4165, 4224, and 4242 Campus Point Court.
- 6) Includes 9605, 9645, 9675, 9685, 9725, 9735, 9805, 9808, 9855, and 9868 Scranton Road and 10055, 10065, and 10075 Barnes Canyon Road.
- (7) Includes 9965, 9975, 9985, and 9995 Summers Ridge Road.
- 8) In addition to the unconsolidated real estate joint ventures listed, we hold an interest in one other insignificant unconsolidated real estate joint venture in North America.
- (9) Represents a joint venture with a local real estate operator in which our joint venture partner manages the day-to-day activities that significantly affect the economic performance of the joint venture.
- (10) Represents a joint venture with a distinguished retail real estate developer for a retail shopping center aggregating 84,837 RSF.



## As of June 30, 2024

	Share	ontrolling Interest of Consolidated eal Estate JVs	Our Share of Unconsolidated Real Estate JVs		
Investments in real estate	\$	4,157,101	\$	124,994	
Cash, cash equivalents, and restricted cash		132,692		4,128	
Other assets		431,584		12,752	
Secured notes payable		(33,581)		(95,547)	
Other liabilities		(279,550)		(5,792)	
Redeemable noncontrolling interests		(16,440)		_	
	\$	4,391,806	\$	40,535	

# Noncontrolling Interest Share of Consolidated Real Estate JVs

## **Our Share of Unconsolidated Real Estate JVs**

		Consolidated K	eai Estat	e JVS	Our Share of Officonsolidated Real Estate 3VS					
		June 30	, 2024			June 30	June 30, 2024			
	Three	Months Ended	Six I	Months Ended	Three I	Months Ended	Six Months Ended			
Total revenues	\$	111,210	\$	222,307	\$	3,156	\$	6,331		
Rental operations		(31,443)		(62,312)		(995)		(2,019)		
		79,767		159,995		2,161		4,312		
General and administrative		(1,004)		(1,682)		(30)		(70)		
Interest		(253)		(469)		(933)		(1,855)		
Depreciation and amortization of real estate assets		(31,364)		(62,268)		(1,068)		(2,102)		
Fixed returns allocated to redeemable noncontrolling interests <sup>(1)</sup>		201		402						
	\$	47,347	\$	95,978	\$	130	\$	285		
Straight-line rent and below-market lease revenue	\$	6,225	\$	15,534	\$	248	\$	530		
Funds from operations <sup>(2)</sup>	\$	78,711	\$	158,246	\$	1,198	\$	2,387		

Refer to "Joint venture financial information" under "Definitions and reconciliations" in the Supplemental Information for additional details.

<sup>(1)</sup> Represents an allocation of joint venture earnings to redeemable noncontrolling interests primarily in one property in our South San Francisco submarket. These redeemable noncontrolling interests earn a fixed return on their investment rather than participate in the operating results of the property.

<sup>(2)</sup> Refer to "Funds from operations and funds from operations per share" in the Earnings Press Release and "Definitions and reconciliations" in the Supplemental Information for additional details.

## **Investments**

June 30, 2024

(Dollars in thousands)



We hold investments in publicly traded companies and privately held entities primarily involved in the life science industry. The tables below summarize components of our investment income (loss) and non-real estate investments (in thousands). Refer to "Investments" under "Definitions and reconciliations" in the Supplemental Information for additional details.

> Realized gains Unrealized losses Investment loss


	Υ	e						
Thre	ee Months Ended	Six	Six Months Ended					
\$	20,578 <sup>(1)</sup>	\$	34,704 <sup>(1)</sup>	\$				
	(64,238) <sup>(3)</sup>		(35,080) (4)					
\$	(43,660)	\$	(376)	\$				

Year Ended December 31, 2023									
\$	6,078 <sup>(2)</sup>								
	(201,475) <sup>(5)</sup>								
\$	(195,397)								

		December 31, 2023								
Investments	Cost		Unr	ealized Gains	Unrealized Losses		Carrying Amount		Carrying Amount	
Publicly traded companies	\$	201,321	\$	42,052	\$	(90,182)	\$	153,191	\$	159,566
Entities that report NAV		510,335		162,559		(33,254)		639,640		671,532
Entities that do not report NAV:										
Entities with observable price changes		94,509		79,609		(1,007)		173,111		174,268
Entities without observable price changes		389,124		_		_		389,124		368,654
Investments accounted for under the equity method		N/A		N/A		N/A		139,282		75,498
June 30, 2024	\$	1,195,289	<sup>(6)</sup> \$	284,220	\$	(124,443)	\$	1,494,348	\$	1,449,518
December 31, 2023	\$	1,177,072	\$	320,445	\$	(123,497)	\$	1,449,518	· · ·	

# **Public/Private Mix (Cost)**

# **Tenant/Non-Tenant Mix (Cost)**





- Consists of realized gains of \$33.4 million and \$62.2 million, partially offset by impairment charges of \$12.8 million and \$27.5 million during the three and six months ended June 30, 2024, respectively,
- Consists of realized gains of \$80.6 million, offset by impairment charges of \$74.6 million during the year ended December 31, 2023.
- Consists of unrealized losses of \$20.2 million primarily resulting from the decrease in fair values of our investments in publicly traded entities and \$44.1 million resulting from accounting reclassifications of unrealized gains recognized in prior periods into realized gains upon our realization of investments during the three months ended June 30, 2024.
- Primarily relates to the accounting reclassifications of unrealized gains recognized in prior periods into realized gains upon our realization of investments during the six months ended June 30, 2024.
- Consists of unrealized losses of \$111.6 million primarily resulting from the decrease in the fair value of our investments in privately held entities that report NAV and \$89.9 million resulting from accounting reclassifications of unrealized gains recognized in prior periods into realized gains upon our sales of investments during the year ended December 31, 2023.
- Represents 2.8% of gross assets as of June 30, 2024. Refer to "Gross assets" under "Definitions and reconciliations" in the Supplemental Information for additional details.




# Liquidity

\$5.6B

### (in millions)

(iii iiiiiiiiiiii)	
Availability under our unsecured senior line of credit, net of amounts outstanding under our commercial paper program	\$ 4,800
Outstanding forward equity sales agreements <sup>(1)</sup>	27
Cash, cash equivalents, and restricted cash	566
Availability under our secured construction loan	61
Investments in publicly traded companies	153
Liquidity as of June 30, 2024	\$ 5,607


# Minimal Outstanding Borrowings and Significant Availability on Unsecured Senior Line of Credit



# Net Debt and Preferred Stock to Adjusted EBITDA<sup>(2)</sup>



# Fixed-Charge Coverage Ratio<sup>(2)</sup>




Refer to "Definitions and reconciliations" in the Supplemental Information for additional details.

- (1) Represents expected net proceeds from the future settlement of 230 thousand shares of common stock under forward equity sales agreements after underwriter discounts.
- (2) Quarter annualized.



# Weighted-Average Remaining Term of 13.0 Years



(1) Refer to footnotes 2 through 4 on the next page under "Fixed-rate and variable-rate debt" for additional details.

## **Summary of Debt (continued)**

June 30, 2024

(Dollars in thousands)



Fixed-rate and variable-rate debt						Weighted	l-Average
	Fixed-Rate Debt	Variable-Rate Debt		Total	Percentage	Interest Rate <sup>(1)</sup>	Remaining Term (in years)
Secured notes payable	\$ 619	\$	134,323	\$ 134,942	1.1%	8.13%	2.4
Unsecured senior notes payable	12,089,561		_	12,089,561	97.3	3.81	13.3
Unsecured senior line of credit <sup>(2)</sup> and commercial paper program <sup>(3)</sup>	_		199,552	199,552	1.6	5.57	3.6 (4)
Total/weighted average	\$ 12,090,180	\$	333,875	\$ 12,424,055	100.0%	3.89%	13.0 (4)
Percentage of total debt	 97.3%		2.7%	100.0%			

(1) Represents the weighted-average interest rate as of the end of the applicable period, including expense/income related to the amortization of loan fees, amortization of debt premiums (discounts), and other bank fees.

(2) As of June 30, 2024, we had no outstanding balance on our unsecured senior line of credit.

(3) The commercial paper program provides us with the ability to issue up to \$2.5 billion of commercial paper notes that bear interest at short-term fixed rates and can generally be issued with a maturity of 30 days or less and with a maximum maturity of 397 days from the date of issuance. Borrowings under the program are used to fund short-term capital needs and are backed by our unsecured senior line of credit. In the event we are unable to issue commercial paper notes or refinance outstanding borrowings under terms equal to or more favorable than those under our unsecured senior line of credit, we expect to borrow under the unsecured senior line of credit at SOFR+0.855%. As of June 30, 2024, we had \$199.6 million of commercial paper notes outstanding with a weighted-average interest rate of 5.57%.

(4) We calculate the weighted-average remaining term of our commercial paper notes by using the maturity date of our unsecured senior line of credit. Using the maturity date of our outstanding commercial paper notes, the consolidated weighted-average maturity of our debt is 13.0 years. The commercial paper notes sold during the six months ended June 30, 2024 were issued at a weighted-average yield to maturity of 5.59% and had a weighted-average maturity term of 16 days.

		Average Debi	t O	utstanding	Weighted-Average Interest Rate June 30, 2024			
		June 3	30, 2	2024				
	Three	Months Ended		Six Months Ended	Three Months Ended	Six Months Ended		
Long-term fixed-rate debt	\$	12,171,633	\$	11,927,318	3.79%	3.75%		
Short-term variable-rate unsecured senior line of credit and commercial paper program debt		335,917		433,681	5.56	5.61		
Blended average interest rate		12,507,550		12,360,999	3.84	3.82		
Loan fee amortization and annual facility fee related to unsecured senior line of credit		N/A		N/A	0.12	0.12		
Total/weighted average	\$	12,507,550	\$	12,360,999	3.96%	3.94%		
			_					

# **Summary of Debt (continued)**

June 30, 2024

(Dollars in thousands)



#### **Debt covenants Unsecured Senior Notes Payable Unsecured Senior Line of Credit** Debt Covenant Ratios(1) June 30, 2024 June 30, 2024 Requirement Requirement Total Debt to Total Assets ≤ 60% 30% ≤ 60.0% 29.2% 0.3% 0.2% Secured Debt to Total Assets ≤ 40% ≤ 45.0% Consolidated EBITDA to Interest Expense 13.2x ≥ 1.50x 4.01x ≥ 1.5x Unencumbered Total Asset Value to Unsecured Debt ≥ 150% 328% N/A N/A **Unsecured Interest Coverage Ratio** N/A N/A ≥ 1.75x 15.84x

## Unconsolidated real estate joint ventures' debt

Unconsolidated Joint Venture	Maturity Date	Stated Rate	Interest Rate <sup>(1)</sup>	ggregate mmitment	Deb	t Balance <sup>(2)</sup>	Our Share
1401/1413 Research Boulevard	12/23/24	2.70%	3.31%	\$ 28,500	\$	28,417	65.0%
1655 and 1725 Third Street	3/10/25 (3)	4.50%	4.57%	600,000		599,718	10.0%
101 West Dickman Street	11/10/26	SOFR+1.95% (4)	7.39%	26,750		18,558	58.2%
1450 Research Boulevard	12/10/26	SOFR+1.95% (4)	7.45%	13,000		8,598	73.2%
				\$ 668,250	\$	655,291	

<sup>(1)</sup> Includes interest expense and amortization of loan fees.

At 100%

<sup>(1)</sup> All covenant ratio titles utilize terms as defined in the respective debt and credit agreements. The calculation of consolidated EBITDA is based on the definitions contained in our loan agreements and is not directly comparable to the computation of EBITDA as described in Exchange Act Release No. 47226.

<sup>(2)</sup> Represents outstanding principal, net of unamortized deferred financing costs, as of June 30, 2024.

<sup>(3)</sup> The unconsolidated joint venture is early in the process of working with prospective lenders to refinance this debt. As of June 30, 2024, our investment in this unconsolidated real estate joint venture was \$11.2 million.

<sup>(4)</sup> This loan is subject to a fixed SOFR floor of 0.75%.

# **Summary of Debt (continued)**

June 30, 2024

(Dollars in thousands)



Unamortized

											(Deferred Financing	
	Stated	Interest	Maturity	Principa	al Payments	Remaining f	or the Perio	ds Ending De	ecember 31,		Cost), (Discount)/	
Debt	Rate	Rate <sup>(1)</sup>	Date <sup>(2)</sup>	2024	2025	2026	2027	2028	Thereafter	Principal	Premium	Total
Secured notes payable												
Greater Boston <sup>(3)</sup>	SOFR+2.70%	8.14%	11/19/26	\$ —	\$ —	\$ 134,648	\$ —	\$ —	\$ —	\$ 134,648	\$ (325)	\$ 134,323
San Francisco Bay Area	6.50%	6.50	7/1/36	32	34	36	38	41	438	619		619
Secured debt weighted-average interest rate/ subtotal		8.13		32	34	134,684	38	41	438	135,267	(325)	134,942
Unsecured senior line of credit and commercial paper program <sup>(4)</sup>	(4)	5.57 (4)	1/22/28 (4)	_	_	_	_	200,000	_	200,000	(448)	199,552
Unsecured senior notes payable	3.45%	3.62	4/30/25	_	600,000	_	_	_	_	600,000	(739)	599,261
Unsecured senior notes payable	4.30%	4.50	1/15/26	_	_	300,000	_	_	_	300,000	(778)	299,222
Unsecured senior notes payable	3.80%	3.96	4/15/26	_	_	350,000	_	_	_	350,000	(899)	349,101
Unsecured senior notes payable	3.95%	4.13	1/15/27	_	_	_	350,000	_	_	350,000	(1,321)	348,679
Unsecured senior notes payable	3.95%	4.07	1/15/28	_	_	_	_	425,000	_	425,000	(1,523)	423,477
Unsecured senior notes payable	4.50%	4.60	7/30/29	_	_	_	_	_	300,000	300,000	(1,138)	298,862
Unsecured senior notes payable	2.75%	2.87	12/15/29	_	_	_	_	_	400,000	400,000	(2,269)	397,731
Unsecured senior notes payable	4.70%	4.81	7/1/30	_	_	_	_	_	450,000	450,000	(2,241)	447,759
Unsecured senior notes payable	4.90%	5.05	12/15/30	_	_	_	_	_	700,000	700,000	(5,121)	694,879
Unsecured senior notes payable	3.375%	3.48	8/15/31	_	_	_	_	_	750,000	750,000	(4,669)	745,331
Unsecured senior notes payable	2.00%	2.12	5/18/32	_	_	_	_	_	900,000	900,000	(7,428)	892,572
Unsecured senior notes payable	1.875%	1.97	2/1/33	_	_	_	_	_	1,000,000	1,000,000	(7,543)	992,457
Unsecured senior notes payable	2.95%	3.07	3/15/34	_	_	_	_	_	800,000	800,000	(7,613)	792,387
Unsecured senior notes payable	4.75%	4.88	4/15/35	_	_	_	_	_	500,000	500,000	(5,185)	494,815
Unsecured senior notes payable	5.25%	5.38	5/15/36	_	_	_	_	_	400,000	400,000	(4,280)	395,720
Unsecured senior notes payable	4.85%	4.93	4/15/49	_	_	_	_	_	300,000	300,000	(2,929)	297,071
Unsecured senior notes payable	4.00%	3.91	2/1/50	_	_	_	_	_	700,000	700,000	10,049	710,049
Unsecured senior notes payable	3.00%	3.08	5/18/51	_	_	_	_	_	850,000	850,000	(11,417)	
Unsecured senior notes payable	3.55%	3.63	3/15/52	_	_	_	_	_	1,000,000	1,000,000	(13,892)	986,108
Unsecured senior notes payable	5.15%	5.26	4/15/53	_	_	_	_	_	500,000	500,000	(7,702)	492,298
Unsecured senior notes payable	5.625%	5.71	5/15/54						600,000	600,000	(6,801)	593,199
Unsecured debt weighted-average interest rate/ subtotal		3.84		_	600,000	650,000	350,000	625,000	10,150,000	12,375,000	(85,887)	12,289,113
Weighted-average interest rate/total		3.89%		\$ 32	\$ 600,034	\$ 784,684	\$ 350,038	\$ 625,041	\$10,150,438	\$12,510,267	\$ (86,212)	\$12,424,055
Balloon payments				\$ —	\$ 600,000	\$ 784,648	\$ 350,000	\$ 625,000	\$10,150,068	\$12,509,716	\$ —	\$12,509,716
Principal amortization				32	34	36	38	41	370	551	(86,212)	(85,661)
Total debt				\$ 32	\$ 600,034	\$ 784,684	\$ 350,038	\$ 625,041	\$10,150,438	\$12,510,267	\$ (86,212)	\$12,424,055
Fixed-rate debt				\$ 32	\$ 600.034	\$ 650.036	\$ 350.038	\$ 425.041	\$10,150,438		\$ (85,439)	
Variable-rate debt				Ψ 0Z	Ψ 000,004	134,648	Ψ 000,000	200,000	ψ10,100, <del>1</del> 00	334,648	(773)	333,875
					<u> </u>			· <del> · _ · _ </del>	<u>—</u>			
Total debt				\$ 32	\$ 600,034	\$ 784,684	\$ 350,038	\$ 625,041	\$10,150,438	\$12,510,267	\$ (86,212)	\$12,424,055
Weighted-average stated rate on maturing debt				N/A	3.45%	3.80%	3.95%	4.47%	3.68%			

- 1) Represents the weighted-average interest rate as of the end of the applicable period, including amortization of loan fees, amortization of debt premiums (discounts), and other bank fees.
- (2) Reflects any extension options that we control.
- (3) Represents a secured construction loan held by our consolidated real estate joint venture for 99 Coolidge Avenue, of which we own a 75.0% interest. As of June 30, 2024, this joint venture has \$60.7 million available under existing lender commitments. The interest rate shall be reduced from SOFR+2.70% to SOFR+2.10% over time upon the completion of certain leasing, construction, and financial covenant milestones.
- (4) Refer to footnotes 2 through 4 under "Fixed-rate and variable-rate debt" in "Summary of Debt" for additional details. In July 2024, we executed an agreement with the lender group to amend and restate our unsecured senior line of credit to, among other changes, extend the maturity date from January 22, 2028 to January 22, 2030, including extension options that we control. We expect that the amendment and restatement will become effective in September 2024 upon the satisfaction of certain conditions.

## **Definitions and Reconciliations**

June 30, 2024



This section contains additional details for sections throughout the Supplemental Information and the accompanying Earnings Press Release, as well as explanations and reconciliations of certain non-GAAP financial measures and the reasons why we use these supplemental measures of performance and believe they provide useful information to investors. Additional detail can be found in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, as well as other documents filed with or furnished to the SEC from time to time.

## Adjusted EBITDA and Adjusted EBITDA margin

The following table reconciles net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP, to Adjusted EBITDA and calculates the Adjusted EBITDA margin:

	Three Months Ended									
(Dollars in thousands)		6/30/24		3/31/24		12/31/23		9/30/23		6/30/23
Net income (loss)	\$	94,049	\$	219,176	\$	(42,658)	\$	68,254	\$	133,705
Interest expense		45,789		40,840		31,967		11,411		17,072
Income taxes		1,182		1,764		1,322		1,183		2,251
Depreciation and amortization		290,720		287,554		285,246		269,370		273,555
Stock compensation expense		14,507		17,125		34,592		16,288		15,492
Gain on sales of real estate		_		(392)		(62,227)		_		(214,810)
Unrealized losses (gains) on non-real estate investments		64,238		(29,158)		(19,479)		77,202		77,897
Impairment of real estate		30,763		_		271,890		20,649		168,575
Impairment of non-real estate investments		12,788		14,698		23,094		28,503		22,953
Adjusted EBITDA	\$	554,036	\$	551,607	\$	523,747	\$	492,860	\$	496,690
Total revenues	\$	766,734	\$	769,108	\$	757,216	\$	713,788	\$	713,900
Adjusted EBITDA margin		72%		72%		69%		69%		70%

We use Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization ("EBITDA"), excluding stock compensation expense, gains or losses on early extinguishment of debt, gains or losses on sales of real estate, impairments of real estate, and significant termination fees. Adjusted EBITDA also excludes unrealized gains or losses and significant realized gains or losses and impairments that result from our non-real estate investments. These non-real estate investment amounts are classified in our consolidated statements of operations outside of total revenues.

We believe Adjusted EBITDA provides investors with relevant and useful information as it allows investors to evaluate the operating performance of our business activities without having to account for differences recognized because of investing and financing decisions related to our real estate and non-real estate investments, our capital structure, capital market transactions, and variances resulting from the volatility of market conditions outside of our control. For example, we exclude gains or losses on the early extinguishment of debt to allow investors to measure our performance independent of our indebtedness and capital structure. We believe that adjusting for the effects of impairments and gains or losses on sales of real estate, significant impairments and realized gains or losses on non-real estate investments, and significant termination fees allows investors to evaluate performance from period to period on a consistent basis without having to account for differences recognized because of investing and financing decisions related to our real estate and non-real estate investments or other corporate activities that may not be representative of the operating performance of our properties.

In addition, we believe that excluding charges related to stock compensation and unrealized gains or losses facilitates for investors a comparison of our business activities across periods without the volatility resulting from market forces outside of our control. Adjusted EBITDA has limitations as a measure of our performance. Adjusted EBITDA does not reflect our historical expenditures or future requirements for capital expenditures or contractual commitments. While Adjusted EBITDA is a relevant measure of performance, it does not represent net income (loss) or cash flows from operations calculated and presented in accordance with GAAP, and it should not be considered as an alternative to those indicators in evaluating performance or liquidity.

In order to calculate the Adjusted EBITDA margin, we divide Adjusted EBITDA by total revenues as presented in our consolidated statements of operations. We believe that this supplemental performance measure provides investors with additional useful information regarding the profitability of our operating activities.

We are not able to forecast fourth quarter net income without unreasonable effort and therefore do not provide a reconciliation for Adjusted EBITDA on a forward-looking basis. This is due to the inherent difficulty of forecasting the timing and/or amount of items that depend on market conditions outside of our control, including the timing of dispositions, capital events, and financing decisions, as well as quarterly components such as gain on sales of real estate, unrealized gains or losses on non-real estate investments, impairment of real estate, and impairment of non-real estate investments. Our attempt to predict these amounts may produce significant but inaccurate estimates, which would be potentially misleading for our investors.

June 30, 2024



#### Annual rental revenue

Annual rental revenue represents the annualized fixed base rental obligations, calculated in accordance with GAAP, for leases in effect as of the end of the period, related to our operating RSF. Annual rental revenue is presented using 100% of the annual rental revenue from our consolidated properties and our share of annual rental revenue for our unconsolidated real estate joint ventures. Annual rental revenue per RSF is computed by dividing annual rental revenue by the sum of 100% of the RSF of our consolidated properties and our share of the RSF of properties held in unconsolidated real estate joint ventures. As of June 30, 2024, approximately 94% of our leases (on an annual rental revenue basis) were triple net leases, which require tenants to pay substantially all real estate taxes, insurance, utilities, repairs and maintenance, common area expenses, and other operating expenses (including increases thereto) in addition to base rent. Annual rental revenue excludes these operating expenses recovered from our tenants. Amounts recovered from our tenants related to these operating expenses, along with base rent, are classified in income from rentals in our consolidated statements of operations.

### Capitalization rates

Capitalization rates are calculated based on net operating income and net operating income (cash basis) annualized, excluding lease termination fees, on stabilized operating assets for the quarter preceding the date on which the property is sold, or near-term prospective net operating income.

### Capitalized interest

We capitalize interest cost as a cost of a project during periods for which activities necessary to develop, redevelop, or reposition a project for its intended use are ongoing, provided that expenditures for the asset have been made and interest cost has been incurred. Activities necessary to develop, redevelop, or reposition a project include pre-construction activities such as entitlements, permitting, design, site work, and other activities preceding commencement of construction of aboveground building improvements. The advancement of pre-construction efforts is focused on reducing the time required to deliver projects to prospective tenants. These critical activities add significant value for future ground-up development and are required for the vertical construction of buildings. If we cease activities necessary to prepare a project for its intended use, interest costs related to such project are expensed as incurred.

## **Cash interest**

Cash interest is equal to interest expense calculated in accordance with GAAP plus capitalized interest, less amortization of loan fees and debt premiums (discounts). Refer to the definition of fixed-charge coverage ratio for a reconciliation of interest expense, the most directly comparable financial measure calculated and presented in accordance with GAAP, to cash interest.

### Class A/A+ properties and AAA locations

Class A/A+ properties are properties clustered in AAA locations that provide innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Class A/A+ properties generally command higher annual rental rates than other classes of similar properties. AAA locations are in close proximity to concentrations of specialized skills, knowledge, institutions, and related businesses.

### Development, redevelopment, and pre-construction

A key component of our business model is our disciplined allocation of capital to the development and redevelopment of new Class A/A+ properties, and property enhancements identified during the underwriting of certain acquired properties, located in collaborative life science mega campuses in AAA innovation clusters. These projects are generally focused on providing high-quality, generic, and reusable spaces that meet the real estate requirements of a wide range of tenants. Upon completion, each value-creation project is expected to generate increases in rental income, net operating income, and cash flows. Our development and redevelopment projects are generally in locations that are highly desirable to high-quality entities, which we believe results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Development projects generally consist of the ground-up development of generic and reusable laboratory facilities. Redevelopment projects consist of the permanent change in use of acquired office, warehouse, or shell space into laboratory space. We generally will not commence new development projects for aboveground construction of new Class A/A+ laboratory space without first securing significant pre-leasing for such space, except when there is solid market demand for high-quality Class A/A+ properties.

Priority anticipated projects are those most likely to commence future ground-up development or first-time conversion from non-laboratory space to laboratory space prior to our other future projects, pending market conditions and leasing negotiations.

Pre-construction activities include entitlements, permitting, design, site work, and other activities preceding commencement of construction of aboveground building improvements. The advancement of pre-construction efforts is focused on reducing the time required to deliver projects to prospective tenants. These critical activities add significant value for future ground-up development and are required for the vertical construction of buildings. Ultimately, these projects will provide high-quality facilities and are expected to generate significant revenue and cash flows.

Development, redevelopment, and pre-construction spending also includes the following costs: (i) amounts to bring certain acquired properties up to market standard and/or other costs identified during the acquisition process (generally within two years of acquisition) and (ii) permanent conversion of space for highly flexible, move-in-ready laboratory space to foster the growth of promising early- and growth-stage life science companies.

Revenue-enhancing and repositioning capital expenditures represent spending to reposition or significantly change the use of a property, including through improvement in the asset quality from Class B to Class A/A+.

Non-revenue-enhancing capital expenditures represent costs required to maintain the current revenues of a stabilized property, including the associated costs for renewed and re-leased space.

## Dividend payout ratio (common stock)

Dividend payout ratio (common stock) is the ratio of the absolute dollar amount of dividends on our common stock (shares of common stock outstanding on the respective record dates multiplied by the related dividend per share) to funds from operations attributable to Alexandria's common stockholders – diluted, as adjusted.

June 30, 2024



## Dividend yield

Dividend yield for the quarter represents the annualized quarter dividend divided by the closing common stock price at the end of the quarter.

## Fixed-charge coverage ratio

Fixed-charge coverage ratio is a non-GAAP financial measure representing the ratio of Adjusted EBITDA to cash interest and fixed charges. We believe that this ratio is useful to investors as a supplemental measure of our ability to satisfy fixed financing obligations and preferred stock dividends. Cash interest is equal to interest expense calculated in accordance with GAAP plus capitalized interest, less amortization of loan fees and debt premiums (discounts).

The following table reconciles interest expense, the most directly comparable financial measure calculated and presented in accordance with GAAP, to cash interest and computes fixed-charge coverage ratio:

	Three Months Ended									
(Dollars in thousands)	6/30/24			3/31/24		12/31/23		9/30/23		6/30/23
Adjusted EBITDA	\$	554,036	\$	551,607	\$	523,747	\$	492,860	\$	496,690
Interest expense	\$	45,789	\$	40,840	\$	31,967	\$	11,411	\$	17,072
Capitalized interest		81,039		81,840		89,115		96,119		91,674
Amortization of loan fees		(4,146)		(4,142)		(4,059)		(4,059)		(3,729)
Amortization of debt discounts		(328)		(318)		(309)		(306)		(304)
Cash interest and fixed charges	\$	122,354	\$	118,220	\$	116,714	\$	103,165	\$	104,713
Fixed-charge coverage ratio:										
<ul> <li>quarter annualized</li> </ul>		4.5x		4.7x		4.5x		4.8x		4.7x
<ul><li>trailing 12 months</li></ul>		4.6x		4.7x		4.7x		4.9x		4.9x

We are not able to forecast fourth quarter net income without unreasonable effort and therefore do not provide a reconciliation for fixed-charge coverage ratio on a forward-looking basis. This is due to the inherent difficulty of forecasting the timing and/or amount of items that depend on market conditions outside of our control, including the timing of dispositions, capital events, and financing decisions, as well as quarterly components such as gain on sales of real estate, unrealized gains or losses on non-real estate investments, impairment of real estate, and impairment of non-real estate investments. Our attempt to predict these amounts may produce significant but inaccurate estimates, which would be potentially misleading for our investors.

# Funds from operations and funds from operations, as adjusted, attributable to Alexandria's common stockholders

GAAP-basis accounting for real estate assets utilizes historical cost accounting and assumes that real estate values diminish over time. In an effort to overcome the difference between real estate values and historical cost accounting for real estate assets, the Nareit Board of Governors established funds from operations as an improved measurement tool. Since its introduction, funds from operations has become a widely used non-GAAP financial measure among equity REITs. We believe that funds from operations is helpful to investors as an additional measure of the performance of an equity REIT. Moreover, we believe that funds from operations, as adjusted, allows investors to compare our performance to the performance of other real estate companies on a consistent basis, without having to account for differences recognized because of real estate acquisition and disposition decisions, financing decisions, capital structure, capital market transactions, variances resulting from the volatility of market conditions outside of our control, or other corporate activities that may not be representative of the operating performance of our properties.

The 2018 White Paper published by the Nareit Board of Governors (the "Nareit White Paper") defines funds from operations as net income (computed in accordance with GAAP), excluding gains or losses on sales of real estate, and impairments of real estate, plus depreciation and amortization of operating real estate assets, and after adjustments for our share of consolidated and unconsolidated partnerships and real estate joint ventures. Impairments represent the write-down of assets when fair value over the recoverability period is less than the carrying value due to changes in general market conditions and do not necessarily reflect the operating performance of the properties during the corresponding period.

We compute funds from operations, as adjusted, as funds from operations calculated in accordance with the Nareit White Paper, excluding significant gains, losses, and impairments realized on non-real estate investments, unrealized gains or losses on non-real estate investments, impairment of real estate primarily consisting of pre-acquisition costs incurred in connection with acquisitions we decided to no longer pursue, gains or losses on early extinguishment of debt, significant termination fees, acceleration of stock compensation expense due to the resignations of executive officers, deal costs, the income tax effect related to such items, and the amount of such items that is allocable to our unvested restricted stock awards. We compute the amount that is allocable to our unvested restricted stock awards using the two-class method. Under the two-class method, we allocate net income (after amounts attributable to noncontrolling interests) to common stockholders and to unvested restricted stock awards by applying the respective weighted-average shares outstanding during each quarter-todate and year-to-date period. This may result in a difference of the summation of the quarter-to-date and vear-to-date amounts. Neither funds from operations nor funds from operations, as adjusted, should be considered as alternatives to net income (determined in accordance with GAAP) as indications of financial performance, or to cash flows from operating activities (determined in accordance with GAAP) as measures of liquidity, nor are they indicative of the availability of funds for our cash needs, including our ability to make distributions.

June 30, 2024



# Funds from operations and funds from operations, as adjusted, attributable to Alexandria's common stockholders (continued)

The following table reconciles net income to funds from operations for the share of consolidated real estate joint ventures attributable to noncontrolling interests and our share of unconsolidated real estate joint ventures:

		ncontrolling l onsolidated F		Our Share of Unconsolidated Real Estate JVs							
		June 30, 2024				June 30, 2024					
(In thousands)		e Months Ended		x Months Ended		e Months Ended	Six Months Ended				
Net income	\$	47,347	\$	95,978	\$	130	\$	285			
Depreciation and amortization of real estate assets		31,364		62,268		1,068		2,102			
Funds from operations	\$ 78,711		\$	158,246	\$	1,198	\$	2,387			

#### **Gross assets**

Gross assets are calculated as total assets plus accumulated depreciation:

(In thousands)	6/30/24	3/31/24		12/31/23		9/30/23		6/30/23
Total assets	\$ 37,847,865	\$	37,699,046	\$	36,771,402	\$	36,783,293	\$ 36,659,257
Accumulated depreciation	 5,457,414		5,216,857		4,985,019		4,856,436	4,646,833
Gross assets	\$ 43,305,279	\$	42,915,903	\$	41,756,421	\$	41,639,729	\$ 41,306,090

### Initial stabilized yield (unlevered)

Initial stabilized yield is calculated as the estimated amounts of net operating income at stabilization divided by our investment in the property. Our initial stabilized yield excludes the benefit of leverage. Our cash rents related to our value-creation projects are generally expected to increase over time due to contractual annual rent escalations. Our estimates for initial stabilized yields, initial stabilized yields (cash basis), and total costs at completion represent our initial estimates at the commencement of the project. We expect to update this information upon completion of the project, or sooner if there are significant changes to the expected project yields or costs.

- Initial stabilized yield reflects rental income, including contractual rent escalations and any rent concessions over the term(s) of the lease(s), calculated on a straight-line basis.
- Initial stabilized yield (cash basis) reflects cash rents at the stabilization date after initial rental concessions, if any, have elapsed and our total cash investment in the property.

### Investment-grade or publicly traded large cap tenants

Investment-grade or publicly traded large cap tenants represent tenants that are investment-grade rated or publicly traded companies with an average daily market capitalization greater than \$10 billion for the twelve months ended June 30, 2024, as reported by Bloomberg Professional Services. Credit ratings from Moody's Investors Service and S&P Global Ratings reflect credit ratings of the tenant's parent entity, and there can be no assurance that a tenant's parent entity will satisfy the tenant's lease obligation upon such tenant's default. We monitor the credit quality and related material changes of our tenants. Material changes that cause a tenant's market capitalization to decrease below \$10 billion, which are not immediately reflected in the twelve-month average, may result in their exclusion from this measure.

### Investments

We hold investments in publicly traded companies and privately held entities primarily involved in the life science industries. We recognize, measure, present, and disclose these investments as follows:

		Stateme	nts of Operations
	Balance Sheet	Gain	s and Losses
	Carrying Amount	Unrealized	Realized
Publicly traded companies	Fair value	Changes in fair value	
Privately held entities without readily determinable fair values that:			Difference between proceeds received upon disposition and historical cost
Report NAV	Fair value, using NAV as a practical expedient	Changes in NAV, as a practical expedient to fair value	
Do not report NAV	Cost, adjusted for observable price changes and impairments <sup>(1)</sup>	Observable price changes <sup>(1)</sup>	Impairments to reduce costs to fair value, which result in an adjusted cost basis and the differences between proceeds received upon disposition and adjusted or historical cost
Equity method investments	Contributions, adjusted for our share of the investee's earnings or losses, less distributions received, reduced by other-than-temporary impairments	Our share of unrealized gains or losses reported by the investee	Our share of realized gains or losses reported by the investee, and other-than- temporary impairments

<sup>(1)</sup> An observable price is a price observed in an orderly transaction for an identical or similar investment of the same issuer. Observable price changes result from, among other things, equity transactions for the same issuer with similar rights and obligations executed during the reporting period, including subsequent equity offerings or other reported equity transactions related to the same issuer.

June 30, 2024



### Investments in real estate

The following table reconciles our investments in real estate as of June 30, 2024:

(In thousands)	 Investments in Real Estate		
Gross investments in real estate	\$ 38,131,253		
Less: accumulated depreciation	 (5,457,414)		
Investments in real estate	\$ 32,673,839		

The following table presents our value-creation pipeline of new Class A/A+ development and redevelopment projects, excluding properties held for sale, as a percentage of gross assets as of June 30, 2024:

	Percentage of Gross Assets
Under construction projects and one committed near-term project expected to commence construction in the next two years (61% leased/negotiating)	9%
Income-producing/potential cash flows/covered land play <sup>(1)</sup>	7%
Land	5%

(1) Includes projects with existing buildings that are generating or can generate operating cash flows. Also includes development rights associated with existing operating campuses. These projects aggregated 1.0% of annual rental revenue as of June 30, 2024 and are included in our industry mix chart as targeted for a future change in use to laboratory space. Refer to "High-quality and diverse client base" in the Supplemental Information for additional details.

Space Intentionally Blank

The square footage presented in the table below is classified as operating as of June 30, 2024. These lease expirations or vacant space at recently acquired properties represent future opportunities for which we have the intent, subject to market conditions and leasing, to commence first-time conversion from non-laboratory space to laboratory space, or to commence future ground-up development:

	Dev/	RSF of Lease Expirations Targeted for Development and Redevelopment					
Property/Submarket	Redev	2024	2025	Thereafter <sup>(1)</sup>	Total		
Committed near-term project: 4161 Campus Point Court/University Town Center	Dev	_	159,884	_	159,884		
Priority anticipated projects:							
311 Arsenal Street/Cambridge/Inner Suburbs	Redev	_	25,312	_	25,312		
269 East Grand Avenue/South San Francisco	Redev	107,250	_	_	107,250		
3301 Monte Villa Parkway/Bothell	Redev	_	50,552	_	50,552		
1020 Red River Street/Austin	Redev		126,034		126,034		
		107,250	201,898	_	309,148		
Future projects:							
100 Edwin H. Land Boulevard/Cambridge	Dev	104,500	_	_	104,500		
446, 458, 500, and 550 Arsenal Street/Cambridge/ Inner Suburbs	Dev	_	_	376,698	376,698		
Other/Greater Boston	Redev	_	_	167,549	167,549		
1122 and 1150 El Camino Real/South San Francisco	Dev	_	_	375,232	375,232		
3875 Fabian Way/Greater Stanford	Dev	_	_	228,000	228,000		
2100, 2200, and 2400 Geng Road/Greater Stanford 960 Industrial Road/Greater Stanford	Dev Dev	_	_	78,501 112,590	78,501 112,590		
Campus Point by Alexandria/University Town Center	Dev	226,144	109,164	_	335,308		
Sequence District by Alexandria/Sorrento Mesa	Dev/ Redev	_	_	686,290	686,290		
830 4th Avenue South/SoDo	Dev	_	_	42,380	42,380		
Other/Seattle	Dev	_	_	76,559	76,559		
100 Capitola Drive/Research Triangle	Dev	_	_	34,527	34,527		
1001 Trinity Street/Austin	Dev	_	72,938	_	72,938		
Canada	Redev			247,743	247,743		
		330,644	182,102	2,426,069	2,938,815		
		437,894	543,884	2,426,069	3,407,847		

(1) Includes vacant square footage as of June 30, 2024.

June 30, 2024



### Joint venture financial information

We present components of balance sheet and operating results information related to our real estate joint ventures, which are not presented, or intended to be presented, in accordance with GAAP. We present the proportionate share of certain financial line items as follows: (i) for each real estate joint venture that we consolidate in our financial statements, which are controlled by us through contractual rights or majority voting rights, but of which we own less than 100%, we apply the noncontrolling interest economic ownership percentage to each financial item to arrive at the amount of such cumulative noncontrolling interest share of each component presented; and (ii) for each real estate joint venture that we do not control and do not consolidate, and are instead controlled jointly or by our joint venture partners through contractual rights or majority voting rights, we apply our economic ownership percentage to each financial item to arrive at our proportionate share of each component presented.

The components of balance sheet and operating results information related to our real estate joint ventures do not represent our legal claim to those items. For each entity that we do not wholly own, the joint venture agreement generally determines what equity holders can receive upon capital events, such as sales or refinancing, or in the event of a liquidation. Equity holders are normally entitled to their respective legal ownership of any residual cash from a joint venture only after all liabilities, priority distributions, and claims have been repaid or satisfied.

We believe that this information can help investors estimate the balance sheet and operating results information related to our partially owned entities. Presenting this information provides a perspective not immediately available from consolidated financial statements and one that can supplement an understanding of the joint venture assets, liabilities, revenues, and expenses included in our consolidated results.

The components of balance sheet and operating results information related to our real estate joint ventures are limited as an analytical tool as the overall economic ownership interest does not represent our legal claim to each of our joint ventures' assets, liabilities, or results of operations. In addition, joint venture financial information may include financial information related to the unconsolidated real estate joint ventures that we do not control. We believe that in order to facilitate for investors a clear understanding of our operating results and our total assets and liabilities, joint venture financial information should be examined in conjunction with our consolidated statements of operations and balance sheets. Joint venture financial information should not be considered an alternative to our consolidated financial statements, which are presented and prepared in accordance with GAAP.

### Key items included in net income attributable to Alexandria's common stockholders

We present a tabular comparison of items, whether gain or loss, that may facilitate a highlevel understanding of our results and provide context for the disclosures included in this Supplemental Information, our most recent annual report on Form 10-K, and our subsequent quarterly reports on Form 10-Q. We believe that such tabular presentation promotes a better understanding for investors of the corporate-level decisions made and activities performed that significantly affect comparison of our operating results from period to period. We also believe that this tabular presentation will supplement for investors an understanding of our disclosures and real estate operating results. Gains or losses on sales of real estate and impairments of assets classified as held for sale are related to corporate-level decisions to dispose of real estate. Gains or losses on early extinguishment of debt are related to corporate-level financing decisions focused on our capital structure strategy. Significant realized and unrealized gains or losses on non-real estate investments, impairments of real estate and non-real estate investments, and acceleration of stock compensation expense due to the resignation of an executive officer are not related to the operating performance of our real estate assets as they result from strategic, corporate-level non-real estate investment decisions and external market conditions. Impairments of non-real estate investments are not related to the operating performance of our real estate as they represent the write-down of non-real estate investments when their fair values decrease below their respective carrying values due to changes in general market or other conditions outside of our control. Significant items, whether a gain or loss, included in the tabular disclosure for current periods are described in further detail in this Supplemental Information and accompanying Earnings Press Release.

### Mega campus

Mega campuses are cluster campuses that consist of approximately 1 million RSF or more, including operating, active development/redevelopment, and land RSF less operating RSF expected to be demolished. The following table reconciles our annual rental revenue and value-creation pipeline RSF as of June 30, 2024:

(Dollars in thousands)		nnual Rental Revenue	Value-Creation Pipeline RSF
Mega campus	\$	1,649,514	21,944,200
Non-mega campus		567,461	10,013,556
Total	\$	2,216,975	31,957,756
Mega campus as a percentage of annual rental revenue and of total value-creation pipeline RSF		74%	69%

### Net cash provided by operating activities after dividends

Net cash provided by operating activities after dividends includes the deduction for distributions to noncontrolling interests. For purposes of this calculation, changes in operating assets and liabilities are excluded as they represent timing differences.

June 30, 2024



## Net debt and preferred stock to Adjusted EBITDA

Net debt and preferred stock to Adjusted EBITDA is a non-GAAP financial measure that we believe is useful to investors as a supplemental measure of evaluating our balance sheet leverage. Net debt and preferred stock is equal to the sum of total consolidated debt less cash, cash equivalents, and restricted cash, plus preferred stock outstanding as of the end of the period. Refer to the definition of Adjusted EBITDA and Adjusted EBITDA margin for further information on the calculation of Adjusted EBITDA.

The following table reconciles debt to net debt and preferred stock and computes the ratio to Adjusted EBITDA:

(Dollars in thousands)	6/30/24	3/31/24	12/31/23	9/30/23	6/30/23
Secured notes payable	\$ 134,942	\$ 130,050	\$ 119,662	\$ 109,110	\$ 91,939
Unsecured senior notes payable	12,089,561	12,087,113	11,096,028	11,093,725	11,091,424
Unsecured senior line of credit and commercial paper	199,552	_	99,952	_	_
Unamortized deferred financing costs	81,942	84,198	76,329	78,496	80,663
Cash and cash equivalents	(561,021)	(722,176)	(618,190)	(532,390)	(924,370)
Restricted cash	(4,832)	(9,519)	(42,581)	(35,321)	(35,920)
Preferred stock	_	_	_	_	_
Net debt and preferred stock	\$11,940,144	\$11,569,666	\$10,731,200	\$10,713,620	\$10,303,736
Adjusted EBITDA:					
<ul> <li>quarter annualized</li> </ul>	\$2,216,144	\$2,206,428	\$2,094,988	\$1,971,440	\$1,986,760
<ul><li>trailing 12 months</li></ul>	\$2,122,250	\$2,064,904	\$1,997,518	\$1,935,505	\$1,895,336
Net debt and preferred stock to Adjusted	d EBITDA:				
<ul> <li>quarter annualized</li> </ul>	5.4x	5.2x	5.1x	5.4x	5.2x
<ul><li>trailing 12 months</li></ul>	5.6x	5.6x	5.4x	5.5x	5.4x

We are not able to forecast fourth quarter net income without unreasonable effort and therefore do not provide a reconciliation for net debt and preferred stock to Adjusted EBITDA on a forward-looking basis. This is due to the inherent difficulty of forecasting the timing and/or amount of items that depend on market conditions outside of our control, including the timing of dispositions, capital events, and financing decisions, as well as quarterly components such as gain on sales of real estate, unrealized gains or losses on non-real estate investments, impairment of real estate, and impairment of non-real estate investments. Our attempt to predict these amounts may produce significant but inaccurate estimates, which would be potentially misleading for our investors.

### Net operating income, net operating income (cash basis), and operating margin

The following table reconciles net income (loss) to net operating income and net operating income (cash basis) and computes operating margin:

	Three Mor	iths	Ended		Six Montl	ns Ended	
(Dollars in thousands)	6/30/24		6/30/23	6/30/24		6/30/23	
Net income	\$ 94,049	\$	133,705	\$	313,225	\$	255,398
Equity in earnings of unconsolidated real estate joint ventures	(130)		(181)		(285)		(375)
General and administrative expenses	44,629		45,882		91,684		94,078
Interest expense	45,789		17,072		86,629		30,826
Depreciation and amortization	290,720		273,555		578,274		538,857
Impairment of real estate	30,763		168,575		30,763		168,575
Gain on sales of real estate	_		(214,810)		(392)		(214,810)
Investment loss	43,660		78,268		376		123,379
Net operating income	549,480		502,066		1,100,274		995,928
Straight-line rent revenue	(48,338)		(29,335)		(96,589)		(62,526)
Amortization of acquired below-market leases	(22,515)	_	(24,789)		(52,855)		(46,425)
Net operating income (cash basis)	\$ 478,627	\$	447,942	\$	950,830	\$	886,977
Net operating income (cash basis) – annualized	\$ 1,914,508	\$	1,791,768	\$	1,901,660	\$	1,773,954
Net operating income (from above)	\$ 549,480	\$	502,066	\$	1,100,274	\$	995,928
Total revenues	\$ 766,734	\$	713,900	\$	1,535,842	\$	1,414,695
Operating margin	72%		70%		72%	_	70%
			,				

Net operating income is a non-GAAP financial measure calculated as net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP, excluding equity in the earnings of our unconsolidated real estate joint ventures, general and administrative expenses, interest expense, depreciation and amortization, impairments of real estate, gains or losses on early extinguishment of debt, gains or losses on sales of real estate, and investment income or loss. We believe net operating income provides useful information to investors regarding our financial condition and results of operations because it primarily reflects those income and expense items that are incurred at the property level. Therefore, we believe net operating income is a useful measure for investors to evaluate the operating performance of our consolidated real estate assets. Net operating income on a cash basis is net operating income adjusted to exclude the effect of straight-line rent and amortization of acquired above- and below-market lease revenue adjustments required by GAAP. We believe that net operating income on a cash basis is helpful to investors as an additional measure of operating performance because it eliminates straight-line rent revenue and the amortization of acquired above- and below-market leases.

June 30, 2024



### Net operating income, net operating income (cash basis), and operating margin (continued)

Furthermore, we believe net operating income is useful to investors as a performance measure of our consolidated properties because, when compared across periods, net operating income reflects trends in occupancy rates, rental rates, and operating costs, which provide a perspective not immediately apparent from net income or loss. Net operating income can be used to measure the initial stabilized yields of our properties by calculating net operating income generated by a property divided by our investment in the property. Net operating income excludes certain components from net income in order to provide results that are more closely related to the results of operations of our properties. For example, interest expense is not necessarily linked to the operating performance of a real estate asset and is often incurred at the corporate level rather than at the property level. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort comparability of operating performance at the property level. Impairments of real estate have been excluded in deriving net operating income because we do not consider impairments of real estate to be property-level operating expenses. Impairments of real estate relate to changes in the values of our assets and do not reflect the current operating performance with respect to related revenues or expenses. Our impairments of real estate represent the write-down in the value of the assets to the estimated fair value less cost to sell. These impairments result from investing decisions or a deterioration in market conditions. We also exclude realized and unrealized investment gain or loss, which results from investment decisions that occur at the corporate level related to non-real estate investments in publicly traded companies and certain privately held entities. Therefore, we do not consider these activities to be an indication of operating performance of our real estate assets at the property level. Our calculation of net operating income also excludes charges incurred from changes in certain financing decisions, such as losses on early extinguishment of debt, as these charges often relate to corporate strategy. Property operating expenses included in determining net operating income primarily consist of costs that are related to our operating properties, such as utilities, repairs, and maintenance; rental expense related to ground leases; contracted services, such as janitorial, engineering, and landscaping; property taxes and insurance; and property-level salaries. General and administrative expenses consist primarily of accounting and corporate compensation, corporate insurance, professional fees, rent, and supplies that are incurred as part of corporate office management. We calculate operating margin as net operating income divided by total revenues.

We believe that in order to facilitate for investors a clear understanding of our operating results, net operating income should be examined in conjunction with net income or loss as presented in our consolidated statements of operations. Net operating income should not be considered as an alternative to net income or loss as an indication of our performance, nor as an alternative to cash flows as a measure of our liquidity or our ability to make distributions.

### Operating statistics

We present certain operating statistics related to our properties, including number of properties, RSF, occupancy percentage, leasing activity, and contractual lease expirations as of the end of the period. We believe these measures are useful to investors because they facilitate an understanding of certain trends for our properties. We compute the number of properties, RSF, occupancy percentage, leasing activity, and contractual lease expirations at 100% for all properties in which we have an investment, including properties owned by our consolidated and unconsolidated real estate joint ventures. For operating metrics based on annual rental revenue, refer to the definition of annual rental revenue herein.

### Same property comparisons

As a result of changes within our total property portfolio during the comparative periods presented, including changes from assets acquired or sold, properties placed into development or redevelopment, and development or redevelopment properties recently placed into service, the consolidated total income from rentals, as well as rental operating expenses in our operating results, can show significant changes from period to period. In order to supplement an evaluation of our results of operations over a given quarterly or annual period, we analyze the operating performance for all consolidated properties that were fully operating for the entirety of the comparative periods presented, referred to as same properties. We separately present quarterly and year-to-date same property results to align with the interim financial information required by the SEC in our management's discussion and analysis of our financial condition and results of operations. These same properties are analyzed separately from properties acquired subsequent to the first day in the earliest comparable quarterly or year-to-date period presented, properties that underwent development or redevelopment at any time during the comparative periods, unconsolidated real estate joint ventures, properties classified as held for sale, and corporate entities (legal entities performing general and administrative functions), which are excluded from same property results. Additionally, termination fees, if any, are excluded from the results of same properties.

Space Intentionally Blank

June 30, 2024



### Same property comparisons (continued)

Redevelopment – under construction

840 Winter Street

311 Arsenal Street Canada

Other

40. 50. and 60 Sylvan Road

651 Gateway Boulevard 401 Park Drive

Alexandria Center® for Advanced Technologies – Monte Villa Parkway

8800 Technology Forest Place

The following table reconciles the number of same properties to total properties for the six months ended June 30, 2024:

months office out of, 2024.			
		Redevelopment – placed into	
Development – under construction	Properties	service after January 1, 2023	Properties
201 Brookline Avenue	1	20400 Century Boulevard	1
1150 Eastlake Avenue East	1	140 First Street	1
9820 Darnestown Road	1	2400 Ellis Road, 40 Moore Drive, and 14	3
99 Coolidge Avenue	1	TW Alexander Drive	3
500 North Beacon Street and 4 Kingsbury	2	9601 and 9603 Medical Center Drive	2
Avenue	2		7
9808 Medical Center Drive	1	Acquisitions after January 1, 2023	Properties
1450 Owens Street	1	Other	5
230 Harriet Tubman Way	1		5
4155 Campus Point Court	1	Unconsolidated real estate JVs	4
10935, 10945, and 10955 Alexandria	3	Properties held for sale	5
Way	3	Total properties excluded from same	62
10075 Barnes Canyon Road	1	properties	02
421 Park Drive	1	Same properties	346
4135 Campus Point Court	1	Total properties in North America as of	
	16	June 30, 2024	408
Development – placed into			
service after January 1, 2023	Properties		
751 Gateway Boulevard	1		
15 Necco Street	1		
325 Binney Street	1		
6040 George Watts Hill Drive	1		
9810 Darnestown Road	1		

5

3

4

2 20

**Properties** 

### Stabilized occupancy date

The stabilized occupancy date represents the estimated date on which the project is expected to reach occupancy of 95% or greater.

### **Tenant recoveries**

Tenant recoveries represent revenues comprising reimbursement of real estate taxes, insurance, utilities, repairs and maintenance, common area expenses, and other operating expenses and earned in the period during which the applicable expenses are incurred and the tenant's obligation to reimburse us arises.

We classify rental revenues and tenant recoveries generated through the leasing of real estate assets within revenues in income from rentals in our consolidated statements of operations. We provide investors with a separate presentation of rental revenues and tenant recoveries in "Same property performance" in this Supplemental Information because we believe it promotes investors' understanding of our operating results. We believe that the presentation of tenant recoveries is useful to investors as a supplemental measure of our ability to recover operating expenses under our triple net leases, including recoveries of utilities, repairs and maintenance, insurance, property taxes, common area expenses, and other operating expenses, and of our ability to mitigate the effect to net income for any significant variability to components of our operating expenses.

The following table reconciles income from rentals to tenant recoveries:

		Thre	Six Months Ended				
(In thousands)	6/30/24	3/31/24	12/31/23	9/30/23	6/30/23	6/30/24	6/30/23
Income from rentals	\$ 755,162	\$ 755,551	\$ 742,637	\$ 707,531	\$ 704,339	\$1,510,713	\$1,392,288
Rental revenues	(576,835)	(581,400)	(561,428)	(526,352)	(537,889)	(1,158,235)	(1,056,191)
Tenant recoveries	\$ 178,327	\$ 174,151	\$ 181,209	\$ 181,179	\$ 166,450	\$ 352,478	\$ 336,097

## Total equity capitalization

Total equity capitalization is equal to the outstanding shares of common stock multiplied by the closing price on the last trading day at the end of each period presented.

### Total market capitalization

Total market capitalization is equal to the sum of total equity capitalization and total debt.

June 30, 2024



## Unencumbered net operating income as a percentage of total net operating income

Unencumbered net operating income as a percentage of total net operating income is a non-GAAP financial measure that we believe is useful to investors as a performance measure of the results of operations of our unencumbered real estate assets as it reflects those income and expense items that are incurred at the unencumbered property level. Unencumbered net operating income is derived from assets classified in continuing operations, which are not subject to any mortgage, deed of trust, lien, or other security interest, as of the period for which income is presented.

The following table summarizes unencumbered net operating income as a percentage of total net operating income:

	I hree Months Ended										
Dollars in thousands)		6/30/24		3/31/24		12/31/23		9/30/23		6/30/23	
Unencumbered net operating income	\$	544,268	\$	546,830	\$	533,382	\$	495,012	\$	500,923	
Encumbered net operating income		5,212		3,964		1,108		1,089		1,143	
Total net operating income	\$	549,480	\$	550,794	\$	534,490	\$	496,101	\$	502,066	
Unencumbered net operating income as a percentage of total net operating income		99.1%		99.3%		99.8%		99.8%		99.8%	

### Weighted-average interest rate for capitalization of interest

The weighted-average interest rate required for calculating capitalization of interest pursuant to GAAP represents a weighted-average rate as of the end of the applicable period, based on the rates applicable to borrowings outstanding during the period, including expense/income related to interest rate hedge agreements, amortization of loan fees, amortization of debt premiums (discounts), and other bank fees. A separate calculation is performed to determine our weighted-average interest rate for capitalization for each month. The rate will vary each month due to changes in variable interest rates, outstanding debt balances, the proportion of variable-rate debt to fixed-rate debt, the amount and terms of interest rate hedge agreements, and the amount of loan fee and premium (discount) amortization.

Space Intentionally Blank

### Weighted-average shares of common stock outstanding - diluted

From time to time, we enter into capital market transactions, including forward equity sales agreements ("Forward Agreements"), to fund acquisitions, to fund construction of our highly leased development and redevelopment projects, and for general working capital purposes. We are required to consider the potential dilutive effect of our Forward Agreements under the treasury stock method while the Forward Agreements are outstanding. As of June 30, 2024, we had Forward Agreements outstanding to sell an aggregate of 230 thousand shares of common stock.

The weighted-average shares of common stock outstanding used in calculating EPS – diluted, FFO per share – diluted, and FFO per share – diluted, as adjusted, during each period are calculated as follows. Also shown are the weighted-average unvested shares associated with restricted stock awards used in calculating amounts allocable to unvested stock award holders for each of the respective periods presented below:

		Thre	Six Months Ended				
(In thousands)	6/30/24	3/31/24	12/31/23	9/30/23	6/30/23	6/30/24	6/30/23
Basic shares for earnings per share	172,013	171,949	171,096	170,890	170,864	171,981	170,824
Forward Agreements							
Diluted shares for earnings per share	172,013	171,949	171,096	170,890	170,864	171,981	170,824
Basic shares for funds from operations per share and funds from operations per share, as adjusted	172,013	171,949	171,096	170,890	170,864	171,981	170,824
Forward Agreements	_	_	_	_		_	_
Diluted shares for funds from operations per share and funds from operations per share, as adjusted	172,013	171,949	171,096	170,890	170,864	171,981	170,824
Weighted-average unvested restricted shares used in calculating the allocations of net income, funds from operations, and funds from operations, as adjusted	2,878	2,987	2,734	2,124	2,163	2,933	2,219